Development of a microtitre plate assay and a rapid membrane-based assay for the detection of antibodies to hepatitis C virus (HCV) in human serum by Tymon, Gráinne
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ABSTRACT
Hepatitis C vims (HCV) was discovered in 1989 and was identified as the causative 
agent o f non-A, non-B hepatitis. Third-generation ELISA techniques, incorporating the 
use o f antigens specific to all hepatitis C viral regions, are used to diagnose HCV 
infection by serum antibody determination. Rapid immunoblot assay (RIBA) testing 
identifies antibodies specific to structural and non-structural viral proteins. RT-PCR is 
established as the gold standard o f HCV RNA detection. A positive result on the 
developed assays does not indicate that the hepatitis C virus is present and replicating. A 
confirmatory test is needed to assess current HCV status and to monitor treatment.
The development o f qualitative anti-HCV immunoglobulin G antibody tests is described 
in this study. A microtitre plate assay, suitable for multiple sample screening was 
optimised for use in standard laboratories. The rapid membrane-based assay, developed 
for use at point-of-care, requires no sample preparation. It is a user-friendly assay 
requiring no laboratory equipment or operator training. Both formats utilise bound 
synthetic peptides specific for non-structural and core regions o f the HCV genome. 
Optimisation of assays was based on testing with characterised sera. Performance 
evaluation of the plate assay was carried out on 530 samples achieving 97.9% specificity 
and 93.6% sensitivity. A total o f 751 samples evaluated on the rapid assay resulted in 
99.4% specificity and 98.9% sensitivity.
xi
Section 1
1.1 History of Viral Hepatitis
1.1.1 Blood Borne and Food Borne Hepatitis
Hepatitis results in the abnormal function of the liver due to the action of specific 
pathogens, causing necrosis and inflammation of hepatic cells by multiple causative 
agents such as bacteria, drugs, toxins, excessive alcohol intake and a number of viruses. 
Research has revealed that viral hepatitis encompasses six major viral agents with 
distinctive serologic characteristics and specific epidemiological attributes each with their 
own infective implications. The viruses so far identified are hepatitis B, hepatitis A, 
hepatitis D (delta hepatitis), hepatitis C, hepatitis E and hepatitis G. There are two 
primary types of viral hepatitis, food-borne hepatitis (hepatitis A and E) and blood-borne 
hepatitis (hepatitis B, C, D and G) (Koop, 1998a).
In 1970, electron microscopy was used to identify hepatitis B virus (HBV); a 42mm 
double-shelled round particle (Dane et a l., 1970), formally called serum hepatitis. HBV 
is much more prevalent and more infectious than HTV and is transmitted through blood 
and body fluids such as seminal fluid, vaginal secretions, breast milk, tears and saliva. It 
contains a partially double stranded DNA genome that replicates via a single stranded full 
length mRNA reverse transcribed into a minus strand genomic DNA (Will et al., 1982). 
Hepatitis A (infectious hepatitis) was discovered by immunoelectron microscopy in 1973 
and is a single stranded RNA virus (Feinstone et a l., 1973). It is transmitted by 
contaminated drinking water and food and generally depends on the hygienic and 
sanitary conditions in a given area. Hepatitis D virus (delta hepatitis, HDV) first 
described in 1977, is a particle o f about 36nm diameter with a HBsAg envelope derived 
from HBV, and a ribonucleic genome (Rizzetto et al., 1977). HDV encodes its own 
protein, the delta antigen but cannot form infectious particles by itself. It depends on the 
helper functions o f HBV to replicate and survive. The disease is usually self-limited, and 
due to its co-dependence on HBV, HDV infection is prevented via the HBV vaccine. 
Hepatitis C virus (HCV) was identified in 1989 as a single stranded RNA molecule with 
a diameter between 40nm and 80nm (Choo et al., 1989). It accounts for the majority of 
non-A, non-B hepatitis cases. In 1988 hepatitis E was shown to be an enteric non-A,
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non-B hepatitis (ET-NANB). It is a non-enveloped spherical single stranded RNA virus, 
commonly found in the Indian Ocean, Africa and in underdeveloped countries and is 
associated with waterborne hepatitis epidemics in these countries (Bradley, 1988). The 
symptoms and modes o f transmission o f hepatitis E resemble those of hepatitis A. 
Hepatitis G virus (HGV) is an RNA virus and was identified from the plasma o f a patient 
suffering from chronic hepatitis (Linnen et al., 1996). It is, therefore, known to be a 
causative agent of acute and chronic hepatitis and is distantly related to hepatitis C virus.
1.1.2 Discovery of H epatitis C Virus (HCV)
Accumulated knowledge of the structures o f HBV and HAV in the early 70’s and 80’s, 
respectively, led to the development of reasonably sensitive and accurate serodiagnostic 
tests. This greatly reduced the transmission o f transfusion-associated hepatitis. 
However, it became apparent that the majority o f patients with hepatitis associated with 
transfusion were seronegative for HBV and HAV. Cases o f viral hepatitis that cannot be 
attributed to Hepatitis A or B viruses or other known hepatotropic agents, such as 
Cytomegalovirus, were referred to as non-A, non-B hepatitis (NANBH). The agent 
causing NANBH eluded identification for almost twenty years, and unlike other hepatitis 
viruses, was identified after a study aimed at its discovery. Serological and immune 
electronmicroscopy, successful in identifying HAV and HBV, failed to detect this 
NANBH agent identified in 1989 as hepatitis C virus (Choo et al., 1989).
Transmission experiments in chimpanzees confirmed the presence o f at least two 
transmissible agents of NANBH, one o f these being HCV, the other agent which is 
chloroform non-sensitive has yet to be identified but is a sporadically occurring, 
community acquired non-A, non-B hepatitis. Through these transmission studies in 
chimpanzees, it was established that the main agent o f post-transfusion NANBH was 
likely to be an enveloped virus with a diameter between 40-80nm (Bradley et al., 1987). 
These studies involved the pooling o f chimpanzee plasma known to contain a relatively 
high titre of the agent. Most o f these sera were shown to contain less than 1,000 
infectious particles per ml o f serum and only after serial passaging of HCV in animals 
was it possible to obtain sera with an unusually high titre (1,000,000 particles/ml) 
(Bradley et ah, 1983, 1985; Choo et a l., 1989).
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In order to clone the viral genome, the virus was first pelleted from the plasma pool. A 
denaturation step was included prior to the synthesis o f complimentary DNA so that 
either DNA or RNA could serve as a template. This was done because it was not known 
whether the genome was DNA or RNA. The resulting cDNA was inserted into a 
bacteriophage expression vector and led to the detection o f a clone, using serum 
obtained from a patient with chronic non-A, non-B hepatitis. This clone was found to 
bind antibodies present in the sera o f several individuals infected with the agent (Choo et 
al., 1989). This clone was used as a probe to detect a larger, overlapping clone. It was 
possible to demonstrate that these sequences hybridised to a positive-sense RNA 
molecule o f around 10,000 nucleotides which was found to be present in the livers of 
infected chimpanzees but was not detectable in uninfected individuals. It was possible to 
use newly detected overlapping clones as hybridisation probes to further select virus- 
specific clones. Thus, the entire HCV genome was sequenced and the complete 
nucleotide sequence was determined as shown and is presented schematically in Figure 
la  (see section 1.2).
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1.2 Structure of the Viral Genome
In spite of the considerable amount of knowledge that has so far been accumulated the 
physical structure of HCV remains essentially unknown. Hepatitis C virus is only about 
50 nanometres in diameter and is so small its colour cannot be determined. 200,000 
hepatitis C viruses placed together would measure a single centimetre. The transmission 
studies described demonstrates the HCV genome to be a single stranded RNA molecule 
of positive polarity containing approximately 10,000 nucleotides which encode a 
polypeptide of about 3,000 amino acids (Figure la) (Choo et al., 1989).
1.2.1 Anatomy of the Virus
The low density of the virus and its sensitivity to organic solvents suggest that the virus 
has a lipid containing envelope. A core o f genetic RNA is surrounded by a protective 
shell o f protein and further encased in the lipid envelope. These features suggest that the 
genetic organisation o f HCV is similar to that o f viruses o f the Flaviviridae family, such 
as the flaviviruses and pestiviruses. The fact that the genetic material is RNA, rather 
than the more stable DNA, gives hepatitis C its reactivity and dangerous ability to 
mutate which has important consequences in the life cycle o f the virus. Mutations occur 
frequently and randomly across the entire length o f the viral RNA producing mutated 
forms, which are so different from their ancestors that the immune system cannot 
recognise them (Koop, 1998b). Hepatitis C requires only a small amount o f RNA to 
encode its core information giving fewer common characteristics that can be identified 
by the immune system.
The quantity of polypeptides encoded by the positive stranded RNA genomes is similar 
to the Flaviviridae family being 3,000-4,000 amino acids (Figure la). Also, the HCV 
proteins are encoded in a single large open reading frame (ORF) that is preceded at the 
5' terminal end by an untranslated highly conserved sequence (Crivelli, 1991). This 
region is resistant to denaturation, possibly because of protein linkage. The polyprotein 
encoded by the flaviviruses is processed into structural (S) proteins and non-structural 
(NS) proteins, The structural proteins form the viral particle whereas the non-structural 
proteins are involved in replication of the virus. Similar characteristics have been
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identified for the HCV genome (Choo et al., 1991; Takamizawa et al., 1991). The HCV 
genome ORF codes for a polypeptide containing structural proteins at the 5' terminus 
and non-structural proteins at the intermediate and 3' regions. The HCV genome 
sequence encodes structural proteins designated E (envelope), M (matrix) and C 
(nucleocapsid or core) followed by non-structural proteins NS1, NS2, NS3, NS4 and 
NS5 originating from the 3' terminal. Therefore, based on similarities between the HCV 
genome and that o f the flavivirus and pestivirus family, HCV is classified as a separate 
genus within the flaviviradae (Heinz et al., 1992).
STRUCTURAL PROTEINS NON-STRUCTURAL PROTEINS
“>  192 192 344 278 609 398 998
\i ^ i
3
C E l E2/NSJ NS2 NS3 NS4 NSS
5'
Size (KDa) - ^ 1 9  33 72 6? 116
0 Amino Acids 3000
Figure la. Structure o f the HCV genome, showing the size (green) and quantity (blue) 
o f the amino acids forming the structural and non-structural proteins (red).
As discussed, cloning of the HCV genome led to its proposed classification, but 
identification of all the native proteins o f  the long ORF can only be assumed by the 
proposed homology with the other flaviviradae family members. This is because it has 
not been possible to infect cell cultures or animals other than chimpanzees, and natural 
infections generally produce only low viral titres lacking precipitating antibodies capable 
o f concentrating virions for visualisation by electron microscopy.
1.2.2 Proteins of the Viral Genome
As can be seen in Figure la, the first of the structural proteins originating from the highly 
conserved amino N-terminus is the core protein, C, consisting of 192 amino acids. 
Possibly the first 70 o f these is the matrix protein which is based on the homology with 
members o f the flaviviradae (Takamizawa et al., 1991). The core protein complexes 
with the genomic RNA to form the nucleocapsid. The amino acid sequence o f this 
protein seems well conserved among different HCV isolates. The next product is a 
33kDa glycoprotein found in the viral envelope and is known as E l or gp35 
(Takamizawa et al., 1991). A second envelope glycoprotein E2, may be generated after 
cleavage by a protease within the viral polyprotein. This 72kDa glycoprotein, gp72 or 
E2/NS1, comprising 344 amino acids, present at the NS1 position makes HCV more 
similar to the pestiviruses rather than to flaviviruses. Significant variability has been 
found among different HCV isolates and 60% o f the amino acid changes have been 
attributed to the heterogeneity observed in the hypervariable domain at the junction 
between the E l and NS1/E2 region gp33 being more conserved than gp72 (Takeuchi et 
al., 1990; Weiner et al., 1991).
The non-structural regions o f the viral genome show greater homology with flaviviruses 
and pestiviruses. This more variable genomic region includes five proteins. NS1 partly 
encodes the gp72 glycoprotein while NS2 containing approximately 278 amino acids and 
NS4 containing 398 amino acids, are thought to be membrane-binding proteins. NS3, 
with 609 amino acids is thought to be a viral helicase and contains an N-terminal 
protease. NS5, a 116kDa protein comprising 998 amino acids it thought to be the 
replicase, an RNA-dependent RNA polymerase (Miller and Purcell, 1990).
1.2.3 Genotype Determination
Following the discovery and identification o f HCV, world-wide viral isolates were 
sequenced and much information on HCV diversity was accumulated. The unstable 
nature of the RNA molecule provides a mutagenic factor allowing the virus to develop 
new genetic variants o f itself. The isolates were separated into distinct genotypes with 
different genotyping methods proposed and attempted. The importance o f the 
determination o f HCV genotypes has been established for a number of reasons. Viral 
genotype has emerged as a clinically significant variable prognostic for the stage of
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development o f HCV infection (Young et a l ,  1993). Several genotypes have unique 
geographical origins, making them convenient markers in epidemiological studies (Zein 
etal., 1996).
After the discovery o f HCV, viral isolates from different geographical locations all over 
the world showed it to be a highly diverse virus. Different research groups have 
separated these isolates into distinct genotypes. Each major genotype may differ in their 
biological effects in terms o f replication, mutation rates, type and severity o f liver 
damage and detection and treatment options. The use o f various genotyping methods 
and genomic regions for genotyping raised the question of whether a direct comparison 
could be made between results from one system and another. To resolve the issue, a 
standard nomenclature system was drawn up and agreed upon by HCV research groups 
(Table la, Column 7).
Olumioto/
Mori
Chayama Simmonds Koliara Ennrooto
Houghton/
Chaa
ProjH)Scd
system
I I la I PT I la
II II lb I K1 II lb
lc
III III 2a II K2a III 2a
IV IV 2b II K2b m 2b
II m 2c
V 3 IV 3a
VI V IV 3b
4 4a
V 5a
6a
Table la. Commonly used HCV genotype nomenclature systems based on 
standardisation by the following research groups: Tsukiyama et al., 1991; Chaa et 
al., 1992; Mori et al., 1992; Okamoto et al., 1992; Chayama et al., 1993; Simmonds 
et a l, 1993; Simmonds et al., 1994.
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Due to its sequence conservation, the 5' non-coding region (5' NCR) is the target for 
most HCV detection assays (Young et al., 1993). However, because this region 
contains genotypically variable sequence positions, techniques for genotyping HCV have 
relied upon the examination o f a limited number o f diagnostic sequence polymorphisms 
in variable regions throughout the 5' NCR (Marshall et al., 1997). Restriction Fragment 
Length Polymorphism (RFLP) analysis (Constantine et al., 1995), line probe assay 
(LiPA) analysis (Stuyver et al., 1993), a second generation LiPA and RT-PCR 
amplification of the HCV 5' NCR, with genotype-specific primers from the capsid 
encoding region, are four examples o f such techniques.
An example o f a second generation LiPA is the commercially available INNO-LiPA 
HCV II*. It is a fast, easy and specific DNA hybridisation test based on the ‘reverse 
hybridisation’ principle. The six major types o f HCV can be readily distinguished in this 
assay, which features completely new sets o f probes for types 4, 5 and 6 and new 
subtyping probes for types 1 and 2. Genotype-specific oligonucleotide probes are 
immobilised as parallel lines on ready-to-use membrane strips and are hybridised with 
target material labelled with alkaline phophatase.
All o f these techniques have shown good concordance with DNA sequencing and are 
considerably simpler to execute than direct sequencing. However, they are restricted in 
terms of the number o f types and subtypes detected and would be difficult to apply in 
geographic areas such as the Middle East and Far East where diverse genotypes 
predominate. Recent reports indicate such diversity is emerging in the U.S. and Europe 
as a result o f considerable immigration and travel, necessitating a more broadly based 
means of genotyping samples (Zein et al., 1996).
Routine direct sequencing, as described above, is not often feasible in a clinical 
laboratory. The high cost and low throughput o f DNA sequencing for the routine 
analysis o f the 5' NCR prompted the development and application in 1997 (Third Wave 
Technologies, Inc., Madison, Wis.) o f a novel DNA-based technology called Cleavase 
Fragment Length Polymorphism (CFLP). The CFLP technology relies on the formation 
of unique secondary structures that result when DNA is allowed to cool following brief 
heat denaturation (Orita et al., 1989). These structures serve as substrates for the 
structure-specific Cleavase I enzyme, which can be used to generate a set o f cleavage 
products from any given DNA fragment (Brow et al., 1996). Formation of these
secondary structures is exquisitely sensitive to nucleotide sequence and the presence of 
sequence polymorphisms results in the generation o f unique collections o f cleavage 
products or structural fingerprints, for each sequence analysed. CFLP analysis exhibited 
complete correlation to nucleotide sequence data and was able to distinguish viral 
genotypes differing by as little as a single nucleotide. Blinded analysis o f CFLP patterns 
compared to patterns from samples o f known genotype resulted in assignments that were 
100% consistent with DNA sequencing at the type and subtype levels. Furthermore, 
CFLP scanning detected variations within a given genotype, indicating that this method 
is suitable for identifying the appearance of new or rare HCV variants over other more 
costly and cumbersome genotyping approaches (Marshall et al., 1997).
1.2.4 The Life Cycle of Hepatitis C
The hepatitis C virus must attach itself to and infect liver cells in order to reproduce. To 
do this it uses particular proteins present on its lipid coat to adhere to a receptor site. 
The protein core of the virus penetrates the plasma membrane and enters the cell. This is 
done by merging the lipid coat o f the virus with the cell’s outer membrane. The 
membrane then engulfs the virus and the viral core enters the cell. Enzymes present in 
liver cells aid in dissolving the protein coat to release the viral RNA in the cell.
The viral RNA then uses the cell’s ribosomes to begin the process o f viral reproduction. 
Viral RNA itself can be directly read by the host cell’s ribosomes functioning like mRNA 
to synthesise RNA transcriptase. Once there is adequate RNA transcriptase, the viral 
RNA will make the new genetic material. Some of this RNA will contain mutations. 
The protective protein coat of the virus is produced by the ribosomes and assembles 
around the new viral RNA forming new viral particles. The viral particles form a 
spherical shell, called a capsid, that fully encapsulates the RNA. The completed particle 
is called a nucleocapsid.
The newly formed viruses travel to the inside portion o f the plasma membrane and attach 
to it. The plasma membrane encircles the virus, then releases it, providing the virus with 
a protective lipid coat which it will use to attach to another liver cell. Each surviving 
virus can produce thousands o f offspring resulting in significant damage to the liver 
(Koop, 1998c).
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1.3 Clinical Infection of Hepatitis C Virus
Currently, there are approximately 200 million people world-wide who are infected with 
HCV. Chronic liver disease is the tenth leading cause o f death among adults in the 
United States, and accounts for approximately 25,000 deaths annually, or approximately 
1% of all deaths. According to the U.S.A. February 1999 consensus statement, HCV 
accounts for 20% of cases of acute hepatitis, 70% of cases of chronic hepatitis, 40% of 
cases of end-stage cirrhosis, 60% of cases of hepatocellular carcinoma and 30% o f liver 
transplants (Shaw, 1999a).
HCV infection is the most common chronic bloodborne infection in the United States 
(Alter et al., 1998). In combination with hepatitis B, it now accounts for 75% of all 
cases o f liver disease globally. Most HCV-infected persons are aged 30-49 years 
(McQuillan et al., 1997), this group o f infected persons reaching ages at which 
complications from chronic liver disease typically occur. It is not surprising that the 
number of deaths attributable to HCV-related chronic liver disease could increase 
substantially during the next 10-20 years. Currently, 8,000 to 10,000 deaths each year in 
the U.S. are a result o f HCV and it is estimated that by the year 2010, 30,000 to 40,000 
patients will die annually of HCV related chronic liver disease.
HCV appears to be a weak RNA virus lacking the properties o f retroviruses that survive 
in infected hosts by integration into cellular DNA. Nevertheless, it is believed to account 
for the majority o f NANB hepatitis cases, causing 60% o f acute cases and over 90% of 
chronic cases. The pathogenicity o f HCV is peculiar, its mechanism capable o f escaping 
host immune elimination and persisting in infected hosts causing various degrees of liver 
damage. The extent o f liver damage is measured by the levels o f liver enzymes such as 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the plasma. 
The presence o f HCV-RNA in the liver and serum play a major role indicating that the 
virus is present and replicating. The spectrum of HCV infection ranges from the acute 
phase, with possible progression to chronic hepatitis causing cirrhosis and hepatocellular 
carcinoma (HCC) (Crivelli, 1991).
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1.3.1 Acute HCV Infection
Acute hepatitis C represents a clinically mild phase of infection. Research has shown that 
75% of cases of acute HCV infection are relatively asymptomatic (Alter et a l ,  1989; 
Aach et al., 1991). 60% have no discernible symptoms; 20-30% may have jaundice and 
10-20% may have non-specific symptoms such as anorexia, malaise or abdominal pain 
(Alter et al., 1998). The incubation period o f HCV appears to be from 15 to 160 days 
after administration o f HCV-contaminated blood or blood derivatives, with a mode o f 45 
to 55 days. In the case o f patients who have received clotting-factor concentrates, 
incubation periods o f less than 30 days have been reported (Bamber et al., 1981). 
However, a more realistic and common time factor of 2 - 26 weeks is reported between 
exposure to HCV and the development of clinical acute hepatitis (Alter et a/., 1989). 
The detection o f serum antibodies indicates that seroconversion has taken place, the 
mean time estimated to be 2.3 weeks (Mattson et al., 1992). In approximately 20% of 
cases the onset o f symptoms might precede anti-HCV conversion.
In patients with transfusion associated hepatitis C, the time between HCV exposure and 
the onset o f hepatic viral replication depicted by HCV-RNA has been found to be as 
short as one week (Farci et al., 1991). In the cases o f patients who do not develop 
chronic hepatitis but have acute self-limiting infections, seroconversion occurs much less 
frequently (Alter et al., 1989; Nishioka et al., 1991). Anti-HCV antibody can be 
detected in 80% of patients within 15 weeks after exposure, in approximately 90% 
within 5 months and in 97% by 6 months after exposure. Rarely is seroconversion 
delayed until 9 months after exposure.
Fluctuating serum ALT levels are a characteristic feature o f hepatitis C infection (Alter et 
al., 1989; Mondelli & Colombo, 1991). The significant association that exists between 
serum HCV antibody and HCV-RNA suggests that antibody may be considered an 
indirect marker o f HCV infection. The presence of anti-HCV antibodies indicates that an 
individual may have been infected with HCV, may harbour infectious HCV and may be 
capable o f transmitting HCV infection. However, the level o f this antibody has been 
found to significantly reduce in patients recovering from acute hepatitis C (after 1 - 4  
years). Its persistence indicates chronic hepatitis infection (Alter et al., 1991).
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1.3.2 Chronic HCV Infection
After acute infection 15-20% of patients appear to resolve their infection. Statistics 
show that 80 - 85% o f acute hepatitis C sufferers follow a chronic course o f infection 
(Drenstag et al., 1983). No clinical or epidemiological features among patients with 
acute infection have been found to be predictive o f either persistent infection or chronic 
disease (Alter et al., 1998).
Regardless o f the route o f infection, approximately 60% o f chronic patients progress to 
cirrhosis and possibly to hepatocellular carcinoma (HCC), resulting in significant 
morbidity and mortality rates. Chronic HCV is therefore associated with a wide 
spectrum of liver disease ranging from the asymptomatic carrier state to severe liver 
damage. These findings indicate that HCV is not necessarily pathogenic and genetic 
heterogeneity o f HCV could be a major cause o f such variability. To distinguish between 
patients with chronic HCV and carriers with unrelated liver disease, evidence o f viral 
infection and the presence o f virus replication markers is necessary.
In many patients, development o f chronic liver disease is heralded by persistent 
elevations in serum ALT activity, presence and persistence o f serum antibodies and 
continued presence of HCV-RNA not only in patient serum, but also in liver tissues. In 
most patients, progression of hepatitis C to cirrhosis averages around 20 years 
(Kiyosawa et al., 1990) and the association o f persistent ALT levels with chronic HCV 
infection remains unclear. In 1995, it was shown that 20 - 40% of patients in a study 
with viremia and chronic hepatitis gave normal liver test results with normal 
aminotransferase levels on multiple analysis over a decade (Hayashi et al., 1997). 
Therefore, ALT determination cannot be used to exclude ongoing hepatic injury and 
long-term follow-up o f infected patients is necessary to determine their prognosis. Some 
investigators have recently reported persistent hepatitis C viremia associated with both 
normal aminotransferase levels and normal or minimal changes on liver biopsy (Prieto et 
al., 1995).
Various clinical and epidemiological factors influence the severity o f chronic hepatitis C 
and the rate of its progression to cirrhosis. Such factors include age at infection, sex, 
duration o f disease, serum ALT levels, co-occurrence o f HBV or HIV infection and
alcoholism. Even the intake o f moderate amounts of alcohol in patients with chronic 
hepatitis C might enhance disease progression. More severe liver injury observed in 
persons with alcoholic liver disease and HCV infection possibly is attributable to alcohol- 
induced enhancement o f viral replication or increased susceptibility o f cells to viral 
injury. The serum titres o f HCV-RNA have been found to be higher in 
immunosuppressed patients than in HIV seronegative patients (Wright et al., 1992). 
Also, recent studies conducted on patients with chronic HCV infection have found that 
distinct genotypes o f HCV are associated with distinct manifestations o f the disease 
(Marshall e ta l., 1997).
1.3.3 Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumours in the 
world, particularly in Africa, China and South East Asia. In these high incidence areas, 
most cases of HCC are associated with HBV infection whereas in low incidence areas 
such as the United States, less than 25% of cases of HCC appear to be related to HBV 
infection (Di Bisceglie et al., 1991).
The identification of HCV and analysis of HCV infection have shown an association 
between chronic HCV infection and HCC. In recent studies, it was found that HCC 
developed only in patients with abnormal ALT levels and so persistence of ALT 
elevations may prove to be a convenient marker for identifying increased risk o f HCC in 
chronic HCV patients. Most studies have reported that cirrhosis develops in 10-20% of 
patients with chronic hepatitis C over a period of 20-30 years, and HCC develops in 1- 
5% with striking geographic variations in rates o f the disease. Early studies for anti-HCV 
found evidence of infection in up to 75% of cases o f HCC in Europe and Japan (Bruix et 
al., 1991) whereas among HCC patients in the U.S., the prevalence o f anti-HCV is 
generally low, ranging from 13 - 29% (Yu et al., 1990). Therefore, HCY infection 
appears to play a less important role in the pathogenesis of HCC in the U.S. than in 
southern Europe and Japan. Positive strand HCV-RNA has been found in the liver tissue 
of patients with HBsAg-negative anti-HCV positive HCC confirming the association of 
HCV-RNA with HCC sufferers (Horiike et al., 1993).
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1.4.1 Disease Progression
Medical intervention and treatment of acute HCV infection is limited, as most cases are 
asymptomatic. For more than six months following initial infection, the disease is 
virtually undetectable. The symptoms are progressive in nature and often very mild. The 
most common symptom, commencing sometimes years after initial infection is fatigue. 
The signs and symptoms associated with symptomatic acute infection include mild fever, 
nausea and vomiting, rashes, abdominal pain, loss o f appetite, painful muscles and joints 
and sometimes diarrhoea. Many cases are undiagnosed because such symptoms are 
suggestive o f a flu-like illness. A minority o f patients report dark urine and light 
coloured stool, followed by jaundice and itching of the skin.
Low level infection, in which the infected individual is virtually asymptomatic but still 
highly contagious, may continue for years, even decades before progressing significantly. 
The course of chronic liver disease is usually insidious, progressing at a slow rate 
without symptoms or physical signs in the majority o f patients during the first two or 
more decades after infection. Frequently, chronic hepatitis C is not recognised until 
asymptomatic patients are identified as HCV-positive during blood-donor screening, or 
elevated ALT levels are detected during routine physical examination.
1.4.2 Acute HCV Treatm ent
In the case of excessive fatigue, frequent rest is advised. It is advised to avoid increasing 
stress on a damaged liver and so alcohol should be avoided. In cases o f bleeding due to 
impaired synthetic liver function, replacement o f coagulation factors takes place.
The use of antiviral agents has been chosen by hepatologists for the treatment o f acute 
hepatitis C to prevent the progression to chronic hepatitis. Acyclovin has been used with 
little success and clinical trials have shown that natural (3-interferon was effective in 
controlling disease activity (Omata et ah, 1991). Recombinant a-interferon showed no 
benefit for the long-term outcome o f the disease.
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1.4.3 Chronic H CV Treatm ent
Due to the severity of chronic HCV infection, effective treatments were looked at to 
reduce progression to cirrhosis and HCC. Those at greatest risk o f such progression 
include anti-HCV positive patients with persistently high ALT levels, detectable HCV 
RNA and a liver biopsy indicating moderate necrosis or inflammation.
Ribavirin is a synthetic nucleotide, which proves effective against both DNA and RNA 
viruses (Fernandez et a l ,  1986). It has been successful in lowering transaminase levels 
in chronic hepatitis C sufferers, although when used alone, it does not eradicate HCV- 
RNA from serum and so is not effective against hepatitis C viral replication. It produces 
side effects such as anaemia, a metallic taste, dry mouth, flatulence, dyspepsia, nausea, 
headaches, irritability, skin rashes and myalgia.
A more effective therapy was observed with the administration o f the antiviral agent 
alpha interferon, (a-interferon). Also called leukocyte interferon, it is composed o f as 
many as sixteen different proteins linked or twined together (Edelhart et a l ,  1982). The 
object of anti-viral treatment o f Hepatitis C virus infection is to eliminate virus 
replication and, thus, prevent the progression to HCV related chronic liver disease. 
Interferons are proteins normally produced by the immune system in response to a viral 
infection. The human body produces over 20 different types o f interferons. They do not 
attack or destroy cells, or have much effect on the cell that stimulates its production. 
Once triggered by viral-RNA in an infected cell, it acts as a warning to surrounding cells. 
The protein part of the molecule, called interferoid, travels through the cellular fluid to 
the cell wall promoting the production of antiviral proteins. These antiviral proteins 
prevent the virus from replicating.
Patients with persistently normal levels o f ALT or pregnant women should not be treated 
with interferon as treatment may actually induce liver enzyme abnormalities. The FDA 
(Food and Drugs Association) does not approve interferon for the treatment o f persons 
between the ages of 18-60 years (Alter et a l ,  1998). Contraindications to treatment with 
interferon include major depressive illness, apathy, irritability, cytopenias, 
hyperthyroidism, renal transplantation and evidence o f autoimmune disease. Flu-like 
symptoms experienced in the first 2-3 weeks of therapy but diminish with continued 
treatment. Symptomatic therapy with Paracetomol of Ibrufen prior to the injection and
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every 6 to 8 hours as needed, is usually sufficient to control the flu-like side effects, as 
does drinking plenty of water and regular exercise. Mild depression should be treated 
with anti-depressants while the patient receives interferon. Patients with severe or 
manic-depression or recent suicidal ideation should not be treated with interferon. Prior 
to the administration o f interferon therapy, careful assessment should be made and the 
risks and benefits discussed with the patient, as often the treatment is more painful than 
the disease symptoms and for this reason is discontinued in 5-15% of cases. High iron 
levels in the liver may reduce the efficacy o f interferon. Interferon can suppress the bone 
marrow and decrease the number o f white cells and platelet cells in the blood. Close 
follow up with frequent monitoring is needed for early detection o f bone marrow 
suppression (Shaw, 1999b). However, the majority of patients taking interferon are able 
to continue to work full-time and carry on their normal daily activities.
In 1986, prior to the identification of HCV, the first report on the use o f a-interferon 
showed that most patients with chronic NANB hepatitis experienced rapid ALT 
normalisation when treated with interferon (Hoofhagle et al., 1997). It succeeded in 
clearing HCV-RNA from serum in 33% and improving liver histology in 50% of patients 
treated. This was based on a thrice-weekly dosage of between IMU/ml and lOMU/ml 
for 12 months (Davis et al., 1989). However, the relapse rates after the completion of 
treatment was high (approx. 50%) with increased ALT levels and reappearance o f HCV- 
RNA. Only about 25% of patients showed a long-term response to therapy. By using 
higher doses of a-interferon and continuing treatment for longer periods of time, a higher 
response rate is observed but the rate o f relapse upon cessation o f treatment is not 
significantly different. A study carried out in 1986 (Crivelli, 1991) established that 
response to a-interferon treatment is dependant on the dosage used and the duration of 
treatment. It also showed that a positive response is seen in parentally transmitted 
hepatitis C along with community-acquired cases. This was also evidence that patients 
with histology of chronic persistent hepatitis are those who had the highest response rate 
(67%) while those with cirrhosis had the lowest (48%), indicating that interferon 
response cannot easily be predicted in chronic HCV patients (Hoofnagle et al., 1997).
It has also been observed that some subtypes of anti-HCV antibody may be useful for 
monitoring interferon therapy. While the antibodies against structural and some non- 
structural antigens are not predictive o f a response, a reduction in NS4-specific 
antibodies and their disappearance were found to be associated with complete response
to interferon without relapse. Other antiviral antibodies are less helpful as they remain 
detectable even in the cases of complete interferon response without relapse.
1.4.4 Combination Therapy
Patients who have persistently abnormal ALT levels and detectable serum HCV-RNA 
after 3 months o f interferon treatment are unlikely to respond to treatment and should be 
discontinued. In the case of such patients, a combination therapy has been introduced. 
The administration of interferon a-2b and ribavirin has been shown to offer a sustained 
response and eradication of HCV-RNA in chronic hepatitis patients (Schvarcz et al., 
1995). Clinical studies o f patients treated with this combination have demonstrated a 
substantial increase in response, drug administration was discontinued in 8% of patients 
after 24 weeks and in 21% o f patients treated for 48 weeks (Shaw, 1999b).
Combination therapy has been approved by the FDA for the treatment of chronic 
hepatitis C in patients who have relapsed following interferon treatment alone and may 
be approved in the future for patients who have not been treated previously. Further 
trials have yet to be conducted using the combination therapy to determine if this 
treatment can completely eradicate the infection or alternatively sustain the suppression 
of viral and liver disease activity. Side effects o f combination therapy with interferon and 
ribavirin include those expected from the use o f interferon along with those unique to 
ribavirin. The most common potentially dangerous side effect from ribavirin use is 
anaemia. Patients with pre-existing anaemia, borderline red blood cell counts or known 
heart disease should not be treated with ribavirin or should be closely monitored.
In the cases o f chronic hepatitis C sufferers who relapse after the administration o f 
combination therapy, a certain number proceed to develop cirrhosis and, to a lesser 
extent, HCC. Liver transplantation may be life-saving at this stage of liver disease but is 
costly and involves continuing health care. This treatment option is further complicated 
by a shortage o f liver donors. For HCV-positive patients undergoing transplantation, re­
infection is almost universal.
At present there is no effective vaccine for hepatitis C. This is largely due to the great 
variation in genotypes o f hepatitis C along with its frequent mutation. Once the host has 
become infected, the virus creates different genetic variations o f itself within the body of 
the host. Thus, if the immune system begins to succeed against one variation, the mutant
strains quickly take over and become new, predominant strains (Koop, 1998d). Thus, 
there is no guarantee that a treatment, test or vaccine against one strain will be effective 
against all of them. As a result, hepatitis C is usually not self-limited.
However, the result of extensive research has led to the possible development o f a HCV 
vaccine. In the study, four HCV epitopes from conserved regions of the HCV genome 
were shown to be associated with strong T-cell responses in HCV-infected patients who 
fully recover from the disease (Shaw, 1999e). The epitopes were selected based on their 
conserved amino acid sequences among known HCV strains, reducing the likelihood of 
mutant strains escaping T-cell responses. Such epitopes, along with other epitopes 
previously reported to stimulate T-cell responses, represent candidates for the 
construction of a therapeutic T-cell based vaccine against HCV. T-cells are believed to 
play an important role in controlling HCV infection. Patients who have recovered from 
HCV infection have mounted T-cell responses whereas those who develop chronic 
infections have weak responses. To be effective the HCV vaccine must provide 
protection against multiple strains o f the virus and must induce T-cells directed to 
conserved viral regions, otherwise the hepatitis C virus may be able to escape the 
immune system’s attack.
In areas of high incidence o f HCV infection, the total administration o f a HCV vaccine 
could potentially be more cost-effective than serological antibody multiple screening. 
Such screening would, inevitably, be followed by the administration o f the vaccine to 
patients with a negative screening response. In low incidence areas, the total 
administration of a HCV vaccine may be a better alternative than sample screening. The 
administration of a vaccine to low-risk people such as police and prison officers would 
also be o f benefit. The effects o f vaccine administration to recovered HCV patients 
would be limited, due to previous exposure.
Further research has revealed that a ribozyme, used to directly attack HCV-RNA, was 
shown to inhibit viral replication (Shaw, 1999f). The enzyme, which demonstrated highly 
specific and dramatic inhibition o f hepatitis C viral replication, has been shown to have 
potent antiviral activity and is expected to be effective against all known HCV genotypes. 
When combined with the anti-viral drug, interferon, the ribozyme has been reported to 
demonstrate greater inhibition. The insight into the structure o f the enzyme complex critical 
to the replication of HCV, points to novel targets for drug development.
18
1.5 Epidemiology and Modes of Transmission of HCV
1.5.1 Global Epidemiology
The existence o f HCV infection has been recognised in virtually all parts o f the world in 
which serological testing has been achieved. It is a global disease. Of the 200 million 
infected people world-wide over four million of those are in the United States and five 
million in Western Europe with the prevalence even higher in Eastern Europe. It occurs 
among persons of all ages, but the highest incidence o f acute hepatitis C is found among 
persons aged 20-39 years and males predominate slightly (Alter et al., 1990).
Hepatitis C shows significant genetic variation in worldwide populations, evidence of its 
frequent rates of mutation and rapid evolution. The basic genotypes and subtypes vary in 
prevalence across different regions o f the world. The prevalence o f hepatitis C is lowest 
in Northern European countries, including Great Britain, Germany and France. The 
prevalence of HCV antibodies in blood donors averages less than 1% for this region. 
Higher rates have been reported in Southeast Asian countries, including India (1.5%), 
Malaysia (2.3%) and the Philippines (2.3%). The incidence in Japan was 1.2%. 
Alarming rates were reported for many African nations, reaching as high as 14.5% in 
Egypt. These studies suggest that over 200 million people around the world are infected 
with hepatitis C, an overall incidence of around 3.3% of the world’s population. 
Statistically, as many, if not more, people are infected with HCV as are with HIV.
The HCV carrier state appears to be more common at low socio-economic levels, 
probably because o f higher rates o f other cofactors. A higher prevalence of infection is 
found among the African Americans and Hispanics than is found among the white 
population. In the United States, anti-HCV was detected in 0.5% of white blood donors. 
In contrast, anti-HCV was detected in 7.1% of Hispanics and 8% o f African Americans 
(McQuillan et al., 1997). In the general population, the highest rates o f infection are 
found within the ages o f 30-49 years. High proportions o f haemophiliacs are also 
infected, although current processes to inactivate the HIV virus also destroy the hepatitis 
C virus. This results in the reduced risk of uninfected haemophiliacs contracting the 
disease.
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The greatest variation in the prevalence o f HCV infection occurs among those with 
different risk factors for infection (Alter et al., 1995). The highest prevalence is found 
among those with direct and repeated exposures to blood or blood products. The 
following table indicates these high-risk groups and highlights the various risk groups 
(Alter ef al., 1998).
High-risk Moclerate-risk Low-risk
Intravenous drug users Long-term haemodialysis Health care workers/
patients Household contact
Haemophiliacs Persons with evidence of Military personnel
multiple sex partners
Those treated with clotting Persons with a history of Volunteer blood donors
factor concentrates sexually transmitted
diseases
Recipients o f transfusions Persons with abnormal Infants bom to infected
ALT levels mothers
Transplant patients Homosexual men
Table lb. List o f  various risk groups associated with HCV infection.
1.5.2 Transmission M odes of H CV
HCV is transmitted primarily through large or repeated direct percutaneous exposures to 
blood or blood products such as clotting factors or immunoglobulins. However, unlike 
many other blood borne viruses such as the HTV virus virtually any source o f blood or 
blood products seems to be capable of carrying the virus, even an indirect source such as 
a used razor. This makes hepatitis C virus far more transmissible than most other blood 
borne viruses including HIV. The virus is also present in saliva and semen, but the level 
of infectious agent in these secretions does not appear to be high enough to pose a 
significant risk (Alter et al., 1998).
The relative importance of the two most common exposures associated with transmission 
of HCV, blood transfusion and intravenous drug use, has changed over time (Alter et al., 
1997). In the United States 15 years ago, infection o f HCV by blood transfusion
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accounted for 20% of cases. Today, it rarely accounts for recently acquired infection. In 
contrast, injecting-drug use has consistently accounted for a substantial proportion of 
HCV infections and currently accounts for 60% o f HCV transmission. A high 
proportion of infections continues to be associated with injecting-drug use, but for 
reasons that are unclear, the dramatic decline in incidence o f acute hepatitis C since 1989 
correlates with a decrease in cases among intravenous drug users.
Other modes of transmission o f HCV include employment in patient care or clinical 
laboratory work, exposure to a sex partner or household member who has had a history 
o f hepatitis, exposure to multiple sex partners, and low socio-economic level (Alter et 
al., 1982). These studies reported no association with military service or exposures 
resulting from medical or dental procedures, tattooing, acupuncture, ear piercing or 
foreign travel. If transmission from such exposures does occur, the frequency might be 
too low to detect (Alter et al., 1998).
The role of breast-feeding in transmission o f HCV was investigated in a study on 42 
healthy anti-HCV negative mothers and 65 asymptomatic mothers with anti-HCV 
antibody. Blood samples were collected from all infants at birth and at 1,3,6,9 and 12 
months. All infants were breast-fed. By three months, five o f the sixty-five mothers 
developed symptomatic liver disease and three o f their infants developed acute viral 
hepatitis. None o f the remaining infants had evidence o f infection up to 1 year and all 42 
mother-infant pairs from the control group remained negative. These results indicate 
that breast-feeding among symptomatic HCV mothers should be avoided (Shaw, 1999c). 
A study carried out in Germany in 1991 showed that children with HCV had a greater 
ability to fight the infection than do adults. The infection cleared without treatment in 
50% of children who acquired HCV through heart surgery, whereas that number was 
only 20% in adults (Shaw, 1999d).
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Methods o f detection o f HCV infection rapidly became available after the identification 
of HCV and its viral genome. The detection o f serum antibodies and HCV-RNA has 
formed the basis for diagnosis of infection and of viral replication. Basic screening tests 
using the enzyme immunoassay (EIA) format involve the utilisation of recombinant and 
synthetic HCV antigens for the detection of anti-HCV antibodies in serum. Continued 
research and development produced an improved recombinant immunoblot assay (RIBA) 
which utilised individual structural and non-structural viral proteins. In a more expensive 
and cumbersome test, serum HCV-RNA is detected by a method known as reverse 
transcription polymerase chain reaction (RT-PCR), which is used as a confirmatory test 
if evidence is pointing towards viral infection (Crivelli, 1991).
1.6.1 M olecular M ethods of Diagnosis
In chronic hepatitis C cases the detection o f HCV-RNA is essential to determine if HCV 
replication is taking place. Serum and liver HCV-RNA is usually associated with the 
presence of anti-HCV antibodies but in a few individuals HCV nucleic acid can represent 
the only detectable HCV marker (Weiner et a l ,  1991). The persistent detection of 
HCV-RNA has proven to be the only marker to differentiate acute from chronic carriers 
hence highlighting the importance of HCV-RNA detection. Polymerase Chain Reaction 
(PCR) can be used for the detection of HCV-RNA in serum, liver and mononuclear cells. 
The use o f a thermostable polymerase allows the dissociation of newly formed 
complimentary DNA or RNA and subsequent hybridisation of primers to the target 
sequence with minimal loss o f enzymatic activity.
The use o f PCR involves a series o f steps. The first of these steps is the synthesis of a 
complimentary DNA copy of the target region o f the RNA genome using reverse 
transcriptase primed by the antigenomic PCR primer. The 5' NCR has been shown to be 
highly conserved and so is the preferred target region for PCR. The concentration of 
virus in serum samples is often very low, so that the mass o f product from the PCR 
reaction is insufficient for visualisation on a stained gel. This necessitates a second round
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of amplification, which utilises Southern hybridisation to detect the primary product. The 
efficiency o f detection o f HCV-RNA is dependent on the conservation of samples, the 
amount of specimen available and the specific primers used.
Amplification of viral nucleic acid by PCR provides a highly sensitive antibody 
independent mode of detecting viral infection and, therefore, has become the gold 
standard in laboratory diagnosis. HCV-RNA occurs in the blood before other markers 
and often within days of infection. Results o f PCR tests for HCV-RNA have been 
compared to those o f antibody tests from second and third generation assays.
In a study carried out in 1991 the PCR-based test was compared to supplementary anti- 
HCV assays (Widell et al., 1991), Ortho anti-HCV (C100-3) ELISA™, Abbot anti-HCV 
(C l00-3) ELISA™, RIBA-1, RIBA-2 and an antibody consumption test referred to as a 
‘neutralisation’ assay. Results confirmed that the presence o f HCV-RNA by PCR 
correlated well with anti-HCV reactivity indicated by the above testing methods. The 
pattern of HCV antibody markers and HCV-RNA during infection is represented in 
Figure lb.
Levels of
Serological
Markers
Infection ► Disease ‘ Recovery  ►
Figure lb. The pattern o f  various H C V  serological, RNA and A LT enzyme markers 
during H C V  infection, disease and recovery (Crivelli, 1991).
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The presence of HCV-RNA detected by PCR has been used in monitoring patient 
response to treatment. In patients undergoing interferon therapy, HCV-RNA 
disappeared from the serum of responders, with persistently normal liver function tests 
checked monthly for 24 months after cessation o f treatment. HCV-RNA was detected 
continuously in the serum of individuals who did not respond to treatment. These 
findings indicate the role o f PT-PCR for monitoring antiviral therapy in chronic HCV 
infection.
The success of PCR for the detection o f serum HCV-RNA has been established, but 
PCR has also detected HCV-RNA in liver biopsy samples from patients with chronic 
hepatitis C and confirmed by Southern blotting (Shieh et al., 1991). The presence of 
minus-strand HCV-RNA has been detected in liver specimens o f chronic hepatitis C 
sufferers, but not in serum samples indicating that HCV-RNA replication predominates 
in the liver. While the detection o f HCV-RNA in liver tissue has succeeded in 
determining the site o f HCV-RNA replication, the role of serum marker assays is 
invaluable as a simple method used for the early detection o f anti-HCV antibodies.
The most accurate way of assessing the severity o f liver damage is by liver biopsy. This 
will establish the activity o f the disease and whether or not permanent damage has 
occurred. Ultasound examination of the liver and CT scan are not reliable to assess liver 
damage. HCV infection affects the liver by causing inflammation leading to death and 
destruction of cells. If  the virus is controlled, inflammation can disappear and the liver 
can regenerate cells. Infection also causes damage by producing fibrosis. Both 
inflammation and fibrosis can be determined by liver biopsy, a biopsy with mild 
inflammation and no fibrosis indicates that progression to severe liver disease is unlikely. 
On the other hand a biopsy with the presence o f fibrosis indicates a likely progression to 
cirrhosis (Shaw, 1999b).
1.6.2 Serological M ethods of Diagnosis
In the previous section, the reactivity of the PCR-based test was compared to that of a 
number o f commercially available anti-HCV screening assays (Figure lb). The routine 
testing for the presence o f anti-HCV antibodies by these methods was described in the 
late 1980’s. The technology used in the development o f these tests is the enzyme 
immunoassay (EIA) and was a successful diagnostic tool for almost 20 years prior to its
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utilisation in the first anti-HCV screening test. This technology and the various types of 
EIA, along with more modern rapid assays will be described in Section 1.7.
1.6.2.1 First Generation Assays
In 1989, the first tests became available and tested for anti-HCV in serum. A 
recombinant C l00-3 antigen was derived in yeast and is specific for antibodies for the 
NS4 region of the viral genome. The captured anti-HCV is then detected by secondary 
anti-human immunoglobulin (IgG) labelled with enzyme (Kuo et a l ,  1989). Screening 
for this anti-C 100-3 greatly reduced the number o f post-transfusion NANBH, up to 60% 
in some countries. This test also detected anti-HCV in approximately 60% o f HCV 
RNA-positive blood donors (Watanabe et al., 1993).
Studies o f anti-C-100-3 kinetics during acute post-transfusion hepatitis suggest that the 
antibody is usually absent during the incubation period and acute phase, becoming 
detectable 2 to 52 weeks after the first liver enzyme elevation (Alter et al., 1990). Not 
all cases o f self-limiting acute hepatitis are detectable by this assay, due to the fact that 
anti-C-100-3 may rapidly disappear or never even reach detectable levels. Anti-C 100-3 
positivity correlates with donor ALT level. Its prevalence was found in high-risk groups 
including intravenous drug users (48-81%) and in patients who had been multiply 
transfused. Anti-C 100-3 was detected in 64-85% o f haemophiliacs who received 
untreated blood or blood products from many donors. Serum anti-C-100-3 correlates 
with HCV-RNA detection in both serum and liver.
Despite the initial success o f this test, problems were observed. A study carried out on 
chronic hepatitis patients showed that false positive results were obtained (Me Farlene et 
al., 1990). This low specificity resulted from the cross reactivity o f human IgG from 
another pathogen or the adhesion of a component to the solid phase resulting in the 
binding o f IgG. It is also believed that multiple freeze-thaw cycles o f stored specimens 
also contributed to the low specificity o f first generation tests (Me Farlene et a l ,  1990).
Contributing to the specificity problem was the intriguing finding of the presence o f anti- 
C-100-3 antibody in the serum o f a high proportion o f patients with autoantibodies, 
particularly in those with antibodies against liver/kidney microsomes and in patients with 
hepatocellular carcinoma (Mishiro et al., 1990). The specificity o f these findings 
suggests that HCV infection significantly affects the host’s immune response.
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1.6.2.2 Second Generation Assays
An attempt was made to increase assay specificity with a second-generation test known 
as recombinant immunoblot assay. This supplementary test increased specificity by 
offering different test conditions and presenting the antigen in a slightly modified form. 
The use o f additional recombinant antigens improved sensitivity compared to that based 
on C100-3 protein alone (Widell et al., 1991). New antigens from the NS3 region (C33c 
protein) and the nucleocapsid (core) region (C22 protein) were used along with the 
C l00-3 antigen, which was expressed in E.coli. These recombinant proteins were 
immobilised on to cellulose strips, and then visualised as discrete bands with 
superoxidedismutase (SOD) used as a control.
The sensitivity and specificity achieved in the second-generation assays presented a great 
improvement over the first generation tests as new HCV infections and positive serum 
specimens were detected earlier by these assays. More than 98% of RNA positive 
samples were detected compared to 60% in first generation tests (Watanabe et a l.,
1993).
1.6.2.3 Third G eneration Assays
The incorporation o f additional antigens to further improve sensitivity and specificity 
formed the basis for the third generation assay. These tests included proteins derived 
from the core, NS3, NS4 and NS5 regions of the genome, as in the Murex Anti-HCV 
(Version III) ELISA®. The Ortho HCV 3.0 ELISA® utilised the antigens C22-3, C200 
expressed as one polypeptide comprising C100-3 and C33c, and NS5 recombinant 
proteins. A more recently developed third generation EIA is the Innogenetics Innotest 
HCV Ab III®. This microtitre plate format boasts optimal coverage of the 
immunodominant HCV epitopes. The use o f these additional proteins allows for earlier 
detection o f seroconversion following HCV infection. The significantly lower sensitivity 
of the first generation assays could be attributed to highly divergent HCV-RNA 
nucleotide sequences that make a single antibody (C l00-3) assay unable to detect.
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1.6.3 Detection of H CV Antigen
Despite the high sensitivity and specificity of these third generation tests they are unable 
to confirm viral infections during periods in the early phase o f infection before the 
production of anti-HCV antibodies (Aoyagi et a l ,  1999). In addition, antibody tests 
cannot distinguish between persons with anti-HCV antibodies who have recovered and 
patients exhibiting an active infection. The detection o f HCV antigen is, therefore, 
necessary. It is detectable as a HCV marker in liver tissues and has been detected 
immunohistochemically using fluorescein isothiocyanate-labelled immunoglobulin G 
(IgG) fractions from sera strongly reactive with recombinant proteins of structural and 
non-structural HCV.
In recent years, methods for detecting viral antigen were developed by applying a 
monoclonal antibody to the HCV core antigen (HCVcAg). This method is reported to 
have a low sensitivity for detecting HCVcAg and required the concentration and 
fractionation o f HCV to detect the antigen. Other such detection methods were reported 
to be useful for monitoring interferon therapy however their low sensitivity and the 
complicated specimen pre-treatment process make it difficult to apply them to the mass 
screening of blood donors. These problems were overcome in a more recent study by 
introducing an efficient specimen pre-treatment method to the EIA for HCVcAg (Aoyagi 
et a l ,  1999). The developed one-step method consists o f a 30-minute incubation of the 
specimen with a solution containing three different types of detergents (Triton X-100, 
CHAPS and sodium dodecyl sulphate). This method sufficiently inactivated the 
interfering anti-core antibody in the sample and the presence o f HCVcAg could be 
successfully detected. This provided an important breakthrough in the early diagnosis 
and monitoring o f HCV infection.
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In recent years, the routine use of immunoassays for the detection and quantitation of 
biologically active substances has become increasingly widespread. The combination of 
sensitivity and specificity offered by immunoassay techniques ensures their use as well- 
established diagnostic tools. There are several known techniques, which can be used in 
immunodiagnostic analysis. Such techniques include enzyme immunoassays (EIA), 
radioimmunoassays (RIA), immunofluorescence assays (IFA) first introduced in the early 
1940’s, blot assays and agglutination assays such as latex, particle and haemagglutinin 
(Coons et al., 1976). The strategy of the EIA consists o f a reaction between the 
immunoreactants, the antibody with the corresponding antigen, and the detection of that 
reaction using enzymes, labelled to the reactants, as indicators.
All immunoassay techniques are based on the same principle involving antibody-antigen 
reactivity; the amount o f complex formed is measured relative to a standard or negative 
sample. The presence o f the complex is determined by fluorescence (IF A), radioactivity 
(RIA) or a substrate colour change (EIA). The technique involves the immobilisation of 
an antibody or antigen onto a solid phase such as a microtitre plate, glass tubes, plastic 
beads or a synthetic membrane.
1.7.1 Application of Protein Coupling and Purification in Im m unoassay
Proteins have evolved in nature to carry out a remarkable variety o f functions, many of 
which are complex interactive roles of subtlety and specificity. This evolutionary process 
has resulted in proteins, which offer a high level o f performance where a huge number of 
molecules exist; the human genome alone is thought to code for between 30,000 and 50,000 
different proteins (Aslam and Dent, 1998).
One of the main features o f a protein’s behaviour is its ability to form complexes with other 
molecules. More often, the more useful applications have resulted from the coupling of 
proteins to these molecules or to a second protein. The complex formed is termed a 
conjugate, in the case where both partners are soluble molecular species. Fields such as
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clinical diagnostics and immunology rely on the use of these coupled protein reagents for 
successful protein applications.
Immunoassay antibody-antigen interactions can be measured by coupling proteins to labels 
forming conjugates, which can be read by fluorescence, luminescence or another suitable 
detection method. Over the last few years, two improved methods o f signal generation have 
been achieved which use DNA fragments as the label (Aslam and Dent, 1998). In the first 
in 1995, detection is subsequently achieved by employing the label to express a 
luminescence-catalysing enzyme and in the second, also in 1995, the product o f PCR 
amplification o f the label is detected by staining after gel electrophoresis.
The application o f protein-protein coupling in ELISA techniques produces a colourimetric 
end-point that can be measured by simple cheap instrumentation, which is readily available 
in most laboratories. The enzymes used in ELISA assays should be stable and pure, as 
performance characteristics are dependent on the reaction parameters o f the 
immunoreagents.
1.7.2 Enzyme-linked Immunosorbent Assays
In 1971, the enzyme-linked immunosorbent assay (ELISA) was first described 
(Avrameas and Guilbert, 1971; Engvall and Perlmann, 1971; Van Weeman and Schuurs, 
1971). It incorporates similar features to the IFA and RIA but offers many advantages 
over these older techniques. These advantages are achieved by substituting the 
radioactive isotope o f the RIA or the fluorochromes of the IFA with an enzyme as a label 
in the immunoassay. Several enzymes, including alkaline phosphatase, horseradish 
peroxidase, glucose oxidase and glucoamylase have been coupled to antigen or antibody 
by the use o f glutaraldehyde, sodium periodate or by other procedures.
The EIA relies on the extremely high catalytic power and specificity o f enzymes, which 
are usually detectable with great ease thus allowing the quantitation o f small amounts of 
enzyme. Enzymatic activity is quantified in a simple fashion such as spectrophotometry. 
The ELISA is a highly sensitive procedure in which a nanogram or lesser amounts of 
antigen or antibody can be accurately quantitated. The advantages of the ELISA over 
the older methods o f RIA and IFA are outlined in Table lc.
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Enzyme Immunoassays (EIA)
RIA and IFA
Very high sensitivity, detectability, and
specificity are possible
Relatively cheap standard laboratory
equipment is required
Reproducibility is high and evaluation is
objective
No radiation hazards
Reagents are relatively cheap and 
generally o f longer shelf life 
Easy disposal o f  waste products
Relatively high specificity and lower 
detectability levels.
Expensive equipment is required to 
measure radioactivity and fluorescence 
Relatively similar reproducibility.
They represent potential health hazards and 
RIA often requires licensing.
Reagents have a short shelf-life.
Necessitates special disposal o f radioactive 
wastes.
Table lc. Comparison o f EIA with RIA and IFA as immunoassay techniques; 
advantages and disadvantages o f the techniques.
The aforementioned serological methods o f diagnosis utilise this ELISA technology. 
Third generation assays such as the Ortho HCV 3.0 ELISA™, and the Murex Anti-HCV 
(Version III) ELISA are currently used worldwide for the detection of anti-HCV 
antibodies in human serum and plasma. The features which benefit these ELISA tests 
over molecular methods o f diagnosis such as PCR-based methods include speed and 
simplicity o f sample preparation, the use o f standard laboratory equipment, cost saving, 
time saving and clear interpretation o f results.
The use o f ELISA tests also reduces the likelihood of sample contamination, which often 
occurs with the PCR-based method. The reagents used in these ELISA assays are safe 
and relatively inexpensive with a long shelf-life. Microtitre plates offer the advantage of 
simultaneous analysis o f many samples. ELISA has shown sensitivity greater than 
agglutination assays and equal to RIA tests while being safer tests to carry out.
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1.7.3 ELISA A ssay Types
There are five main types o f ELISA tests used in immunodiagnostics, all incorporating 
the formation of antigen-antibody interactions. They include the indirect ELISA (Figure 
1.7.1), the double antibody sandwich ELISA (Figure 1.7.2), the competitive ELISA 
(Figure 1.7.3), the double-antigen sandwich assay (DAGS) (Figure 1.7.4) and the class- 
specific antibody capture assay (Figure 1.7.5). The anti-HCV ELISA described in the 
previous section is an example o f an indirect ELISA. The different ELISA types and are 
now described and employ following drawing keys as shown below.
Microtitre plate well Specific antigen
*  0  
Specific antibody Capture antibody
E .
Enzyme conjugate label Substrate reagent
Anti-human IgG antibody Total class antibody
1.7.3.1 Indirect ELISA (Figure 1.7.1)
This is used mainly where the analyte is serum antibody as in the anti-HCV assay. The 
microtitre well is coated with purified antigen or recombinant or synthetic proteins. The 
test specimen is incubated on the coated wells, any antibody present forming a complex 
with the immobilised solid phase antigens. Following a wash step, a conjugate 
containing labelled anti-species immunoglobulin (IgG or IgM) is then added to the plate. 
Unbound conjugate is washed away and the complex formed is developed with an 
appropriate substrate. The measured amount is proportional to the quantity o f specific 
antibody present. Such a test is represented by the Innogenetics Innotest HCV Ab HI® 
Assay.
1. Antigen coated 
onto microwell
E E S
4. Substrate forms 
a complex with 
enzyme
Add sample
Wash.
Add Substrate
2. Specific antibody 
binds to antigen
A A. Wash, Add enzyme
E—r i?-HE
A
m
3. Enzyme-labelled 
anti-IgG binds 
antibody
Figure 1.7.1. Indirect ELISA assay protocol
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1.7.3.2 Double Antibody Sandwich ELISA (Figure 1.7.2)
This format involves the capture o f the analyte, the antigen, between two specific 
antibodies. One purified antibody is coated on to the microtitre well and the test sample 
incubated. A wash step then removes unbound sample and the well is incubated with 
anti-species secondary antibody labelled with enzyme. After washing, the Ab-Ag-Ab- 
conjugate complex is incubated with substrate and the developed colour indicates the 
quantity of antigen present in the test sample. The Trinity Biotech Rotavirus™ EIA 
represents such a test.
1. Antibody coated 
onto microwell
E
E
E
E
4. Substrate forms 
a complex with 
enzyme
Add sample Wash.
Add Substrate
2. Specific antigen 
binds to antibody
Wash, Add enzyme
3. Enzyme-labelled 
specific antibody 
binds to antigen
Figure 1.7.2. Double Antibody Sandwich ELISA assay protocol.
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1.7.3.3 Competitive ELISA (Figure 1.7.3)
The first EIA described belonged to this group. The principle behind this test differs 
from the sandwich assay and the indirect assay. Unlike those tests, the development of 
colour in a competitive assay is indirectly proportional to the quantity o f analyte in the 
sample. The wells are coated with antibody and simultaneous incubation o f free antigen 
in the sample and enzyme-labelled antigen results in competition of sample and conjugate 
for reactive sites on the solid phase. Since a restricted number o f antibodies are available 
the enzyme activity is lowered. The development of colour upon substrate incubation 
indicates the binding o f conjugate rather than positive sample and so a negative sample is 
interpreted. The Trinity Biotech Osteocalcin EIA™ Test is an example o f a competitive 
assay.
1. Antibody coated 
onto microwell
Add sample and 
enzyme-labelled antigen
V /
2. Free antigen and enzyme-labelled 
compete for binding sites on the 
bound antibody
Wash. Add substrate
^ .. S S
E\
No enzynie-substrate Complex formed
complex-No colour -Colour visible
' ' I
N /
Positive Sample Negative sample
Figure 1.7.3. Competitive ELISA assay protocol.
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1.7.3.4 Double-Antigen Sandwich Assay (DAGS) (Figure 1.7.4)
The double-antigen sandwich assay has recently been introduced as a format, which enables 
the detection o f all classes o f antibodies generally not detected by the indirect (anti-gamma 
globulin) format (Burgisser et al., 1999). As in the case o f the indirect assay (Figure 1.7.1), 
the microtitre well is coated with purified recombinant protein or antigen. All classes of 
specific antibody present in the test sample is bound to the immobilised antigen during the 
first incubation. Unbound material is removed by washing the wells and during the second 
incubation step bound antibodies are labelled with specific antigen-peroxidase conjugates. 
After a second washing step, the fraction o f bound enzyme is determined by a chromogenic 
reaction. The intensity o f colour is proportional to the presence of all classes of specific 
antibody in the sample. An example o f such a test is the Orgenics HIV 1 &2 DoubleCheck™ 
rapid EIA.
1. Antigen coated 
onto microwell
4. Substrate forms 
a complex with 
enzyme
Add sample
| /N |
2. Specific antibody 
binds to antigen
Wash, Add enzyme
Wash,
Add Substrate
E. E
E—
>— -<f
—E 3. Antigen-labelled 
peroxidase bind 
with antibody
Figure 1.7.4. Double Antigen Sandwich ELISA assay protocol (DAGS).
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This format is used to capture antibodies in a test sample, specific for an immunoglobulin 
class required. Plates are coated with capture antibodies (anti-IgG, IgM or IgA). The test 
antibody solution is then incubated on the coated wells and the total IgG, IgM or IgA 
antibody present in the sample is bound to the coated anti-immunoglobulin. A wash step 
removes all unbound material prior to a second incubation with specific antigen, which binds 
to any specific antibody bound to the solid phase. Following a further washing step is 
incubation with specific antibody conjugated to peroxidase. The colour intensity on addition 
of chromogenic substrate is proportional to the quantity o f specific class antibody present in 
the test specimen. An example of a class-specific HCV IgM assay was developed in 1997.
1.7.3.5 Class-Specific Antibody Capture Assay (Figure 1.7.5)
E \ / v / E
1. Capture antibody coated 
onto microwell
4. Substrate forms 
a complex with 
enzyme
Add sample Wash,
Add Substrate
E-
2. Total class antibody
binds to bound anti-globulin
Wash, Add antigen and enzyme
E
~E
3. Labelled specific 
antibody and antigen 
bind to bound antibody
Figure 1.7.5. Class-Specific Antibody Capture ELISA assay protocol.
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1.7.4 Rapid Technology
The need for simple, rapid and inexpensive diagnostic tools prompted the development, 
globally, o f a range o f new products. These rapid formats follow the same basic 
antibody-antigen interaction principle as the ELISA technique but differ in the nature o f 
the solid phase and in the technology used for antigen or antibody detection.
1.7.4.1 Agglutination Reactions
An agglutination reaction occurs when antibody molecules combine with particulate 
antigens. The most commonly used particulate antigens are whole bacteria or red cells. 
Because o f the great sensitivity o f agglutination reactions, many soluble antigens have 
been placed on red cells or inert particles. These passively coated cells or particles 
agglutinate in the presence of specific antibody. Such inert particles are in the form of 
polystyrene latex beads in the case o f the Cambridge Biotech CAPILLUS ~HIV-1/HIV-2 
Assay. This test employs the use o f H IV -1 and HIV-2 polypeptides, which have been 
expressed and purified. These proteins are bound to polystyrene latex beads to form the 
basis of the direct latex agglutination assay for the detection of HIV-1 and HIV-2 
antibodies.
The latex reagent and the test sample are mixed together on a thin flat slide and are 
drawn through the flow channel by capillary action. Samples, which are positive and 
contain antibodies to HIV, cause the antigen-coated latex to agglutinate. This capillary 
action enhances the binding of the specific antibodies to the latex, which promotes 
aggregation. The reaction is then read visually or with the use of a digital reader once 
the latex solution reaches a viewing window on the slide. A smooth appearance is 
considered non-reactive or negative whereas a clumpy aggregated solution indicates a 
positive result. This is a fast, effective and easy to use test.
1.7.4.2 Precipitation Reactions
When a soluble antigen and it’s specific antibody are in contact in solution, the resultant 
antibody-antigen complexes may become insoluble and precipitate (White, 1978). The 
precipitation rate depends on the on the proportions o f the reactants and on the 
temperature, salt concentration and to some extent, the pH o f the solution.
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The precipitation reaction can be induced by mixing antigen and antibody in test tubes or 
in Lang-Levy pipettes (White, 1978). It can also be obtained by carefully overlaying one 
reactant with the other in a narrow test tube so that diffusion can take place. The 
antibody-antigen interaction is then visible as a precipitation ring at the liquid surface. 
The Swift-Wilson-Lancefield precipitation test combines these techniques and is 
performed in capillary tubes. Precipitation is observed at the interface and also in the 
lower part o f the tubes. A precipitation reaction will take place when antigen and 
antibody are allowed to diffuse in gels.
1.7.4.3 Lateral Flow [inmunocliromatography
This format involves the adhesion of antibody, antigen or recombinant protein onto a 
solid phase porous membrane in a technique known as immunochromatography. It is 
used in the detection o f viral antibody and antigen and is a rapid, simple method, which 
does not require the use o f laboratory equipment. Its speed and simplicity offers 
advantages over other methods of analysis without compromising test sensitivity and 
specificity. Lateral flow tests such as the Trinity Biotech HIV 1/2 SeroCard® utilises an 
enzyme-labelled conjugate but these tests may employ gold conjugates, latex tests as 
manufactured by Quidel or carbon tests from Medix Biotech.
In recent times many diagnostic test kits became commercially available utilising the 
principles o f immunochromatography. The first major target analyte for this test format 
was human chorionic gonadotropin (hCG) for the detection o f pregnancy. This was 
followed by tests for detecting a wide range o f analytes amongst which were luteinizing 
hormone (LH), Streptococcus, Chlamydia. Tests for better known infectious diseases 
were also developed including human immunodeficiency virus (HIV), as described in the 
Orgenics HTV 1&2 DoubleCheck™ rapid EIA, Hepatitis B antibody and antigen, as 
described in Chembio’s Hepatitis B Stat-Pak™ rapid immunochromatographic assay for 
the detection of HBsAg, and also tests for Hepatitis C virus as described at a later stage.
The Uni-Gold™ HBsAg test utilises the principle o f lateral flow. It is a rapid 
immunochromatographic test for the presence of hepatitis B surface antigen (Figure lc). 
The method employs a combination o f antibody-dye-conjugate, in this case colloidal 
gold, and solid phase antibodies specific to HBsAg. A conjugate pad is impregnated
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with the colloidal gold-conjugated antibodies but they remain unbound to the pad. The 
sample flows through this absorbent pad during which time the labelled antibody binds to 
HBsAg if present. The conjugate is solubilised and the complex then passes on to a 
chromatrographic membrane strip, Specific antibodies are immobilised on to a region of 
this strip known as the test line and are referred to as capture antibodies.
Test Line Absorbent Pad
I  /
___________________________________________ ; I I
t t
Conjugate Pad Control Line
Figure lc. Uni-Gold™ HBsAg test, a rapid, colloidal gold-based assay fo r detection 
of HBV surface antigen, is an example o f lateral flow  immunochromatography-a 
positive result is interpreted by colour on the test line along with the control line.
As the antigen-antibody complex moves along the strip, a line of immobilised complex 
forms on the test line. A control line is included in the test device, which consists o f 
immobilised anti-gold antibodies. Any unbound colloidal gold will flow up the 
membrane and form a control complex. In both cases the results are interpreted visually 
by the appearance of a line o f colour at the test line and the control line.
An example o f an HCV-specific lateral flow test is the Innogenetics INNO-LIA HCV Ab 
III® test. It is a third generation line immunoassay consisting of a nylon strip coated with 
recombinant proteins and antigens specific for immunodominant HCV epitopes. It is 
used in the confirmation and differentiation o f antibodies to HCV. A phosphatase- 
labelled conjugate detects the specific antibodies, which are represented as bands on the 
strip. The results can be determined visually.
1.7.4.4 Vertical Flow Iinniunochrom atograpliy
In certain chromatrographic tests the flow o f the sample and antibody-antigen complexes 
occurs vertically. The Orgenics ImmunoComb®II H.pylori test is an example o f such a 
test. The solid phase consists of a comb with projections, sensitised with antibodies to
Sample Pad
V
human IgG on an upper spot and H. pylori antigens on a lower spot. A plate contains 
ready-to-use reagents for each stage of the test. Upon sample incubation H. pylori 
antibodies present in the sample bind to the specific antigens on the lower spot. 
Simultaneously, any IgG will bind to the anti-human IgG on the upper spot to act as a 
control. In the next step, captured anti-H pylori IgG will react with anti-human IgG 
alkaline phosphatase (AP), which is present in the plate. The bound AP then reacts with 
chromogenic components. The results are visible as grey-blue spots on the surface of the 
ImmunoComb.
1.7.4.5 Flow-Through Iinmunochroimitograpliy
The Cambridge Biotech Recombigen® HIV-l/HIV-2 Rapid Test Device (RTD) is an 
example of an assay in which the sample and test reagents flow through the test device. 
It is an indirect assay utilising recombinant proteins representing the immunodominant 
regions o f HIV-1 and HIV-2. These recombinant antigens are separately coated onto 
microlatex particles and each is impregnated on the membrane surface of the device in 
separate spots (Figure Id). A HIV-l/HIV-2 procedural control is also impregnated onto 
the membrane.
Figure Id. Recombigen ™ HIV 1/2 RTD device is an example o f  
flow-through immunochromatography.
Diluted patient samples are applied to the device, which flow through the latex particles 
on the membrane surface. Antibodies to the virus, if present, bind to the antigen-coated 
latex particles. Enzyme-labelled, anti-human antibodies are added to the device and
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allowed to flow through the membrane. A wash step removes unbound conjugate and 
the addition o f substrate solution produces a blue dot, indicating the presence o f H IV -1 
and/or HIV-2 antibodies. The plastic housing as shown in Figure li contains an 
absorbent reagent reservoir.
1.7.5 Proposed Development of anti-HCV Antibody Tests
Both the microtitre plate assay and the rapid membrane-based assay are examples o f the 
indirect assay, described in Figure lc. The development o f both assays followed a similar 
method and started with evaluation o f peptides for use on the solid phase. This was 
done by testing with characterised sera. When an initial solid phase was chosen a 
number o f different parameters were investigated. These included evaluation o f enzyme 
conjugate dilution, enzyme conjugate diluent, sample dilution and incubation times of 
various stages o f the assay.
During development, initial performance was evaluated with clinical samples o f known 
status. Upon optimisation of tests, clinical trials were carried out to assess the 
performance of both tests off-site. The assay protocol used for both the microtitre plate 
test and the rapid test are outlined in section 1.7.5.1 and 1.7.5.2.
1.7.5.1 ELISA Test Development
The proposed method for the development o f a qualitative microtitre plate assay follows 
the following protocol. The microwells are coated with purified antigens or recombinant 
proteins containing sequences from the various regions of HCV. During the first 
incubation at optimal temperature any specific anti-HCV antibody binds to the solid 
phase forming an antigen-antibody complex.
A washing step removes any unbound specimen and a second incubation with an 
enzyme-labelled anti-human IgG conjugate detects the presence, if  any, o f captured 
antibody. An antigen-antibody-anti-human antibody-enzyme complex is formed. A 
further washing step removes excess conjugate and is followed by incubation with a 
suitable substrate. Quantitation is based on a colour change relative to a negative 
control, the formation o f colour being directly proportional to the presence of specimen
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antibody. The reaction is stopped with an acidic agent and the interpretation is achieved 
visually or using a spectrophotometer.
1.7.5.2 Rapid Test Development
Another form o f lateral flow membrane technology is used in the development of a rapid 
test for antibodies to HCV. The porous nature of this solid phase membrane necessitates 
the need for an additional step prior to adhesion of antigen to the membrane. The 
antigen is immobilised in carrier-bound form, the peptide coupled to a high molecular 
weight protein such as bovine serum albumin (BSA). A combination o f carriers may be 
used provided the carrier does not interfere with the ability o f the peptide to bind 
antibodies. This allows the adhesion o f low molecular weight peptides and antigens to 
the porous membrane. The carrier-peptide complex is purified prior to immobilisation to 
the solid phase (Figure le).
The first step in the test is the addition o f test sample to the membrane at the sample 
ports. The sample flows up the membrane to the reaction site where the immobilised 
antigen forms a complex with any antibody present in the sample.
Control Sitc-
HCV Test Card
>o o*
O O
Site of peptide
Sample ports
Figure le. HCV rapid SeroCard test device showing the site o f  bound peptides during 
spotting and o f test specimen during assay procedure.
A wash step removes unbound sample prior to the incubation o f an anti-human IgG 
labelled conjugate. This test does not involve coupling of antibody to latex or colloidal 
gold to form a conjugate. Following another wash step to remove free conjugate an 
appropriate substrate is added to the membrane and the resulting colour is read visually. 
The intensity o f the colour is directly proportional to the quantity o f antibody present in 
the test sample.
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Section 2
Materials and 
Methods
2.1 Raw Material Suppliers
2.1.1 Chem icals and Raw M aterial Suppliers
Table 2.1 outlines, in alphabetical order, the suppliers o f the chemicals and raw materials
used in the development o f both the microtitre plate assay and the rapid assay.
Supplier Address
Alex Mitchell 
Plastics
Unit 5, IDA Estate, East Wall Road, Dublin 3, 
Ireland
Biosynth AG Rietlistr, 4, Postfrach 125, Staad 9422, 
Switzerland
Boston Biomedica, 
Inc.
375, West street, W. Bridgewater, MA 02379, 
United States o f America
Cork Blood Bank St. Finbarr’s Hospital, Cork, 
Ireland
Dako Denmark House, Angel Drove, Ely, Cambridgeshire, CB74ET, 
United Kingdom
Eurodiagnostica Idoen SE-205, 12 Malmo, 
Sweden
Genzyme 50 Gibson Drive, West Mailing, Kent, ME 19 GHG, 
United Kingdom
Gibco BRL c/o Life Technologies Ltd., P.O. Box 35, 3 Fountain Drive, 
Inchinnan Business Park, Paisley PA4 9RF,
United Kingdom
Hi-Tech Products 8530 Roland St, Buena Park, CA 90621, 
United States o f America
International 
Enzymes Inc.
c/o Aalto Bio Reagents Ltd., 14 Main Street, Rathfarnham, Dublin 
14, Ireland
Kirkegaard and 
Perry Laboratories
2 Cessna Court, Gaithersgury, Maryland, 
United States o f America
Lennox
Laboratories
JFK Drive, Naas Road, Dublin 12 
Ireland
NUNC
Incorporated
2000 North Aurora Road, Naperille, Illinois 60566, 
United States o f America
Pro-Pac Ltd. Unit 4, Turnpike Industrial Estate, Ballymount, Dublin 22, 
Ireland
Riedel de Hein c/o R.B. Chemicals Ltd., Hoechst House, Cookstown Industrial 
Estate, Tallaght, Co. Dublin
Safe-Pak Dunboyne Industrial Park, Dunboyne, Co. Meath, 
Ireland
Silgelac 171 Avenue Georges, Clemenceu 92024, Nan Terro, Cedex, 
France
Sigma Aldrich Airton Road, Tallaght, Dublin 24, 
Ireland
Table 2.1.List o f suppliers o f raw materials fo r  use in the ELISA and rapid assays
2.2 Materials Used in ELISA Test
2.2.1 Chem icals used in ELISA Test
Chemical Supplier Cat. No. G rade
Bovine Serum Albumin Sigma A-7030 Minimum 98%
Cytochrome C (from Horse Heart) Sigma C-7752 Minimum 95%
Hydrochloric Acid (Cone.) Sigma H-7020 ACS Reagent
Sodium Azide Sigma S-2002 Minimun 99.5%
Sodium Carbonate RdH S-6139 ACS Reagent
Sodium Chloride Sigma S-7653 Sigma Ultra
Sodium Hydrogen Carbonate RdH 31437 ACS Reagent
di-Sodium Hydrogen Phosphate RdH 30435 Reagent
Sodium di-Hydrogen Phosphate RdH 04269 Extra Pure
Sodium Hydroxide (Pellets) Sigma S-0899 ACS Reagent
Sucrose Sigma S-5016 ACS Reagent
Sulphuric Acid RdH S-1526 ACS Reagent
Tetra Methyl Benzidine (TMB) Dako SI 599 Reagent
Thimerosal Sigma T-5125 Minimun 95%
Trizma Base Sigma T-1503 Reagent Grade
Trizma Hydrochloric Sigma T-3253 Reagent Grade
Triton X -100 Sigma X-100 Laboratory Grade
Polyoxyethylenesorbitan 
Monolaurate (Tween 20)
Sigma P-1379 Reagent Grade
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2.2.2 Buffers and Reagents used in ELISA Test
0 .1M lx Phosphate Buffered Saline* nH 7.2
Sodium Chloride 8.7g
25X Phosphate Buffered Saline 40ml
Sodium Azide 0.5g
1M Sodium Hydroxide as required
1M Hydrochloric Acid as required
Adjusted to pH 7.2 ± 0.1 and made to 1000ml with deionised water
0.1M 25X Phosphate B n flem l Saline (PBS)
Potassium Phosphate Monobasic 2.72g
Potassium Phosphate Dibasic 27.9g
1M Sodium Hydroxide as required
1M Hydrochloric Acid as required
Adjusted to 1000ml with deionised water and adjusted to pH 7.8 ± 0.2
1M Sodium Hydroxide
Sodium Hydroxide 40g
Deionised Water 1000ml
1M Hydrochloric Acid
Hydrochloric Acid (Cone) 83 ml
Deionised Water 917ml
EIA Blocking Buffer
Sucrose 50g
Bovine Serum Albumin 5g
Adjusted to 1000ml with Carbonate Coating Buffer
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Sodium Chloride 198.69g
Tris Base 60.57g
Tween 20 25ml
Thimerosal O.lg
Hydrochloric Acid (Cone) as required
1M Sodium Hydroxide as required
Adjusted to 1000ml with deionised water and adjusted to pH 7.4 ± 0,2
C arbonate Coating Buffer
Sodium Carbonate 1.22g
Sodium Hydrogen Carbonate 3 ,22g
Thimerosal O.lg
1M Hydrochloric Acid as required
1M Sodium Hydroxide as required
Adjusted to pH 9.6+0.1 and made tolOOOml with deionised water
Sample Diluent
10X Tris Buffered Saline 100ml
Bovine Serum Albumin 50g
Bovine Gamma Globulin lOg
Thimerosal O.lg
Goat Serum (Heat Inactivated) 50ml
Adjusted to 1000ml with deionised water 
IX W ash Reagent
25X Tris Wash Reagent 40ml
Deionised Water 960ml
25X Wash Reagent
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IPX Tris Buffered Saline
TrisHCl 117.2g
Tris Base 31,06g
Sodium Chloride 87.65g
Hydrochlorc Acid (Cone) as required
1M Sodium Hydroxide as required
Adjusted to pH 7.2 -7.5 and made to 1000ml with deionised water
Enzyme Conjugate Reagent
Triton X -100 0.5ml
Foetal Bovine Serum 100ml
Goat anti-human IgG-HRP Conjugate as required
Cytochrome C Conjugate Diluent 899.5ml
Cytochrome C Conjugate Diluent
di-Sodium Hydrogen Phosphate 17.8g
Sodium di-Hydrogen Phosphate 15 6g
Bovine Serum Albumin 5g
Cytochrome C 0.25g
Thimerosal O.lg
Adjusted to pH 6.6+0.1 and made to 1000ml with deionised water
4N Stopping Reagent
Sulphuric Acid 108.75ml
Deionised Water 891.25ml
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2.2.3 Raw M aterials and Equipment used in ELISA Test 
Raw M aterials
96-Well Plates NUNC Inc.
lg  Indicating Desiccant Silgelac
Ziplock Foil Pouch Safe-Pak
Plate Sealers Kennilworth
Eauinm ent Used in Plate C oatine
Multi-Channel Pipettes, 50-300(0.1 Eppendorf
Single-Channel Pipettes, 2-20p,l, lO- lOOOjil Eppendorf
Multidrop Plate Coater Labsystems
ELx50 Auto-Strip Washer Bio-Tek Instruments
MR 5000 Plate Reader Dynatech
LX-850 Printer Epson
A dditional Eauipm ent
pH Meter 245 Corning
PM 400 Balance and LC-P45 Printer Mettler Toledo
HR60 AND Analytical Balance Mettler Toledo
AD1311 Printer Mettler Toledo
Laminar Air Flow Cabinet NU-425-600E Nuaire
Incubating Chambers D-6450 Heraeus Instruments
Waterbath Grant
Magnetic Stirrer SM 1 Stuart Scientific
Peristaltic Filtering Pump 313S Watson Marlow
Hotplate Magnetic Stirrer 34532 Snijders
Autovortex Mixer SA2 Stuart Scienfic
Autoclave SAL Type UCC 16 MP 6D1
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2.3 Materials Used in Rapid Test
2.3.1 Chemicals used in Rapid Test
Chemical Supplier Cat. No. G rade
Amino-methyl-propanal (AMP) Sigma A-6518-2 Minimum 95%
BCIP Biosynth AGB-7500 Minimum 99.2%
Bovine Gamma Globulin (BGG) Sigma G-5009 99% Purity
Bovine Serum Albumin (BSA) Sigma A-7030 Minimum 98%
Casein Lennox 440202C Reagent
Glutaraldehyde 25%(v/v) Sigma G-5882 Grade 1
Hydrochloric Acid (Cone) Sigma H-7020 ACS Reagent
Imidazole Sigma 1-0125 99% Purity
Magnesium Chloride Sigma M-9272 ACS Reagent
Potassium Phosphate, (Dibasic) Sigma P-3786 ACS Reagent
Potassium Phosphate, (Monobasic) Sigma P-5379 Minimum 99%
Sephacryl S-200 Gel Pharmacia 17-0584-01 Reagent
Sodium Azide Sigma S-2002 Minimum 99.5%
Sodium Chloride Sigma S-7653 Sigma Ultra
Sodium Cyanoborohydride Sigma S-8628 Minimum 90%
Sodium Hydroxide (Pellets) Sigma S-0899 ACS Reagent
Sucrose Sigma S-5016 ACS Reagent
Thimerosal Sigma T-5125 Minimum 97%
Trizma Base Sigma T-1503 Reagent
Trizma Hydrochloric Sigma T-3253 Reagent
Triton X-405 Sigma X-405 70% Aqueous
Zinc Chloride Sigma Z-3500 ACS Reagent
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2.3.2 Buffers and Reagents used in Rapid Test
0.1 [VI Ix Phosphate Buffered Saline, n il 7.2 (Column Elution Buffer)
Sodium Chloride 8.7g
25X Phosphate Buffered Saline 40ml
Sodium Azide 0.5g
1M Sodium Hydroxide as required
1M Hydrochloric Acid as required
Adjusted to pH 7.2 ± 0.1 and made to 1000ml with deionised water
O.IM 2SX Phosphate Buffered Saline (PBS)
Potassium Phosphate Monobasic 2.72g
Potassium Phosphate Dibasic 27.9g
1M Sodium Hydroxide as required
1M Hydrochloric Acid as required
Adjusted to 1000ml with deionised water and adjusted to pH 7.8 + 0.2
1M Sodium Hydroxide
Sodium Hydroxide 
Deionised Water
1M Hydrochloric Acid
Hydrochloric Acid (Cone) 83ml
Deionised Water 917ml
2X Phosphate Buffered Saline (PBS)
Sodium Chloride 8.7g
25XPBS 80ml
Deionised Water 960ml
40g
1000ml
Control Dilution Buffer
10X Tris Buffered Saline (TBS) 100ml
Bovine Serum Albumin 50g
Bovine Gamma Globulin 10g
Thimerosal O.lg
Adjusted to 1000ml with deionised water
IPX T ris Buffered Saline
TrisHCl 117.2g
Tris Base 31.06g
Sodium Chloride 87.65g
Hydrochlorc Acid (Cone) as required
1M Sodium Hydroxide as required
Adjusted to pH 7.2 -7.5 and made to 1000ml with deionised water
Blocking Buffer
25X PBS 40ml
Sucrose 20g
Sodium Chloride 8.7 5 g
Casein 7.5g
Triton X-405 0.5ml
Thimerosal O.lg
Adjusted to 1000ml with deionised water
1M Magnesium Chloride with Azide
Magnesium Chloride 203.3g
Sodium Azide lg
Adjusted to 1000ml with deionised water
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10XTBS 100ml
Bovine Serum Albumin 20g
1M Magnesium Chloride with Azide 1ml
0 .1M Zinc Chloride with Azide 1ml
Sodium Azide 0.95g
Goat anti-human IgG Aik. Phos. as required
Hydrochloric Acid (Cone) as required
1M Sodium Hydroxide as required
Adjusted to pH 7.4±0.1 and made to 1000ml with deionised water
Enzyme Conjugate Reagent
0.1M Zinc Chloride with Azide
Zinc Chloride
Sodium Azide 
Deionised Water
13.6g
0.095g
1000ml
W ash Reagent
Imidazole 
Sodium Chloride 
Sodium Azide 
Casein
Hydrochloric Acid (Cone)
13.6 lg
8.77g
0.95g
7-5g
1.83ml
Adjusted to pH 7.6-8.4 and made up to 1000ml with deionised water
1M Magnesium Chloride 
Magnesium Chloride 
Thimerosal
Adjusted to 1000ml with deionised water
52
203.3g 
O.lg
Substrate Reagent
AMP 96ml
Hydrochloric Acid (Cone) 48ml
1M Magnesium Chloride 1ml
Sodium Azide 0.95g
BCIP lg
5N Sodium Hydroxide as required
Adjusted to pH 9.8±0.1 and made to 1000ml with deionised water
5N Sodium Hydroxide
Sodium Hydroxide Pellets 200g
Adjusted to 1000ml with deionised water
2.3.3 Biological Components used in ELISA and Rapid Tests
Component Supplier C at No. G rade
HCV Core peptide Eurodiagnostica N/A N/A
HCV 52 (NS4) peptide Eurodiagnostica N/A N/A
HCV 15 (Core) peptide Eurodiagnostica N/A N/A
HCVNS3 peptide Eurodiagnostica N/A N/A
HCV NS5 peptide Eurodiagnostica N/A N/A
E47 (Envelope) peptide Eurodiagnostica N/A N/A
E 51 (Envelope) peptide Eurodiagnostica N/A N/A
MS94-23 (Core) peptide Eurodiagnostica N/A N/A
PS9401-1 (NS3) peptide Eurodiagnostica N/A N/A
PS9401-2 (NS3) peptide Eurodiagnostica N/A N/A
PS9401-12 (NS3) peptide Eurodiagnostica N/A N/A
PS9307-8 (NS5) peptide Eurodiagnostica N/A N/A
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PS9307-9 (NS5) peptide Eurodiagnostica N/A N/A
NS4a peptide Eurodiagnostica N/A N/A
NS3 Recombinant Protein Eurodiagnostica N/A N/A
Goat anti-human IgG-AP Genzyme RIA 4334 Affinity
conjugated Purified
Goat anti-human IgG-HRP KPL Laboratories 074-1002 Affinity
conjugated Purified
Goat Serum Gibco BRL 16210-072 Mycoplasma
Screened
Foetal Bovine Serum Gibco BRL 10108-165 Mycoplasma
Screened
HCV-Positive Serum IE1 2017 N/A
Boston Biomedica PHV901 N/A
HCV-Negative Human Serum Cork Blood Bank N/A N/A
2.3.4 Equipment and Raw M aterials used in Rapid Test
Assembled Cards
Moulded 2-position Test Cards 
Cut Absorbent Pads 
Glass Cut Membrane 
White Backing Label 
0.25g Indicating Desiccant 
Foil Pouch
Equipment Used in Card Spotting
Card Spotter Model 1 JVADGS001-2 
Card Blocker Model 1JVADGB001-2 
Robotics Pouchmaster XII 
Vacuum Chamber Z696
Alex Mitchell Plastics 
Hi-Tech Products 
Hi-Tech Products 
Hi-Tech Products 
Silgelac 
Pro-Pak Ltd
JV&A Design Group 
JV& A Design Group 
About Packaging 
Severn Science
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Equipment Used in Conjugation o f Peptide
Concentration Units B15
Sprectrophotometer UV/VIS 6105
Conjugation System consisting of 
LKB Pump P-l 
LKB Optical Unit 
LKB Control Unit 
LKB Redifrac (Fraction Collector) 
LKB REC 101 (Chart Recorder)
Additional Equipm ent 
pH Meter 245
PM 400 Balance and LC-P45 Printer 
HR60 AND Analytical Balance 
AD1311 Printer
Laminar Air Flow Cabinet NU-425-600E 
Incubating Chambers D-6450 
Waterbath
Magnetic Stirrer SM 1
Peristaltic Filtering Pump 313S
Hotplate Magnetic Stirrer 34532
Autovortex Mixer S A2
Autoclave SAL Type UCC 16 MP 6D1
0.2|nm filters to filter reagents as necessary
Clean, dry glassware
Syringes
Latex gloves
Face masks
Safety glasses
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Amicon Inc.
Jenway
Pharmacia Biotech
Corning 
Mettler Toledo 
Mettler Toledo 
Mettler Toledo 
Nuaire
Heraeus Instruments
Grant
Stuart Scientific 
Watson Marlow 
Snijders 
Stuart Scienfic
2.4 Methods Used in ELISA Test
2 .4 .1. Coating of Peptide onto M icrotitre Wells
This procedure bound the peptides for evaluation on to the plastic wells o f the
microtitre plate for use as the solid phase
1) At a chosen coating concentration, the peptide was allowed to mix in 1M IX 
PBS, pH 7.2 (coating buffer).
2) 100(0.1 of coating solution was applied to each well using a multi-channel 8-head 
pipette or an automated coating machine.
3) The plate was sealed and incubated for 2 hours at 37°C or overnight at 4°C.
4) The coating solution was then washed off the plate.
5) Following washing, the plates were then blocked by dispensing 250|ol of EIA 
blocking buffer onto each well.
6) An incubation o f 2 hours at 37°C follows before the blocking buffer was tapped 
out of each w e ll. The plate was allowed to dry uncovered overnight at 37°C.
7) The blocked plate was then placed in an airtight bag or pouch containing a 
desiccant and stored at 4°C for use.
2.4.2 Procedure for W ashing M icrotitre Plates
During the coating o f the plates and during the assay protocol, this procedure was
carried out to wash away unbound material from the solid phase.
1) The wash buffer was prepared to working strength by diluting 25X wash buffer 
with deionised water.
2) Using an automated plate washer or an appropriate multi-channel pipette, 300jol 
of wash buffer was dispensed into each well and allowed to soak for 
approximately 10 seconds.
3) The buffer was aspirated either by suction or manually by inverson of the plate.
4) The above procedure was repeated until the plate has been washed and aspirated 
a total o f five times.
5) Following the final aspiration the plate was dried by repeated tapping on to a dry 
tissue.
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2.4.3 Procedure to Optimise the Solid Phase
This procedure was followed when choosing a peptide suitable for coating on to the
microtitre plate.
1) A number of peptides specific for various regions o f the HCV genome were 
sourced externally (see Biological Components, section 2.3.3).
2) The peptides were evaluated individually, and also were pooled prior to coating 
to form different peptide combinations. This is described in section 3.1.2.
3) The coating solution was made from a stock solution known to contain a 
l.Omg/ml solution o f each peptide. This l.Omg/ml stock was made as follows. 
For every mg o f peptide added to a clean glass container lml o f IX PBS, pH 7.2 
was added. For example, if 1.4mgs peptide is weighed, 1.4ml IX  PBS is added.
4) From this stock l.Omg/ml solution o f the desired coating concentrations were 
made ie. xng/ml and were coated according to the coating procedure in section
2.4.1.
5) The different solid phase combinations were known to contain peptides from 
various viral regions and were tested with characterised sera.
2.4.4 Assay Protocol for ELISA Test
The procedure for running the HCV E1A test followed the following protocol.
1) 10(^ 1 of sample or control was added to the microtitre well using a calibrated 
pipette capable o f delivering this volume, such as a 2-20pi multipipette.
2) To the well was added 90|jl o f sample diluent giving a sample dilution of 1 in 10.
3) The sample was mixed by gently tapping the plate.
4) The plate was covered with a plate sealer and placed in an incubator set at 37°C 
for a period o f 30 min.
5) The sample was then tapped into a biological waste container and the wells 
washed five times according to the procedure outlined.
6) Any bound antibodies were then incubated with lOO i^l of enzyme conjugate. This 
conjugate was goat anti-human IgG antibody bound to HRP.
7) The plate was incubated at 37°C for a further 30 min.
8) Following this incubation the plate was washed five times to remove any 
unbound conjugate.
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9) The next step was the addition o f TMB substrate. This was ready to use and 100 
|j.l was added directly to each well.
10) This substrate incubation took place at 25 °C with the excluson o f light. The 
incubation time for the substrate was 15 min.
11) The reaction was stopped by the addition o f 50[j,l o f stopping reagent per well.
12) Results were read immediately on a plate reader measured with a dual 
wavelength o f 450nm and 630nm.
2.4.5 Inactivation of Goat Serum
This procedure was carried out to inactivate all proteins in the goat serum prior to use in 
the ELISA conjugate diluent.
1) The waterbath was switched on and allowed to heat until it reached a
temperature o f 56 ±1°C.
2) The temperature was recorded with a calibrated thermometer.
3) The container containing the goat serum was placed in the waterbath when it
reached the desired temperature.
4) The goat serum was stirred occasionally while heating.
5) The temperature o f the serum was monitored carefully until it reached a
temperature o f 56±1°C.
6) The temperature was taken only after mixing ensuring uniformity.
7) Once the serum had reached the desired temperature it was maintained for a 
period o f 30 min.
8) Readings were taken every 5 min. during the 30 min. period.
9) When the incubaton time had elapsed the serum was removed from the waterbath
and allowed to cool to room temperature.
10) The serum was then 0.2(j,m filtered.
11)It was then aliquotted into glass universals and stored at -20°C.
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2.5 Methods Used in Rapid Test
2.5.1 Procedure for Conjugation of Peptide to Protein
This procedure was carried out prior to the spotting o f peptide to the membrane.
Due to the porous nature of the membrane the smaller weight peptide was
conjugated to a carrier protein of large molecular weight, BSA.
1) The quantity o f peptide to be conjugated was carefully weighed (.rings).
2) Dialysed BSA (6.5mg/ml) was added to this peptide at a fixed ratio. For every 
mg of peptide weighed, 0.33ml o f BSA was added. The BSA and peptide 
solution was allowed to stir for 15 min. during which time light was excluded.
3) The solution was then dispensed in 1ml volumes into glass tubes containing 
magnetic stirring bars.
4) A 1% (v/v) glutaraldehyde solution was prepared by adding 40pl o f 25% (v/v) 
glutaraldehyde to 960pl of column elution buffer, previously removed which did 
not contain azide.
5) To each 1ml volume o f the peptide/BSA soluton was slowly added 50(il o f 1% 
(v/v) glutaraldehyde solution. Each tube was covered with parafilm and allowed 
to stir, again excluding light.
6) Towards the end o f the designated conjugation time a 20mg/ml sodium 
cyanoborohydride solution was prepared. This was done by adding 2ml of 
deionised water to 40mgs of sodium cyanoborohydride. This serves to stop the 
conjugation reaction.
7) 25pi o f above stopping solution was added per 1ml o f conjugated peptide/BSA 
solution. Each tube was allowed to stir for 15 min., again ensuring exclusion of 
light.
8) All the conjugated peptide/BSA tubes was pooled into a glass container and was 
purified either by dialysis or by column purification.
2.5.2 Purification of Conjugated Peptide by Dialysis
Following conjugation o f peptide to BSA, it was purified, as described below, to
remove any unbound or free peptide or BSA.
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1) Column elution buffer, prepared during the conjugation, o f peptide is used as 
dialysis buffer.
2) Into the dialysis buffer was added a piece o f  dialysis/visking tubing o f sufficient 
length to hold the conjugated peptide. This served to soften the tubing.
3) Having sealed one end o f  the tubing with a clamp or a double knot the peptide 
was carefully pipetted into the tubing and the outer end sealed.
4) The sealed tubing was placed into a large beaker containing approximately 2 
litres o f buffer. The beaker was covered with parafilm and placed at 4°C, stirring 
constantly.
5) Over a period o f 2 days the dialysis buffer was replaced with 2 litres o f  fresh 
buffer to give a total o f 4 changes using approximately 10 litres o f  dialysis buffer.
6) On completion o f dialysis the conjugated peptide was removed from the tubing 
and stored in a glass container at 4°C.
2.5.3 Purification of Conjugated Peptide by Column Chromatography
As an alternative method to dialysis, the conjugated material could also be purified by
column chromatography. This also served to separate the unbound material from the
conjugated mixture.
1) A Sephacryl S-200 column was equilibrated with column elution buffer.
2) A number o f  tubes were labelled and the chromatography syytem was prepared 
to allow for the collection o f 2ml fractions from the column.
3) Allowing the gel bed to run until almost dry the conjugated peptide was loaded 
onto the top o f the column and the fractions were collected immediately. When 
the sample had eluted into the gel the buffer was used to top up the column and 
the fractions were collected either by gravity or by using the pump connected to 
the conjugation system.
4) Using a visual check along with absorbance readings obtained from the 
spectrophotometer set at 280nm, fractions were identified which were believed to 
contain purified conjugated peptide. When using absorbance readings the 
spectrophotometer was blanked with column elution buffer before the fractions 
were analysed.
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2.5.4 D eterm ination of Peptide Fractions-Neiitralisation Assay
After the purification o f peptide by chromatography, the fractions containing 
conjugated peptide were identified using the neutralisation assay. A visual check and 
the specrophotometer readings served as an aid to identify these fractions.
1) The fractions obtained from the absorbance readings were identified. Five 
additional fractions either side o f the identified fractions were also chosen.
2) 1ml of peptide-specific positive serum was dispensed into a sufficient number of 
labelled tubes. This serum served as the neutralisation reagent.
3) 10 [il o f each identified fraction was added into its corresponding tube and the 
mixture was inverted gently.
4) The tubes were incubated at room temperature for approximately 30 min. This 
allowed time for any peptide in the fraction to bind to specific antibody in the 
neutralisation reagent, therefore, neutralising the serum.
5) Using these samples as test specimen, the rapid assay was carried out as per 
usual. From the results it was possible to determine which fractions contained 
peptide. A positive result indicated neutralisation did not occur and therefore no 
peptide was present in that corresponding fraction.
6) All peptide-containing fractions were pooled and stored at 2-8°C.
2.5.5 Concentration of Conjugated Peptide
In certain cases, the volume of conjugated peptide purified by chromatography was 
large due to a large quantity o f peptide fractions. Reduction o f volume was carried 
out using concentration units or by osmosis.
1) The concentration units involved loading the sample onto Amicon B15 units 
using a clean glass pasteur pipette.
2) After a certain length of time depending on volume the sample reached a set 
mark, for example lml, and was carefully removed.
3) The other method involved the use o f osmosis. The sample was placed in dialysis 
tubing and left in a bed of sucrose.
4) When the sample reduced to a final set volume it was removed.
5) The reduced sample in either case was placed in a glass container and stored at 2- 
8°C until required for card spotting.
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2.5.6 Spotting of Peptide on Solid Phase M em brane
Following purification of peptide either by dialysis or chromatography, it was
evaluated for use on the membrane solid phase. This involved the spotting or
adhesion of peptide as described.
1) The peptide was spotted on the card membrane following conjugation.
2) A stock spotting solution was made prior to spotting. A 1/10 stock was made by 
diluting 50(0.1 of conjugated peptide in 450^1 of 2X PBS. A series of working 
dilutions were then made.
3) Cards were then spotted using a multipipette by pipetting 5j.il o f spotting solution 
onto the top right port o f the card.
4) 6pl o f 2X PBS were pipetted onto the top left port and 10pl o f control dilution 
buffer onto the bottom right port.
5) Cards were covered and dried overnight at a temperature o f 18-25°C for 18-24 
hours.
6) Following drying, the cards were blocked by pipetting 50p,l of blocking buffer to 
each of the two top ports.
7) They were then dried overnight in a vacuum drying chamber.
8) Following removal from the vacuum drier they were pouched in foil pouches 
containing an indicating desiccant.
2.5.7 Assay Protocol for Rapid Test
This procedure outlines the protocol followed for the testing o f samples on the rapid
test card.
1) One drop of wash reagent was added to both bottom ports to wet the membrane.
2) Approximately 50(j.l o f sample was added to both bottom ports and allowed to 
absorb into the membrane.
3) Sample was incubated for 30 seconds.
4) One drop of wash reagent was added to the sample ports to wash the sample 
towards the reactive sites (top ports).
5) After two min., one drop of wash buffer was added to both top ports.
6) This was followed by one drop o f enzyme conjugate reagent to both ports.
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7) Upon absorption the enzyme was incubated for two minutes.
8) The unbound conjugate was washed by adding one drop of wash reagent to each 
of the top ports and absorbed.
9) This wash procedure was repeated until washed four times each time ensuring the
drop had absorbed before adding a subsequent drop.
10) The final step was the addition o f two drops o f substrate reagent to the top ports.
This was followed by a five minute incubation.
11) Results were read immediately after the five min. had elapsed.
2.5.8 Preparation of Dialysed BSA
Dialysed BSA at a concentration o f 6.5mg/ml was used as the carrier protein in the
conjugation of peptide as described in section 2.5 .1. It serves as the larger molecule,
which binds with the smaller weight peptide allowing spotting o f the peptide on to
the porous membrane.
1) The first step in the preparation o f dialysed BSA was the formulation o f 
approximately 12 litres of IX  PBS which was used as dialysis buffer.
2) A quantity of the prepared dialysis buffer equal to half the desired final volume of 
dialysed BSA was placed in a glass container.
3) For each ml o f the desired final volume of dialysed BSA required 6.5mg o f BSA 
was weighed and added to the container.
4) The BSA was allowed to dissolve into the PBS buffer without stirring.
5) A length o f dialysis tubing capable o f holding the solution was softened by 
placing in the dialysis buffer.
6) Once dissolved the hydrated BSA was pipetted into the dialysis tubing and both 
ends o f tubing were sealed.
7) The tubing was placed into a beaker containing approximately 2 litres of dialysis 
buffer.
8) A magnetic stirring bar was placed in the beaker and the solution was stirred at a 
temperature of 2-8°C.
9) The entire volume of dialysis buffer was changed three times per day over a 
period of two days.
10) At the end of dialysis the contents o f the tubing was placed in a graduated glass 
cylinder.
63
I l)T he solution was made up to the final volume with dialysis buffer.
12) The top of the cylinder was covered with parafilm and the dialysed BSA was 
mixed by inverting five times.
13) The solution was aliquoted into volumes of approximately 1ml and stored at a 
temperature o f -20°C.
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Sections 3 and 4
3.1 Evaluation of Synthetic Peptides
Sections 3.1 to 3.6 describe the procedures involved in the process o f  development o f 
the microtitre plate assay. Various assay parameters were investigated to reach the 
optimised test. Commencing with the solid phase peptides, various diluents and 
dilutions for the enzyme conjugate were investigated along with the sample diluent and 
sample dilution.
At various stages o f development, all parameters outlined above were tested with 
clinical samples to ascertain specificity and sensitivity o f  the assay. These clinical 
samples were obtained from three suppliers, International Enzymes, Inc. (IEI), Cork 
Blood Bank and Boston Biomedica, Inc. It is not known whether the samples were 
positive by PCR. Interpretation was carried out by the supplier based on results o f the 
Ortho 2.0 Anti-HCV EIA Test and Abbott 2.0 Anti-HCV EIA Test. Specimens had not 
been inactivated and were treated as potentially infectious material, following good 
laboratory safety practice. All samples had been tested and found negative for anti-HIV 
antibody and Hepatitis B surface antigen.
During the evaluation o f assay parameters, the method employed by Trinity Biotech for 
the assay o f samples was followed. Samples were assayed in duplicate, the mean o f 
these determinations taken as the absorbance value. For the purpose o f the initial 
evaluation steps, a value o f 0.25 absorbance units was assigned as the cut-off value 
above which a sample was considered positive and below which the interpretation was 
negative. For subsequent steps, which involved large volume testing, a cut-off value 
was determined. The value was calculated as the mean negative value ± two standard 
deviation units (x ± 2  SD). Throughout development, result interpretation involved no 
further statistical analysis.
3.1.1 Suitability of Peptides for M icrotitre Plate Coating
A total o f  15 peptides were available for evaluation in this study. Initial experiments 
were carried out to predict the best peptide for coating, as there was no prior 
recommendation. The peptides available for evaluation along with the viral region 
specific to each peptide is outlined in table 3.1.1a. Prior to the adhesion onto the 
microtitre wells, each peptide was conjugated to the carrier protein BSA, according to
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Section 2.5.1. This method o f conjugation o f peptide to protein is well established 
within Trinity Biotech and has been used efficiently and successfully to conjugate HIV 
peptides. Each complex was stored at 4°C prior to use.
Peptide No. Peptide ID Region j
1 HCVNS3-1 peptide NS3
2 E47 (Envelope) peptide Envelope
3 HCV 52 peptide NS4
4 HCV Core peptide Core
5 HCV NS5 peptide NS5
6 HCV 15 peptide Core
7 E51 (Envelope) peptide Envelope
8 MS94-23 (Core) peptide Core
9 PS9401-1 (NS3) peptide NS3
10 PS9401-2 (NS3) peptide NS3
11 PS9401-12 (NS3) peptide NS3
12 PS9307-8 (NS5) peptide NS5
13 PS9307-9 (NS5) peptide NS5
14 NS4a peptide NS4
15 NS3 Recombinant Protein NS3
Table 3.1.1a Specific viral regions o f peptides evaluatedfor suitability 
fo r  microtitre plate coating.
Each conjugated peptide was then coated at coarse coating dilutions between 1/10 and 
1/5,000. Coating solutions were made up in carbonate coating buffer and coated 
following procedure in Section 2.4.1.
For the purpose of this initial testing, the following protocol was used.
Sample Dilution 
Incubation Times 
Incubation Temperature 
Plate Washing 
Conjugate Dilution
1 in 20 
30 min.
37°C
300(J.l x 5 washes
1/70,000 (as per manufacturer’s instructions)
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Following the procedure described in Section 2.4.4, each peptide dilution was tested. 
For the purpose o f this investigation only one known HCV positive serum sample and 
one known HCV negative sample was tested. The data, which accompanied the 
positive sample, confirmed that it represented all regions o f  the HCV genome.
Results are expressed as a positive/negative (P/N) ratio o f  absorbance values read at 
450nm with a reference filter o f  630nm. (Figure 3.1.1a). Only readings o f  peptide 
coated at 1/5,000 are shown because at stronger dilutions the absorbance o f the positive 
serum gave a value beyond the range o f  the plate reader.
9 
8 
7 
6 
5
P/N Ratio
4
3 
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1 
0
Figure 3.1.1a Positive-negative ratios obtained fo r initial evaluation o f peptides tested 
on microtitre plate ELISA with known positive and negative sample.
Based on the results from Figure 3.1.1a, four peptides were chosen for further analysis. 
These peptides were selected as they gave the highest P/N ratios as shown in Table 
3.1.1b.
Peptide Number Name Viral Region P/N Ratio
1 HCV NS3-1 NS3 6.2
3 HCV 52 NS4 6.4
4 HCV Core Core 8.1
6 HCV 15 Core 7.4
Table 3.1.1b P /N  ratios o f  chosen peptides from  initial evaluation.
-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Peptide Number
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Two o f the four peptides selected were specific to the HCV Core region (HCV 15, HCV 
Core); one was specific to the NS4 region (HCV 52) and one to the NS3 region (HCV 
NS3-1).
3.1.2 Additional Titration o f Peptides
These four peptides were further evaluated in an attempt to improve assay sensitivity. It 
was decided to coat these peptides individually at coating dilutions between 1/5,000, 
which gave the positive/negative ratios in Table 3.1.1b, and also at weaker coating 
dilutions up to 1/15,000.
To evaluate the effect o f combining peptides, two additional coating solutions were 
investigated. The core peptides HCV 15 and HCV Core were pooled and also a full 
combination o f the four peptides was examined. Table 3.1.2a shows the final dilutions 
and the combinations used.
Each dilution o f each peptide or combination was tested with one positive sample and 
one negative sample in order to choose a coating dilution. Again this positive sample 
represented all regions o f  the HCV genome.
Figure 3.1.2a represents the positive/negative ratio achieved. An optimum coating 
dilution was then chosen to test the peptides with characterised sera.
ce
z£
■Peptide 1 
Peptide 3 
Peptide 4 
Peptide 6 
Core pool 
-Full  Pool
C o a t i n g  D i l u t i o n
Figure 3.1.2a Further titration ofpeptides fo r  ELISA solid phase: results are 
expressed as P/N  ratio fo r  each coating dilution.
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Peptide/Combination Viral Region Coating Dilution
Peptide 1 HCV NS3-1 All peptides at final
Peptide 3 HCV 52 coating dilutions o f
Peptide 4 HCV Core 1/5,000, 1/6,000,
Peptide 6 HCV 15 1/7,000, 1/8,000,
Core Pool HCV 15, HCV Core 1/9,000, 1/10,000,
Full Pool HCVNS3-1, HCV 1/12,000 and 1/15,000.
52,HCV Core, HCV 15
Table 3.1.2a Dilutions and viral regions o f peptides and combinations 
coated in titration ofpeptides fo r  ELISA solid phase.
As can be seen from Figure 3.1.2a, the optimum coating dilution for all peptides and 
peptide combinations was at 1/10,000.
3.1.3 Testing w ith C haracterised Sera
With a coating dilution o f 1/10,000, the peptides above were tested with characterised 
HCV sera to determine which solid phase gave the best sensitivity and specificity.
A total o f  nine samples (ID 1 -9) were used in this evaluation including three negative 
serum samples. The assay protocol in section 3.1.1 was followed.
The samples supplied had been characterised using o f the Ortho RIBA 3.0 Assay. The 
viral regions specific to the samples are shown in Table 3.1.3a, along with the 
corresponding coated peptides specific to these viral regions.
Sample ID Viral Region Specific Peptide
1 NS3, Core 1,4,6
2 NS4, Core 3,4,6
3 Core 4,6
4 NS3, NS4 1,3
5 Core 4,6
6 NS4, Core 3,4,6
7 Neg. None
8 Neg. None
9 Neg. None
Table 3.1.3a Nine samples characterised by Ortho RIBA 3.0 assay showing the viral 
region specific to samples and the coated peptide specific to the viral regions.
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Each sample was tested on the four peptides individually and also on the core pool and 
the full pool combinations.
The absorbance reading o f each sample was read at 450nm with a reference filter o f 
630nm. The readings obtained with each sample are represented in Figure 3.1.3a.
Sam ple Identification
Figure 3.1.3a Absorbance readings o f nine characterised serum samples on wells 
with peptide coated at a dilution o f 1/10,000.
To represent these results and determine which peptide gave the best specificity and 
sensitivity, an initial coarse value o f >0.25 absorbance units was interpreted as a 
positive reading and <0.25 absorbance units as a negative reading.
These values served as a guideline only, the main area o f interest lay in achieving a 
peptide or combination, which gave the highest positive value with a corresponding low 
negative reading. Based on this criteria, Table 3.1.3b shows the sensitivity and 
specificity achieved.
As can be seen from the table, the full pool was the only combination in picking up all 
characterised samples 1 to 6. The negative samples were close to the cut-off value o f 
0.25 absorbance units, samples 7, 8 and 9 giving readings o f  0.21, 0.22 and 0.24 
absorbance units, respectively. The individual peptides and the core pool were unable 
to detect all the samples.
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Viral
Sample
Region
PI
(NS3)
P3
(NS4)
P4
(Core)
P6
(Core)
Core Pool
Full
Pool
1 N S3, Core + - + + + +
2 NS4, Core - + + + + +
3 Core - - + + + +
4 NS3, NS4 + + - - - +
5 Core - - + + + +
6 NS4, Core - + + + + +
7 Neg. - - + - + -
8 Neg. - - - - - -
9 Neg. - - - - - -
Sensitivity 33.3% 50% 83.3% 83.3% 83.3% 100%
Specificity 100% 100% 66.6% 100% 66.6% 100%
Table 3.1.3b Initial sensitivity and specificity o f peptide combinations; 
+ represents a positive absorbance reading;
- represents a negative absorbance reading.
The full pool solid phase, with all peptides coated at a dilution o f 1/10,000, was chosen 
for further evaluation tests.
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3.2 Improvements to Assay Sensitivity and Specificity
In an attempt to improve the differentiation between positive and negative readings, 
certain components and parameters were investigated.
Up to this point, the coating solution was the only parameter to be evaluated and all 
work was carried out without examining other areas.
These areas were evaluated and included
• Sample Diluent
• Conjugate Titration
• Conjugate Diluent
• Sample Dilution
3.2.1 Evaluation o f Sam ple Diluent
The sample diluent was the first o f these to be evaluated. All the solid phase evaluation 
tests were carried out with the samples diluted in control dilution buffer. The addition 
o f certain components to this buffer was investigated to determine which, if  any, would 
give any improvement to test sensitivity and specificity. It was decided to add protein 
and serum to the diluent in the hope that it would reduce the negative readings by 
binding non-specific proteins in the sample.
The proteins chosen to add to control dilution buffer were Bovine Serum Albumin 
(BSA), Human Serum Albumin (HSA), Rabbit Serum (RS) and Goat Serum (GS). 
Each component was added to a final concentration of 1% (v/v), 2% (v/v), 5% (v/v) and 
10% (v/v).
As some precipitate was present in the diluents following addition o f protein, each 
diluent was filtered with a 0.2pm filter containing a 0.45pm pre-filter prior to use.
To evaluate the sample diluent, one positive serum sample and three negative serum 
samples were diluted in each test diluent and tested as normal. Based on the results o f
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Section 3.1, the solid phase used for this evaluation was the full pool combination 
coated at a dilution o f 1/10,000.
Table 3.2.1a gives the absorbance values achieved for each sample in each diluent. 
Figure 3.2.1a shows these results expressed as a positive/negative ratio for each 
component added. As three negative samples were tested, the mean absorbance o f these 
readings was calculated and used to obtain the positive/negative ratio. Again, the 
samples were assayed in duplicate.
Component added, 
%  (v/v)
Positive Reading
Mean Negative 
Absorbance
P/N Ratio
BSA 1% 1.346 0.237 5.7
2% 1.142 0.224 5.1
5% 1.366 0.305 4.5
10% 1.371 0.298 4.6
HSA 1% 1.117 0.228 4.9
2% 1.012 0.199 5.1
5% 1.126 0.209 5.4
10% 1.236 0.221 5.6
RS 1% 1.194 0.230 5.2
2% 1.281 0.268 4.8
5% 1.198 0.292 4.1
10% 1.267 0.325 3.9
GS 1% 1.221 0.207 5.9
2% 1.186 0.189 6.3
5% 1.202 0.156 7.7
10% 1.179 0.178 6.6
Table 3.2.1a. Absorbance and P/N  values o f positive and negative samples diluted in
sample diluents fo r  evaluation.
Table 3.2.1a and Figure 3.2.1a indicate that the addition o f goat serum gave the highest 
positive/negative ratios. As can be seen from Table 3.2.1a, 5% (v/v) goat serum gave 
the lowest absorbance reading for the negative samples and also gave the best positive 
to negative ratio.
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P/N Ratio 4-
BSA
Component Added (v/v)
Figure 3.2.1a. P/N  ratio achieved with sample added to sample diluent, containing 
bovine serum albumin, normal human serum, rabbit serum and goat serum.
All further evaluations used 5% (v/v) goat serum in sample diluent.
3.2.2 Evaluation o f Enzym e Conjugate
Following the evaluation o f sample diluent was that o f  the enzyme conjugate. The 
HCV indirect assay utilised anti-human IgG labelled to peroxidase as the enzyme.
A total o f  two goat anti-human IgG peroxidase-labelled conjugates were purchased for 
evaluation, one lot from Kirkegarrd and Perry Laboratories (KPL) and the other from 
Genzyme. All previous work had utilised the KPL conjugate at 1/70,000. This working 
dilution was recommended by the manufacturer and was used as a coarse titre. The 
KPL conjugate was titred between 1/10,000 and 1/120,000 and Genzyme between 
1/1,000 and 1/12,000. These values were above and below their recommended working 
dilutions for use in EIA’s.
For this initial evaluation all dilutions were made in a cytochrome C-based diluent 
supplied by Trinity Biotech, pic., and used in other EIA procedures.
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One positive sample and one negative sample were used in this initial evaluation o f  both 
conjugates.
1 / 10 , 0 0 0  1 /2 0 , 0 0 0  1 /4 0 , 0 0 0  1 / 6 0 , 0 0 0  1 /8 0 , 0 0 0  1 / 1 0 0 , 0 0 0  1/1 20 , 0 0 0
K P L  Con j uga t e  Ti tre
Figure 3.2.2a. P/N  ratios achieved in titre o f KPL anti-human 
IgG-peroxidase conjugated.
Figure 3.2.2a represents the positive to negative ratio achieved with the KPL conjugate 
and Figure 3.2.2b shows that o f the Genzyme conjugate.
1/1,000 1/2,000 1/4,000 1/6,000 1/8,000 1/ 10,000 1/12,000
Conjugate Titre
Figure 3.2.2b. P/N ratios achieved in titre o f Genzyme 
anti-human IgG-peroxidase conjugated.
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As can be seen from Figure 3.2.2a the KPL conjugate titred well between 1/10,000 and 
1/120,000. The best positive to negative ratio was obtained at a dilution o f 1/80,000. In 
the case o f the Genzyme conjugate the best ratio was obtained at a dilution o f 1/8,000 
although the absorbance value for the positive sample was lower than that achieved with 
the KPL conjugate.
These absorbance readings and P/N ratios for both conjugates are shown in Table 3.2.2a 
and 3.2.2b.
Dilution Positive reading Negative reading P/N ratio
1/10,000 1.988 0.686 2.9
1/20,000 1.699 0.514 3.3
1/40,000 1.654 0.318 5.2
1/60,000 1.587 0.212 7.5
1/80,000 1.458 0.184 7.9
1/100,000 1.127 0.179 6.3
1/120,000 0.893 0.175 5.1
Table 3.2.2a. Absorbance and P/N  values o f KPL conjugate evaluation.
Dilution Positive reading Negative reading P/N Ratio
1/1,000 1.669 0.541 2.9
1/2,000 1.521 0.447 3.4
1/4,000 1.395 0.317 4.4
1/6,000 1.288 0.247 5.2
1/8,000 1.257 0.193 6.5
1/10,000 1.199 0.187 6.4
1/12,000 1.022 0.179 5.7
Table 3.2.2b. Absorbance and P/N  values o f Genzyme conjugate evaluation.
The absorbance values and the positive to negative ratios o f both conjugate evaluations 
indicate that the best differentiation was observed with the KPL conjugate at a dilution 
o f 1/80,000.
3.2.3 Evaluation o f Enzym e C onjugate D iluent
As stated in Section 3.2.2 the KPL and Genzyme goat anti-human peroxidase 
conjugates were diluted in a cytochrome C-based diluent. This diluent did not contain 
any serum or detergent or additional components, which are known to reduce negative 
readings. The addition o f such components to the KPL enzyme conjugate diluent was 
the next parameter to be investigated. The KPL conjugate at 1/80,000 was chosen.
76
For this purpose, two detergents, Tween 20 and Triton X-100 were evaluated. They 
were added separately to the cytochrome C diluent at a concentration o f  0.1% (v/v), 
0.05% (v/v), 0.02% (v/v) and 0.01% (v/v). Goat serum was also added, at a 
concentration o f 5%. Cytochrome C conjugate diluent without added components was 
used as a control diluent.
For this investigation, one positive serum sample and three negative serum samples 
were assayed. Table 3.2.3a shows the absorbance readings obtained on the assay.
Component added, 
(v/v)
Positive Neg. 1 Neg. 2 Neg. 3
Mean
Neg.
Tween 20 0.1% 1.906 0.241 0.247 0.266 0.251
0.05% 1.727 0.283 0.262 0.251 0.265
0.02% 2.069 0.299 0.276 0.254 0.276
0.01% 1.998 0.287 0.269 0.277 0.277
Triton X-100 0.1% 1.708 0.228 0.191 0.208 0.209
0.05% 1.659 0.158 0.175 0.186 0.173
0.02% 1.565 0.161 0.185 0.201 0.182
0.01% 1.762 0.187 0.202 0.225 0.204
Goat Serum 5% 0.563 0.151 0.198 0.246 0.198
Reference 1.693 0.221 0.213 0.196 0.211
Table 3.2.3a, Absorbance readings obtained upon addition o f components to the 
diluent fo r  KPL anti-human IgG-peroxidase conjugatedin ELISA test.
The positive/negative ratios are given in Table 3.2.3b. The mean o f the three negative 
readings is used to calculate the P/N ratio. These positive to negative ratios are 
represented diagrammatically in Figure 3.2.3a.
Component (v/v) P/N Ratio 1
Tween 20 0.1% 7.59
0.05% 6.51
0.02% 7.49
0.01% 7.21
Triton X-100 0.1% 8.17
0.05% 9.58
0.02% 8.59
0.01% 8.63
Goat Serum 5% 2.84
Reference 8.04
Table 3.2.3b. P/N  ratios achieved with addition o f components to the diluent fo r KPL 
anti-human IgG-peroxidase conjugated, in ELISA test
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■  0.1% (v/v) Tween
■  0.05% (v/v)Tween
□  0.02% (v/v) Tween
□  0.01% (v/v) Tween
■  0.1% (v/v) Triton
■  0.05% (v/v) Triton
■  0.02% (v/v) Triton
□  0.01% (v/v) Triton
■  Goat Serum
■  Ref.
Component Added
Figure 3.2.3a. P/N  ratios achieved with above components added to 
KPL conjugate diluent, in ELISA test.
From the data shown it was clear that Triton X-100 was the best diluent. Table 3.2.3a 
shows that it gave cleaner negative readings with high positive values. It was selected 
based on its specificity and positive/negative ratio. The best Triton X-100 dilution was 
0.05%.
3.2.4 Investigation of Optimum  Sam ple D ilution
Up to this stage, all investigative work was carried out by premixing serum samples in 
tubes, at an approximate dilution o f 1 part sample in 19 parts control dilution buffer i.e. 
a 1 in 20 dilution. The next step was to investigate the effect o f mixing the samples in 
the microwell, which eliminated the premixing step in the tube. This was done by 
adding the required quantity o f sample to the well followed by the addition o f  diluent, 
which served to mix the sample.
Each sample was mixed to give a final dilution o f 1 in 5, 1 in 10, 1 in 20 and 1 in 40 as 
shown in Table 3.2.4a. The final ‘in-well’ volume was 100|xl. Samples applied 
undiluted to the well were also examined.
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Undiluted 1/5 1/10 1/20 1/40
Volume Sample lOOfj-1 20 (xl 10(al 5|nl 2.5|xl
Volume Diluent None 80fxl 90^1 95fxl 97.5^1
Table 3.2.4a. Sample dilutions (/d) investigatedfor ELISA evaluation.
For the purpose o f this investigation, four positive samples, numbered 1 to 4 and four 
negative samples, numbered 5 to 8 were diluted as described above.
Two o f the positive samples, 1 and 4 were chosen for this evaluation, as they were 
weakly positive samples, whereas samples 2 and 3 were known stronger samples.
Table 3.2.4b gives the absorbance values obtained for each o f the eight samples at each 
dilution and these figures are represented in Figure 3.2.4a.
Dilution Pos. 1 Pos. 2 Pos. 3 Pos. 4 Neg. 1 Neg. 2 Neg. 3 Neg. 4
Undiluted 0.966 2.500 1.549 0.837 0.306 0.154 0.199 0.189
1 in 5 0.869 1.977 1.498 0.654 0.256 0.126 0.165 0.163
1 in 10 0.759 1.935 1.256 0.625 0.198 0.092 0.132 0.124
1 in 20 0.578 1.382 0.925 0.412 0.167 0.089 0.101 0.105
1 in 40 0.457 1.251 0.797 0.367 0.135 0.087 0.087 0.093
Table 3.2.4b. Absorbance readings obtained in ELISA sample dilution evaluation.
■  U n d ilu  te  d
■  1 in 5 d i l u t i o n
■  1 in 1 0  d i l u t i o n
□  1 in 2 0 d i lu t io n
□  1 in 4 0 d i lu t io n
Ftlrn DSBt i film
P o s  1 P o s  2 P o s 3  P o s 4 N e g 1  N e g  2 N e g  3 N e g  4 
S a m p l e s  T e s t e d
Figure 3.2.4a. Sample absorbance readings obtained with samples tested on ELISA 
plate test, fo r  evaluation of various sample dilutions.
79
The positive/negative ratio for each positive sample was calculated for all sample 
dilutions. The negative reading was taken as the mean o f the four negative sample 
readings. This is shown in Table 3.2.4c.
Undiluted 1 in 5 1 in 10 1 in 20 1 in 40
Mean Negative absorbance c) 0.212 0.178 0.137 0.116 0.101
Positive 1 4.96 4.88 5.54 4.98 4.52
Positive 2 11.79 11.16 14.12 11.91 12.38
Positive 3 7.30 8.41 9.16 7.97 7.89
Positive 4 3.94 3.67 4.56 3.55 3.63
Table 3.2.4c. P/N  ratios o f samples diluted ‘in weir as shown in Table 3.2.4a.
The ratios for the positive samples are represented in Figure 3.2.4b. The results 
indicated that the best in-well dilution was at 1 in 10 o f sample in control dilution buffer 
as it gave the best positive/negative ratios for all four positive samples tested.
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Undiluted 1 in  5 1 in  10 1 in  20 1 in 40
dilution dilution dilution dilution
Sample dilution
Figure 3.2.4b. P/N ratios o f positive samples obtained with samples tested on ELISA 
plate test fo r  evaluation o f various sample dilutions.
Positive 1
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3.2.5 Final Assay Parameters
As a result o f  the investigations described in Section 3.1 and 3.2, the following assay 
parameters were used in the analysis o f  serum samples in the proceeding sections. The 
assay protocol is outlined below.
Plate: Full Pool o f peptides coated at 1/10,000
HCV NS3-1, HCV 52, HCV Core and HCV 15 
Sample: 1/10 in-well dilution in control dilution buffer with 5% (v/v) goat
serum (lOjol sample + 90j.il diluent)
Conjugate: 1/80,000 KPL goat anti-human IgG-peroxidase conjugated, in
cytochrome C diluent with 0.05% (v/v) Triton X-100 added.
Assay Protocol: IOOjj.1 sample
30 min. @ 37°C 
Wash x 5 times 
100 jo. I conjugate 
30 min. @ 37°C 
Wash x 5 times 
lOOjol substrate 
15 min. @ 25°C
Read at 450nm with a reference filter o f 630nm 
Sensitivity and Specificity
The following formulae were used to calculate the sensitivity and specificity for 
all evaluations carried out (Hart, 1980).
Sensitivity Specificity
True positives-false negatives True negatives-false positives
True positives True negatives
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At this point, using the chosen parameters outlined in Section 3.2.5, a number o f  HCV 
positive and negative serum or plasma samples were evaluated.
The samples, which were received from International Enzymes Incorporated (IEI) were 
known to be specific for certain viral regions as recommended by the supplier.
3.3.1. Interpretation o f Analysis Data
A total o f  88 samples were received from IEI. These samples had been previously 
characterised by Ortho™ Recombinant ImmunoBlot Assay (RIBA).
These characteristics were represented as RIBA bands, each band representing a 
specific viral region o f the HCV genome, which is shown in Table 3.3.1a.
RIBA Band Viral Region
C100 NS4
C33 NS3
C22 Core
5-1-1 NS5
Table 3.3. la . Ortho ™ RIBA banding o f  IEI samples and corresponding viral region.
A total o f  two or more bands must be present if  the sample to be termed a positive 
sample. The presence o f  one band only indicates a negative or indeterminate (Ind.) 
sample. It is not known whether or not indeterminate samples are positive by PCR. 
They were termed negative or indeterminate as a result o f Ortho Anti-HCV RIBA 2.0 
testing carried out by the supplier.
All IEI samples, along with 45 negative samples received from Cork Blood Bank were 
tested as described previously. Table 3.3.1b shows the samples available for analysis 
and the RIBA banding. The absorbance values obtained on testing are included.
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Sample
1E1 Lot 
Number RIBA Band
Viral
Region(s)
Interpretation Absorbance
1 473 C100, C33 NS4, NS3 Pos. 0.520
2 678 C33, C22 NS3, Core Pos. 0.292
3 682 C33, C22 NS3, Core Pos. 0.641
4 687 C33, C22 NS3, Core Pos. 1.348
5 694 C33, C22 NS3, Core Pos. 0.613
6 696 C33, C22 NS3, Core Pos. 0.852
7 699 C33, C22 NS3, Core Pos. 0.819
8 700 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.198
9 701 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.482
10 702 C22 Core only Neg./Ind. 0.138
11 703 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.237
12 706 C33, C22 NS3, Core Pos. 0.646
13 708 C33, C22 NS3, Core Pos. 0.173
14 709 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 1.339
15 710 C33, C22 NS3, Core Pos. 0.564
16 711 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.290
17 712 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.835
18 713 5-1-1, C100,
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.203
19 714
5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core Pos.
0.408
20 717 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.822
21 718 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.613
22 719 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.683
23 722 C22 Core only Neg./Ind 0.169
24 725 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.081
25 727 5-1-1, C100,
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.125
26 728 C33, C22 NS3, Core Pos. 0.417
27 729 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.900
28 731 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.092
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Sample
IE1 Lot 
Number RIBA Band
Viral
Region(s)
Interpretation Absorbance
29 736 C33, C22 NS3, Core Pos. 0.956
30 738 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.373
31 739
5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.430
32 741 C33, C22 NS3, Core Pos. 0.225
33 742 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.121
34 743 C33, C22 NS3, Core Pos. 0.214
35 746 C33, C22 NS3, Core Pos. 0.815
36 748 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.286
37 750 C33, C22 NS3, Core Pos. 0.171
38 753 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.405
39 754 5-1-1, C100,
C33, C22
NS5, NS4, 
NS3, Core
Pos. 0.211
40 762 C22 Core only Neg./Ind. 0.121
41 767 C22 Core only Neg./Ind. 0.112
42 779 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.670
43 859 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.316
44 865 C33, C22 NS3, Core Pos. 1.468
45 894 C22 Core only Neg./Ind. 0.122
46 903 C22 Core only Neg./Ind. 0.123
47 904 C22 Core only Neg./Ind. 0.065
48 913 C22 Core only Neg./Ind. 0.076
49 935 C22 Core only Neg./Ind. 1.103
50 937 C22 Core only Neg./Ind. 0.078
51 943 C100, C33 NS4, NS3 Pos. 0.214
52 944 C22 Core only Neg./Ind. 0.087
53 945 C33, C22 NS3, Core Pos. 0.303
54 946 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.845
55 947 C22 Core only Neg./Ind. 0.882
56 950 C33, C22 NS3, Core Pos. 0.894
57 951 C33, C22 NS3, Core Pos. 0.348
58 953 C22 Core only Neg./Ind. 0.102
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Sample
1E1 Lot 
Number RIBA Band
Viral
Region(s)
Interpretation Absorbance
59 958 C33, C22 NS3, Core Pos. 0.082
60 959 C22 Core only Neg./Ind. 0.060
61 961 C33, C22 NS3, Core Pos. 1.589
62 963
C33, C22, 5- 
1-1
NS3, Core, 
NS5 Pos.
0.748
63 981 C33, C22 NS3, Core Pos. 0.190
64 985 C22 Core only Neg./Ind. 0.095
65 991 C22 Core only Neg./Ind. 0.133
66 992 C22 Core only Neg./Ind. 0.083
67 993 C22 Core only Neg./Ind. 0.164
68 995 C33, C22 NS3, Core Pos. 0.916
69 996 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.112
70 997 C22 Core only Neg./Ind. 0.158
71 998 C22 Core only Neg./Ind. 0.197
72 999 C22 Core only Neg./Ind. 0.091
73 1013 C22 Core only Neg./Ind. 0.114
74 1025 C22 Core only Neg./Ind. 0.134
75 1039 C22 Core only Neg./Ind. 0.194
76 1053 C100, C33, C22, 5-1-1
NS4, NS3, 
Core, NS5
Pos. 0.619
77 1055 C22 Core only Neg./Ind. 0.090
78 1059 C22 Core only Neg./Ind. 0.129
79 1070 C33 NS3 only Neg./Ind. 0.085
80 1072 C22 Core only Neg./Ind. 0.282
81 1076 C22 Core only Neg./Ind. 0.074
82 1077 C33 NS3 only Neg./Ind. 0.074
83 1081 C22 Core only Neg./Ind. 0.220
84 1086 C22 Core only Neg./Ind. 0.116
85 1110 C22 Core only Neg./Ind. 0.287
86 1112 C22 Core only Neg./Ind. 0.113
87 1115 C33, C22 NS3, Core Pos. 0.108
88 1265 C33 NS3 only Neg./Ind. 0.263
Table 3.3.1b. IEI samples with RIBA banding and absorbance readings with ELISA
parameters outlined in section 3.2.5.
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The absorbance values obtained for the 45 Cork blood bank negative samples are shown 
in Figure 3.3.1a. See Appendix 1 for raw data.
Sample Number
Figure 3.3.1a. Absorbance values o f 45 negative samples in ELISA test 
with parameters outlined in section 3.2.5.
3.3.2 D iscrepant Sam ples
From the 45 negative samples, a cut-off value was determined. This value was 
calculated by adding two standard deviations to the mean negative value (x + 2 SD) and 
was given a value o f 0.145 absorbance units.
3.3.2.1 False Negative Samples
Sample Absorbance RIBA Banding Expected Result
725 0.081 C l00, C33, C22 Positive
731 0.092 5-1-1, C100, C33, C22 Positive
742 0.121 5-1-1, C100, C33, C22 Positive
958 0.082 C33, C22 Positive
996 0.112 C100, C33, C22 Positive
1115 0.108 C33, C22 Positive
Table 3.3.2a. False negative IEI samples from  initial evaluation o f ELISA test, 
using parameters outlined in section 3.2.5.
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3.3.2.2 False Positive Samples
Sample Absorbnace RIBA Banding Expected Result
722 0.169 C22 Neg./Ind.
935 1.103 C22 Neg./Ind.
947 0.882 C22 Neg./Ind.
993 0.164 C22 Neg./Ind.
997 0.158 C22 Neg./Ind.
998 0.197 C22 Neg./Ind.
1039 0.194 C22 Neg./Ind.
1072 0.282 C22 Neg./Ind.
1081 0.220 C22 Neg./Ind.
1110 0.287 C22 Neg./Ind.
1265 0.263 C33 Neg./Ind.
C4 0.217 Not available Neg.
Table 3.3.2b. False positive samples from  initial evaluation o f ELISA test. 
A negative (Neg.) or indeterminate (Ind.) reading is based on 
RIBA bands as outlined in section 3.3.1.
3.3.3 Sensitivity and Specificity from Initial Evaluation
A total o f  88 IEI samples were assayed. The analysis data shows that 35 o f these 
samples contained only one RIBA band and were therefore treated as negative samples 
and included in the specificity results along with the 45 Cork Blood Bank negative 
samples. This gave a total o f 80 negatives. The remaining 53 positive samples 
contained two or more RIBA bands.
Table 3.3.3a shows the initial specificity and sensitivity results based on the cut-off 
value o f 0.145 absorbance units.
Sensitivity Specificity
53 True Pos.-6 False Nee. 
53 True Pos.
80 True Nee.-12 False Pos. 
80 True Neg.
47/53 x 100 68/80 x 100
88.6% 85%
Table 3.3.3a. Initial Sensitivity and Specificity on negatives and IEI positives, using
parameters outlined in section 3.2.5.
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Based on the sensitivity and specificity results obtained in Section 3.3, the solid phase 
was further evaluated. The peptides contained in the full pool were coated as shown in 
Table 3.4a.
Peptide Viral Region RIBA Band Coating Concentration
HCVNS3-1 NS3 C33 1/10,000
HCV 52 NS4 C100 1/10,000
HCV Core Core C22 1/10,000
HCV 15 Core C22 1/10,000
Table 3.4a. Peptides and coating concentrations used in ELISA fu ll pool solid phase. 
3.4.1 Additional Evaluation of Peptide Titration
Each o f the peptides contained in the full pool was titred individually at dilutions 
greater than the full pool dilution o f 1/10,000. A set o f combinations were coated and 
designated A to G. These combinations contained peptide with coating combinations as 
shown in Table 3.4. la. The full pool was included as a reference solid phase.
H C V N S3-1 HCV 52 HCV Core HCV 15
A - - - 1/800
B - - 1/3,000 -
C - 1/800 - -
D 1/500 - - -
E 1/600 - - -
F - 1/600 1/2,500 -
G - 1/800 - 1/800
Full Pool 1/10,000 1/10,000 1/10,000 1/10,000
Table 3.4.1a. Peptides and coating concentrations o f combinations in re-titre 
offu ll pool peptides, designated A to G.
To determine which solid phase gave the best sensitivity and specificity, the 
combinations were tested with 18 o f the IEI samples, the discrepant samples from the 
full pool peptide coated at 1/10,000, and 10 o f the Cork blood bank negatives.
Sample
Lot
A B C D E F G FP
473(+) 0.206 0.220 0.417 0.242 0.244 0.380 0.368 0.420
687(+) 2.223 1.272 0.139 0.122 0.128 1.225 2.001 1.248
694(+) Over 1.757 0.113 0.150 0.125 1.658 2.036 0.513
700(+) 1.195 2.110 Over 0.203 0.124 1.816 1.604 1.098
706(+) 2.165 1.796 0.175 0.168 0.137 1.709 2.016 0.545
709(+) Over 2.308 0.249 0.228 0.199 0.543 2.196 1.139
727(+) Over 2.020 1.474 0.306 0.343 2.264 2.427 1.025
728(+) 0.377 0.338 0.146 0.147 0.144 0.340 0.362 0.317
741(+) 1.877 1.792 0.559 0.922 1.037 1.813 1.827 0.127
743(+) 0.584 1.561 0.127 0.125 0.116 1.630 0.638 0.119
748(+) 0.127 1.273 0.666 0.214 0.138 1.465 0.592 0.183
779(+) 0.284 0.287 0.698 0.091 0.077 0.720 0.742 0.470
937(Ind) 0.168 0.235 0.130 0.140 0.156 0.251 0.148 0.068
944(Ind) 0.103 0.081 0.098 0.088 0.104 0.086 0.094 0.077
959(Ind) 0.099 0.107 0.103 0.085 0.099 0.089 0.097 0.050
985(Ind) 0.175 0.112 0.123 0.208 0.099 0.108 0.176 0.085
991 (Ind) 0.175 0.112 0.119 0.137 0.136 0.112 0.165 0.103
1053(+) Over 1.916 0.725 0.146 0.156 1.996 Over 0.519
C l 0.146 0.131 0.167 0.081 0.082 0.081 0.190 0.098
C2 0.109 0.125 0.109 0.124 0.103 0.121 0.191 0.107
C3 0.097 0.102 0.126 0.067 0.068 0.084 0.103 0.087
C4 0.154 0.147 0.135 0.124 0.188 0.154 0.161 0.165
C5 0.130 0.136 0.155 0.082 0.073 0.136 0.126 0.108
C6 0.095 0.084 0.073 0.058 0.075 0.069 0.078 0.056
C7 0.085 0.076 0.095 0.088 0.091 0.072 0.086 0.091
C8 0.056 0.065 0.078 0.095 0.101 0.087 0.069 0.102
C9 0.087 0.102 0.098 0.087 0.100 0.084 0.095 0.099
CIO 0.125 0.112 0.135 0.123 0.115 0.124 0.111 0.135
Table 3.4.1b. Absorbance readings o f selected samples on new combinations of fu ll 
pool peptides, designated A to G. The readings o f the fu ll pool o f peptides all at 
1/10,000 are shaded, fo r  comparison. Samples are characterised based on RIBA 
banding as shown in Table 3.3.1a. These results are represented in Figure 3.4.1a.
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Figure 3.4.1a, Absorbance readings o f selected samples on re-titre offull pool 
peptide combinations, A to G, and also fu ll pool peptides, coated at 1/10,000.
Table 3.4.1c compares the absorbance o f samples, which gave false positive results on 
full peptide pool coated at 1/10,000 (Table 3.3.2b), with the value obtained with the 
new combination o f flail pool peptides, designated A to G.
Sample Lot A C D E F G FP
722 0.107 0.124 0.154 0.145 0.121 0.103 0.114 0.109
935 0.124 0.157 0.236 0.154 0.099 0.137 0.189 0.254
947 0.112 0.138 0.248 0.141 0.151 0.125 0.252 0.322
993 0.145 0.178 0.166 0.157 0.136 0.153 0.179 0.168
997 0.083 0.101 0.135 0.099 0.087 0.098 0.112 0.154
998 0.147 0.158 0.175 0.151 0.135 0.154 0.165 0.177
1039 0.092 0.121 0.201 0.132 0.127 0.174 0.121 0.154
1072 0.071 0.124 0.187 0.112 0.212 0.142 0.128 0.181
1081 0.189 0.211 0.274 0.201 0.164 0.196 0.107 0.250
1110 0.084 0.179 0.212 0.154 0.167 0.145 0.128 0.187
1265 0.143 0.169 0.176 0.122 0.163 0.149 0.198 0.263
Table 3.4.1c. Comparison o f absorbance values o f samples, which gave false positive 
readings on fu ll pool peptide coated at 1/10,000, with combinations designated A to G.
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Table 3.4.1d compares the absorbance values o fth e  false negative samples, on full pool 
peptides coated at 1/10,000 from Table 3.3.2a, with the readings achieved on 
combinations A to G.
Sample Lot A B C D E F G FP
725 0.234 0.204 0.422 0.315 0.550 0.429 0.495 0.132
731 2.099 1.648 0.687 0.144 0.139 1.670 1.943 0.231
742 2.419 1.974 Over 0.152 0.126 Over Over 0.265
958 Over 2.280 1.338 0.199 0.172 2.284 Over 0.326
996 0.525 0.369 0.208 0.149 0.126 0.467 0.366 0.135
1115 0.625 0.456 0.136 0.123 0.156 0.599 0.561 0.108
Table 3.4. Id. Comparison o f  absorbance values o f  samples, which gave fa lse  
negative readings on fu ll  pool ofpeptides coated at 1/10, 000, now tested with
combinations designated A  to G.
3.4.2 Testing o f Chosen Com bination
As can be seen from Table 3.4.1c, there was an improvement in sensitivity with an 
increase in the absorbance readings o f  the false negative samples previously not 
detected with the full peptide pool, HCV 15, HCV Core, HCV 52 and HCV NS3-1, 
coated at 1/10,000. Specificity was also improved, as the absorbance values o f the false 
positive samples were lower as shown in Table 3.4.Id.
Based on this analysis, Table 3.4.2a shows a chosen solid phase combination.
HCV 15 HCV Core HCV 52 HCV NS3-1
1/800 1/2,500 1/600 1/500
Table 3.4.2a. New peptide coating dilutions chosen after testing o f  samples giving 
fa lse  positive and negative results on fu ll pool peptides coated at 1/10, 000.
On the above peptide combination, all available HCV positive and negative material 
was assayed. This consisted o f 45 negative sample from cork blood bank and the 88 
samples from IEI. Along with these samples a HCV seroconversion panel PHV 901 
supplied by Boston Biomedica, Inc. was also assayed. The specific region represented
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by the members o f this panel is shown in Table 3.4.2b. The data was obtained using the 
Ortho™ Anti-HCV RIBA 2.0 Assay.
Panel ID
Specific
Region Expected Result
Absorbance
PHV901-01 - Negative 0.187
PHV901-02 - Negative 0.176
PHV901-03 NS3 Indeterminate 0.354
PHV901-04 NS3 Indeterminate 0.234
PHV901-05 NS3 Indeterminate 0.203
PHV901-06 NS3 Indeterminate 0.232
PHV901-07 NS3, NS4 Positive 1.051
PHV901-08 NS3, NS4 Positive 0.829
PHV901-09 NS3, NS4 Positive 1.100
PHV901-10 NS3, NS4 Positive 1.029
PHV901-11 NS3, NS4 Positive 1.562
Table 3.4.2b. Viral region and absorbance readings o f HCV seroconversion panel; 
panel tested on the new fu ll pool peptide combination shown in Table 3.4.2a.
Figure 3.4.2a compares the absorbance reading o f the 88 IEI samples tested with new 
combination in Table 3.4.2a with that obtained with the foil pool o f  peptides, all coated 
at 1/10,000. See Appendix 2 for raw data.
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Figure 3.4.2 a. Comparison o f IEI samples tested on new combination offull pool 
peptides as shown in Table 3.4.2a, and also on fu ll pool peptides,
HCV 15, HCV Core, HCV 52 and HCVNS3-1 all coated at 1/10,000.
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The absorbance readings obtained for the negative samples from Cork blood bank are 
shown in Table 3.4.2d.
New Combination Full New Combination Full
Sample Pool Sample Pool
C l 0.151 0.141 C24 0.153 0.111
C2 0.174 0.126 C25 0.184 0.142
C3 0.153 0.070 C26 0.143 0.077
C4 0.256 0.217 C27 0.165 0.066
C5 0.190 0.082 C28 0.163 0.072
C6 0.103 0.068 C29 0.116 0067
C7 0.147 0.110 C30 0.172 0.059
C8 0.148 0.069 C31 0.187 0.075
C9 0.133 0.068 C32 0.132 0.079
CIO 0.127 0.065 C33 0.198 0.095
C l l 0.099 0.082 C34 0.212 0.104
C12 0.139 0.098 C35 0.102 0.067
C13 0.160 0.085 C36 0.155 0.066
C14 0.182 0.071 C37 0.111 0.072
CIS 0.150 0.081 C38 0.141 0.069
C16 0.232 0.143 C39 0.165 0.107
C l 7 0.167 0.135 C40 0.125 0.076
C18 0.136 0.074 C41 0.194 0.085
C19 0.149 0.110 C42 0.191 0.097
C20 0.127 0.085 C43 0.185 0.070
C21 0.113 0.065 C44 0.197 0.098
C22 0.122 0.105 C45 0.181 0.073
C23 0.143 0.058
Table 3.4.2d. Absorbance readings o f  negative samples tested on new fu ll pool 
combination and the fu ll pool with all peptides, H C V  15, H C V  Core, H CV 52 and
H C V  NS3-1, coated at 1/10,000.
The increase in solid phase coating dilutions resulted in an increase in the absorbance 
values o f  the positive readings as is seen from Table 3.4.2b. However Table 3.4.2d 
shows that, although sensitivity had improved, there was also an increase in the 
absorbance values o f some o f the negative readings.
3.4.3 Sensitivity and Specificity on Im proved Solid Phase
To calculate the sensitivity and specificity o f  the new solid phase, a cut-off value was 
determined. The cut-off value was calculated as the mean o f the negative readings ± 2 
standard deviation units (x ±2 SD).
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Using a cut-off value o f 0.206 the sensitivity and specificity was calculated as shown in 
Table 3.4.3a.
The specificity figures were calculated without the inclusion o f the 35 indeterminate 
samples.
Specificity Sensitivity
45 True Neg. -  3 False Pos. 53 True Pos.- 3 False Neg.
45 True Neg. 53 True Pos.
42/45x 100
50/53 x 100
93.3% 94.3%
Table 3.4.3a. Sensitivity and specificity based on samples tested on new combination 
o f  peptides. H C V  IS  at 1/800, H C V  core at 1/2,500,
H C V  52 at 1/600 and HCV NS3-1 at 1/500.
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3.5 Evaluation of Direct Coating of Peptide
In an attempt to reduce the negative values and also to improve sensitivity, it was 
decided to coat the HCV peptides directly on to the microwells omitting the conjugation 
o f peptide to BSA.
This procedure involved dissolving a known quantity o f  the peptide raw material in a 
coating buffer and then coating as per Section 2.3.1.
3.5.1 Com parison o f CCB and PBS as D irect C oating Buffers
A stock o f 1 mg/ml o f the coating peptide was made. An accurate quantity of 
approximately lm g o f peptide was weighed and the corresponding volume o f buffer 
was added to give a 1 mg/ml solution.
e.g. 1 mg/ml solution contains
1,100jog peptide + 1.1ml buffer 
700|og peptide + 700|ol buffer
Two coating buffers were evaluated for this purpose, carbonate coating buffer, pH 9.6 
(CCB), used previously, and 0.1M phosphate buffered saline, pH 7.4 (PBS).
To evaluate both buffers, HCV 15 peptide was chosen and dilutions made as shown in 
Table 3.5.1a. A sub-stock o f  10|og/ml was made from lmg/ml (lOOOjog/ml) stock.
4pg/ml 2fog/ml lUg/ml 0.5ng/ml
Volume 10fjg/ml 
stock
4.8ml 6ml o f  4(ig/ml 6ml o f 2p.g/ml 6ml o f 1 fog/ml
Volume CCB/PBS 5.2ml 6ml 6ml 6ml
Table 3.5.1 a. Dilutions o f  H CV 15 peptide coatedfor evaluation 
o f  direct coating o f  peptide.
The wells were tested with two positive samples, 741, which gave high absorbance 
values previously, 700 which gave a medium to low positive reading, and two negative 
samples, C ll  and C l2.
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Figure 3.5.1a represents the absorbance readings o f  the samples assayed and compares 
both coating buffers.
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Figure 3.5.1a. Absorbance readings o f  samples in comparison o f  carbonate coating 
buffer and phosphate buffered saline as buffers fo r  direct coating ofpeptide.
As can be seen phosphate buffered saline was the preferred buffer because at lower 
coating concentrations at l^ig/ml and 0.5^g/ml o f  HCV 15, the absorbance values did 
not decrease. This was not observed in the case o f  carbonate coating buffer.
3.5.2 Titration o f Peptides Coated D irectly
Based on results obtained from directly coating the HCV 15 peptide, the remaining 
peptides were also coated in 0.1M PBS, pH 7.4.
A set o f peptide combinations at varying concentrations was made and designated 1 to 
6, as shown in Table 3.5.2a.
Combination HCV NS3-1 
(Hg/nil)
HCV 52 
(M-g/ml)
HCV Core 
(fig/ml)
HCV 15 
(Hg/inl)
1 0.25 0.5 0.5 0.5
2 0.25 0.5 0.25 0.25
3 0.25 1.0 1.0 1.0
4 0.25 1.0 0.5 0.5
5 0.25 1.0 0.5 1.0
6 0.25 0.25 0.25 0.25
unconjugated peptide to the plate.
Table 3.5.2a. Peptide combinations, designated 1 to 6, to evaluate direct coating of
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Each of the above combinations 1 to 6, was evaluated using 54 of the IEI positive 
samples and 20 Cork blood bank negative samples.
The readings obtained are represented in Figure 3.5.2a. See Appendix 3 for raw data.
•  Combination 1 
■  Combination 2 
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•  Combination 4  
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•  Combination 6
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Figure 3.5.2 a. Absorbance values o f  IEIpositive and negative samples on wells 
coated with directly coated un conjugated peptide combinations, designated 1 to 6.
Analysis o f results indicated that the best combination o f peptide and coating 
concentration was achieved with combination 5. This combination succeeded in picking 
up all 45 positive samples with higher absorbance reading than the other combinations, 
although negative samples were slightly higher than had been previously achieved 
where the solid phase was coated with conjugated peptide.
Combination 5 contained HCV 15 
HCV 52 
HCV Core 
HCV NS3
1.0pg/ml 
1.0pg/ml 
0.5(.ig/ml 
0.25|ig/ml
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Figure 3.5.2b compares the absorbance readings o f  the negative samples C l to C20, 
tested on combination 5, coated with unconjugated peptide in the direct coating method, 
and the new full pool solid phase coated with conjugated peptide.
Negative Sample
Figure 3.5.2b. Comparison o f  negative samples assayed on ELISA wells 
coated with the fu ll pool o f  conjugated peptides, with directly coated unconjugated
peptide.
Although there was an improvement in sensitivity with the direct coating method the 
readings for the negative samples are slightly higher. In order to reduce the slight 
background observed with this method, the enzyme conjugate was re-evaluated.
3.5.3 Approaches to Im prove Specificity w ith D irect Coating M ethod
Based on previous evaluation, the KPL conjugate was at a dilution o f  1/80,000 (Figure 
3.2.2a) in Cytochrome C diluent with 0.05% Triton X-100 (Figure 3.2.3a).
3.5.3.1 Titre o f the KPL Conjugate
The conjugate was further titred between 1/80,000 and 1/120,000. The titred conjugate 
was tested with negative samples C l to C12 and also with one positive sample, 709, and 
one indeterminate sample, 996, on solid phase combination 5, directly coated.
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Table 3.5.3a shows the absorbance values obtained with all samples. The absorbance
readings o f  the 12 negative readings are represented in Figure 3.5.3a.
Sample 1/80,000 1/90,000 1/100,000 1/120,000
C l 0.193 0.164 0.145 0.132
C2 0.212 0.198 0.175 0.163
C3 0.213 0.185 0.162 0.144
C4 0.225 0.201 0.157 0.132
C5 0.210 0.187 0.169 0.155
C6 0.132 0.121 0.101 0.087
C7 0.199 0.163 0.142 0.129
C8 0.175 0.156 0.136 0.122
C9 0.163 0.145 0.132 0.119
CIO 0.175 0.135 0.121 0.109
C l l 0.189 0.165 0.143 0.125
C12 0.162 0.139 0.120 0.106
709 2.500 2.213 2.196 1.845
996 0.573 0.544 0.491 0.387
Table 3.5.3a. Absorbance readings o f  samples in further titre o f
KPL anti-human IgG-peroxidase conjugated, to improve specificity 
with direct coating o f  unconjugated peptide.
■  1 / 8  0 , 0  0 0
0 . 3 -
0 . 2 8  -i 
0 . 2  6 -  
0 . 2 4 -  
0.2 2 -  
0 . 2 -  
0 .18- 
0 . 1 6 -
A b s o r b a n c e 0 .14- 
0 .12- 
0 . 1 -  
0 . 0  8 -  
0 . 0 6  -  
0 . 0 4 -  
0 . 0 2  -  
0 -
S a m p l e  N u m b e r
Figure 3.5.3a. Absorbance readings o f  negative samples 
in evaluation o f  KPL anti-human IgG-peroxidase conjugated, 
to improve specificity tested on directly coated peptide.
■  1 / 9 0 , 0 0 0  
□ 1 /1 0 0 , 0  0 0 
□  1 /1 2 0,000
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The conjugate titre chosen was at 1/100,000. As can be seen from the above data, the 
absorbance values o f  the negative readings decreased at this dilution while not 
compromising on sensitivity, as the readings for samples 709 and 996 show.
3.5.3.2 Addition o f Serum to the Conjugate Diluent
To further improve specificity, the conjugate diluent was further evaluated. Various 
quantities o f  Foetal Bovine Serum (FBS) and Goat Serum (GS) were added to the 
Cytochrome C diluent. The components were added at 5% (v/v), 10% (v/v), 20% (v/v). 
With the conjugate diluted at 1/100,000, the same samples were assayed. Cytochrome 
C diluent with no additives was used as a control conjugate.
20% (v/v) 
FBS
10% (v/v) 
FBS
5% (v/v) 
FBS
20% (v/v) 
GS
10% (v/v) 
GS
5% (v/v) 
GS
Control
C l 0.071 0.079 0.073 0.065 0.072 0.081 0.145
C2 0.098 0.111 0.102 0.053 0.065 0.078 0.175
C3 0.074 0.081 0.086 0.048 0.052 0.065 0.162
C4 0.070 0.069 0.072 0.041 0.045 0.057 0.157
C5 0.089 0.096 0.095 0.082 0.078 0.096 0.169
C6 0.065 0.061 0.069 0.046 0.048 0.052 0.101
C7 0.062 0.073 0.071 0.047 0.053 0.066 0.142
C8 0.075 0.081 0.086 0.049 0.042 0.054 0.136
C9 0.078 0.084 0.082 0.045 0.054 0.059 0.132
CIO 0.075 0.072 0.074 0.041 0.047 0.045 0.121
C ll 0.099 0.123 0.112 0.050 0.055 0.062 0.143
C12 0.081 0.089 0.088 0.051 0.046 0.054 0.120
709 1.872 1.925 2.139 0.596 0.621 0.832 2.196
996 0.379 0.422 0.478 0.133 0.195 0.265 0.491
Table 3.5.3b. Absorbance readings o f  samples tested with addition
o f  serum to conjugate diluent to improve specificity.
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Figure 3.5.3b. Absorbance readings o f  negative samples tested, with addition 
o f  serum to conjugate diluent, to improve specificity on directly coated peptide.
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Figure 3.5.3b shows the absorbance values o f the negative samples only. The addition
o f goat serum gave the lowest negative readings but sensitivity was reduced
significantly as can be seen in Table 3.5.3b.
The diluent, which gave the best specificity and sensitivity based on both negative and 
positive readings, was cytochrome C diluent with the addition o f 5% (v/v) FBS.
3.5.4 Im proved A ssay Param eters
As a result o f  the investigation o f directly coating the peptide as described in Section 
3.5, the following assay parameters were used in the final evaluation o f samples. The 
assay protocol is outlined below.
Plate: Combination 5 Coated Directly
HCV 15 LO^g/ml
HCV 52 1.0ng/ml
HCV Core 0.5(ig/ml
HCVNS3 0.25fjg/ml
Sample: 1 in 10 in-well dilution in control dilution buffer with 5% (v/v) goat
serum (10p.l sample + 90(j.l diluent)
Conjugate: 1/100,000 KPL conjugate in cytochrome C diluent with 0.05% (v/v)
Triton X-100 and 5% (v/v) Foetal Bovine Serum
Assay Protocol: lOOfal sample
30 min. at 37°C 
Wash x 5 times 
100(j,l conjugate 
30 min. at 37°C 
Wash x 5 times 
lOO i^l substrate 
15 min. at 25°C
Read at 450nm with a reference filter o f 630nm.
101
3.6 Final Evaluation of HCV ELISA
For the final evaluation o f the ELISA assay, a total o f 93 negative samples and 88 IEI 
samples were evaluated along with the 11 members o f  the seroconversion panel.
These 192 samples were tested with the parameters outlined in Section 3.5.4 and 
compared with the previous parameters as outlined in Section 3.2.5.
Table 3.6a shows the peptide quantity contained in both methods.
Peptide HCV 15 HCV Core HCV 52 HCV NS3-1
Direct Coat l.OfOg/ml 0.5|xg/ml 1.0|ig/ml 0.25|ig/ml
Conjugated 1/800 1/2,500 1/600 1/500
Table 3.6a. Peptides combinations contained in directly coated 
and conjugated coating methods.
3.6.1 Com parison of A bsorbance Readings with both m ethods
3.6.1.1 Assay of DEI Samples
Figure 3.6.1a compares the absorbance readings obtained for the IEI samples using both 
solid phase coating methods. See Appendix 4 for raw data.
S a m p le  n u m b e r
Figure 3.6.1a. Absorbance o f  IEI samples on conjugated and directly coated peptide
fo r  fin a l evaluation o f  H CV ELISA.
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3.6.1.2 Assay of Negative Samples
Figure 3.6.1b compares the absorbance readings obtained for the negative samples using 
both methods. See Appendix 5 for raw data.
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Figure 3.6. lb . Absorbance o f  negative samples assayed on directly coated and 
conjugated peptide fo r fin a l evaluation o f  H C V  ELISA.
3.6.1.3 Assay o f Seroconversion Panel
Panel ID Specific Region Expected Result Conj ugated Directly
PHV901-01 - Negative 0.187 0.098
PHV901-02 - Negative 0.176 0.084
PHV901-03 NS3 Indeterminate 0.354 0.365
PHV901-04 NS3 Indeterminate 0.234 0.451
PHV901-0S NS3 Indeterminate 0.203 0.318
PHV901-06 NS3 Indeterminate 0.232 0.209
PHV901-07 NS3, NS4 Positive 1.051 1.265
PHV901-08 NS3, NS4 Positive 0.829 1.023
PHV901-09 NS3, NS4 Positive 1 . 1 0 0 0.897
PHV901-10 NS3, NS4 Positive 1.029 1.255
PHV901-11 NS3, NS4 Positive 1.562 2 . 1 1 2
Table 3.6.1a. Absorbance readings o f  H C V  seroconversion panel on solid phase 
peptide, both coated directly and conjugated to carrier protein.
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3.6.2 Sensitivity and Specificity of ‘In-house’ Evaluation of ELISA
A cut-off value was determined using the method applied previously. This value was 
used to calculate the sensitivity and specificity achieved with both coating methods.
The Ortho™ RIBA banding indicated that 53 IEI samples were positive and these results 
were used to calculate the sensitivity results. As previously done, the specificity results 
were calculated with and without the inclusion o f the indeterminate samples.
The calculations for both coating methods are shown in Table 3.6.2a and 3.6.2b.
Specificity
Sensitivity
93 True Nee. -  6 False Pos. 
93 True Neg.
53 True Pos.- 3 False Nee. 
53 True Pos.
87/93 x 100 50/53 x 100
93.5% 94.3%
Table 3.6.2a. Sensitivity and specificity with solid phase coated with conjugated
peptide fo r  ‘in-house ’ evaluation.
Specificity Sensitivity
93 True Nes. -  1 False Pos. 
93 True Neg.
53 True Pos.- 0 False Nee. 
53 True Pos.
92/93 x 100 53/53 x 100
98.9% 100%
Table 3.6.2b. Sensitivity and specificity with solid phase coated with directly coated
peptide fo r  ‘in-house’ evaluation.
A comparison o f the sensitivity and specificity results as shown above, is represented in 
Figure 3.6.2a.
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Figure 3.6.2a. Sensitivity and specificity achieved during various 
stages o f  development o f  H CV ELISA.
The peptide combinations and coating concentrations used in each method is shown in
Table 3.6.2c.
Solid Phase HCV 15 HCV Core HCV 52 HCV NS3-1
Full pool conjugated peptide All Coated at 1/10,000
Improved conjugated peptide 1/800 1/2,500 1/600 1/500
Directly coated peptide l.Ofig/ml 0.5|ig/ml 1.0^g/ml 0.25|ag/ml
Table 3.6.2c. Peptide combinations and dilutions o f  peptide evaluated during 
development o f  H C V  ELISA assay.
Based on the data shown in Figure 3.6.2a, all clinical evaluations were carried out on 
plates coated with peptide directly coated on to the well.
3.6.3 Perform ance Evaluation at an External Site
The performance o f the HCV ELISA test was evaluated at an external trial site. The 
off-site location chosen was Public Health Laboratory Service (PHLS), Birmingham. 
Based on the internal evaluation results as outlined in the previous section, the 
evaluation at the PHLS was carried out with plates on which the peptide was directly 
coated. The assay parameters were as shown in Section 3.5.4.
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3.6.3.1 HCV ELISA Evaluation Results
A total o f  530 serum or plasma specimens were tested at the Public Health Laboratory, 
Heartlands Hospital, Birmingham. All specimens had been previously tested as part o f 
routine testing at the Serology Laboratory, PHLS, and had been confirmed by RIBA 
testing. Analysis o f  these samples showed that 281 samples were found to be anti-HCV 
negative and 249 were anti-HCV positive by RIBA banding. All specimens had been 
stored at -20°C prior to thawing for testing by the ELISA test. The cut-off value was 
determined as before by calculating the mean negative control absorbance reading + 2 
standard deviation units.
O f the 249 confirmed positive samples assayed, a total o f  233 samples gave a positive 
reading on the HCV ELISA test. A total o f 275 samples o f the 281 known negatives 
gave a negative reading on the ELISA. These results are summarised in Table 3.6.3a.
Specificity Sensitivity J
281 True Nee. -  6 False Pos. 249 True Pos.- 16 False Nee.
281 True Neg. 249 True Pos.
275/281 x 100 233/249x 100
97.9% 93.6%
Table 3.6.3 a. ELISA performance evaluation results from  PHLS, Birmingham.
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Figure 3.6.3a. Distribution o f  negative sample absorbance readings 
at PHLS H C V  ELISA evaluation.
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The absorbance readings obtained at the performance evaluation are represented in the 
histograms in Figures 3.6.3a and 3.6.3b. The distribution o f the readings for the 
negative samples tested is shown in Figure 3.6.3a and that o f  the positive readings in 
Figure 3.6.3b. The absorbance readings are divided into different histogram ranges and 
the amount o f samples, which gave a reading within a particular range, are shown. As 
can be seen from Figure 3.6.3a, 199 o f the 281 negative samples tested gave a reading 
within a range o f 0 to 0.05 absorbance units.
Nirrberof
sarrpJes 
in range
Absorbance at 450nm
Figure 3.6.3b. Distribution o f  positive sample absorbance readings 
at PHLS H C V  ELISA evaluation.
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4.1 Evaluation of Peptides on the Test Card Membrane
The development o f the rapid assay followed a similar format to that used in the 
development o f the ELISA test. Both assays are examples o f  an indirect ELISA as 
outlined in section 1.7.4.2. Due to the success achieved in the ELISA format with the 
immobilised HCV peptides, the same peptides were analysed for use on the test card 
format. Many tedious steps are omitted in the development o f the rapid test with the 
availability o f  reagents and buffers for evaluation. The first step involved the assembly 
o f the test card device.
4.1.1 Assem bly o f Test Cards
The assembly of each rapid card device consisted o f four raw material components.
• A moulded 2-port test card,
• An absorbent pad,
• A glass cut membrane and
• A white backing label.
The test card components are shown in Figure 4.1.1a and the assembled test card (front 
view and back view) shown in Figure 4.1.1b. The diagrams are shown without the 
addition o f the backing label.
Test Card Mould Absorbent Pads Glass Cut Membrane
Figure 4.1.1a Components used to assemble SeroCard test device.
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HCV Test Card
O  O
O  O
Front
Figure 4.1.1b Front and back view o f  assembled SeroCard device
without backing label.
The cards were assembled manually. As is seen from the diagram, the absorbent pads 
were placed in grooves at either end o f the test card. The membrane was then placed in 
position over these pads stretching the length o f  the card. Finally, the backing label was 
applied to ensure the components remained in position.
4.1.2 Adhesion o f Peptides to Card M em brane
In the same manner as peptides were coated to microtitre plate wells, the peptides were 
evaluated for adhesion to the card membrane. To do this, a quantity o f peptide was 
spotted or dispensed on to the top ports o f the test card membrane. The spotting sites 
are shown in Figure 4 .1.2a.
Control port 
no peptide spotted
HCV Test Card
O  O
O  O
Reaction port; 
site o f peptide
Control dilution 
buffer
Figure 4.1.2a Site o f  spotted peptide and control spots 
on spotted SeroCard test device
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Due to the high specificity and sensitivity obtained with the peptide combination used in 
the microtitre plate assay, the same combination o f  peptide was evaluated for use on the 
test card membrane.
In the case o f  the microtitre plate assay, the peptides were coated both as conjugated and 
as unconjugated peptide. Due to the porous nature o f  the test card membrane the 
peptides were conjugated to the carrier protein, BSA, prior to spotting. This conjugation 
procedure is shown in section 2.1.1 and the peptides spotted as in section 2.1.7.
4.1.2.1 Determination o f Spotting Dilution
The coating volume used in the microtitre plate test was 100(0.1 per well. The proposed 
spotting volume for the rapid method was supplied by Trinity Biotech pic., and was 5 pi 
o f  spotting solution per port.
This card spotting volume was twenty times smaller than the corresponding plate 
coating volume o f lOOjol. Due to this volume decrease, the concentrations o f the 
peptides were increased accordingly, also by a factor o f twenty.
The peptides and the coating concentrations used in the plate assay (section 3.4.2) are 
shown in Table 4.1.2a. Based on these coating dilutions at 1 OOjol, the corresponding 
spotting dilutions at 5(ol are also shown.
Peptide
Volume. Applied 
Plate Test Card
Coating Concentration 
Plate Test Card
HCV 15 lOOpl 5 pi 1/800 1/40
H C V  Core lOOpl 5|ol 1/2,500 1/125
H CV 52 lOOfol 5 pi 1/600 1/30
HCVNS3-1 lOOpl 5 pi 1/500 1/25
Table 4.1.2a Coating dilutions o f  peptides used in ELISA test and the corresponding
spotting dilution on test card membrane.
Using the dilutions outlined in Table 4.1.2a, spotting solutions were formulated for each 
o f  the four peptides. In addition, the four peptides were combined in one solution
giving the above final spotting dilutions. All dilutions were made in 2x phosphate 
buffered saline (2x PBS).
4.1.2.2 Spotting o f Cards
The procedure used to spot, block and dry the cards followed a method supplied by 
Trinity Biotech pic. To spot, 5^1 of the four individual peptide spotting solutions, along 
with the full combination, were applied to the top right port as shown in Figure 4.1.2a. 
As a control, 5pl o f the diluent, 2x PBS was spotted on to the top left port. On the 
bottom right port under the peptide spot 10(j.l o f  control dilution buffer was spotted.
The cards were incubated, blocked and dried as per the spotting procedure described in 
section 2.5.5.
4.1.3 Test Form at and Interpretation o f Results
The wash reagent, enzyme conjugate reagent, substrate reagent and stopping reagent, 
along with the initial test format, were all supplied by Trinity Biotech pic. They were 
supplied in bottles containing a dropper tip to dispense the reagent. One drop o f reagent 
corresponded to a volume o f approximately 50(j,l. Samples were applied using a 
dropper pipette, which dispensed approximately 40(.xl o f liquid.
4.1.3.1 Test Form at for HCV Rapid Assay
Step Reagent Volume Applied Location Incubation time
1 Wash reagent 1 drop Bottom ports Until absorption
2 Test specimen 1 drop Bottom ports 30 seconds
3 Wash reagent 1 drop Bottom ports 30 seconds
4 Wash reagent 1 drop Top ports Until absorption
5 Enzyme reagent 1 drop Top ports 1 min.
6 Wash reagent 4 x 1  drop Top ports Until absorption
7 Substrate reagent 2 drops Top ports 5 min.
8 Stopping reagent 1 drop Top ports Until absorption
Table 4.1.3a Test protocol fo r  assay o f HCV SeroCard.
I l l
4.1.3.2 Interpretation of Results
Results were interpreted based on the formation o f  colour on the reactive top right port 
o f the test card after the substrate incubation time had elapsed. In the case o f  a positive 
reading, a blue colour formed at the reaction site following the addition o f substrate. 
The intensity o f  colour was directly proportional to the amount o f HCV antibody 
present in the sample. To indicate a negative reading, no colour appeared at the reactive 
port. In the case o f a colour o f  equal strong intensity on both top ports, the result was 
termed invalid. Figure 4.1.3 a highlights these interpellations.
A
HCV Test Card
O •
,o ° J
\
HCV Test Card
O o
O O
)
Positive Result Negative Result Invalid Result
Figure 4.1.3a Colour interpretation o f  SeroCard assay results showing 
a positive, negative and invalid test result.
To enable the recording o f results, during the development o f  the assay, the colour 
intensity was given a numerical value 0 to 10. A result was designated two numbers, 
for example, (0,7), which reads the colour intensity o f  both the left and the right ports. 
The stronger the colour intensity the higher the number. Figure 4.1.3b shows the 
intensity and the corresponding numerical value used.
Figure 4.1.3b Representation o f  colour intensity with the corresponding numerical 
value fo r  interpretating SeroCard test result 
112
4.1.4 Testing with Characterised Sera
Using the cards spotted with the dilutions shown in Table 4.1.2a and with the format 
outlined in Table 4.1.3a, a total o f nine samples were tested. The samples were those 
used in the initial evaluation o f the solid phase in section 3.1.3 o f the ELISA test 
development and were characterised using the Ortho™ RIBA 3.0 Assay. The 
characterisation is shown in Table 4.1.4a
Sample ID Viral Region Specific Peptide
1 NS3, Core NS3-1, HCV Core, HCV 15
2 NS4, Core HCV 52, HCV Core, HCV 15
3 Core HCV Core, HCV 15
4 NS3, NS4 HCV NS3-1, HCV 52
5 Core HCV Core, HCV 15
6 NS4, Core HCV 52. HCV Core, HCV 15
7 Neg. None
8 Neg. None
9 Neg. None
Table 4.1.4a Characterisation o f  nine samples by RIBA banding fo r  evaluation o f
SeroCard test device.
The results achieved for the above samples on the individually coated cards along with 
the combination cards are shown in Table 4.1.4b.
Sample ID HCV 15 HCV Core HCV 52 HCV NS3-1 Com bination
at 1/40 at 1/125 at 1/30 at 1/25 of full pool
1 0,2 0,3 0,0 0,1 0.4
2 0,3 0,4 0,2 0,0 0.5
3 0,2 0,2 1,1 0,0 0.2
4 0,0 0,0 0,1 0,1 0,2
5 0,3 0,2 0,0 0,0 0,3
6 0,4 0,3 0,3 0,0 0.5
7 0,0 0,0 0,1 0,0 1,1
8 0,0 1,1 0,0 0,0 0,0
9 0,0 0,0 0,0 0,0 0,0
Table 4.1.4 b Results o f  initial testing o f  nine characterised samples on 
combinations o f  peptides spotted on SeroCard membrane as shown in Table 4.1.2a.
Table 4.1.4b is represented graphically in Figure 4.1.4a. Each result was assigned a 
value, called a numerical difference, derived from subtracting the lower control port
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value from the reactive port value. I f  the result ‘0,5’ was achieved then the numerical 
difference was ‘5 ’ and in the case o f ‘1,1’ the value was ‘O’. The highest specificity was 
achieved for negative sample giving a value o f  ‘O’, while the opposite was true in the 
case o f positive samples, where a higher numerical difference was preferable.
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Figure 4.1.4a Numerical difference values achieved fo r  each 
peptide combination in initial testing o f  characterised samples.
As can be seen from Figure 4.1.4a, the cards spotted with a combination o f all four 
peptides gave the highest numerical difference for the six positive samples while a 
numerical value o f ‘0 ’ was obtained with the negative samples. Closer examination o f 
the graph shows that 100% specificity was achieved with all peptides coated, with the 
exception o f  HCV 52 which showed one false positive (sample 7 gave a reading o f  0,1).
4.1.4.1 Initial Sensitivity and Specificity
Based on the results achieved in the previous section, the following specificity and 
sensitivity was obtained as shown in Table 4.1.4c.
HCV 15 HCV Core HCV 52 HCV NS3-1 Combination 
of full pool
Sensitivity 5/6 5/6 3/6 2/6 6/6
83.3% 83.3% 50% 33.3% 100%
Specificity 3/3 3/3 2/3 3/3 3/3
100% 100% 66.6% 100% 100%
Table 4.1.4c Sensitivity and specificity results achieved fo r  initial SeroCard testing.
4.2 Attem pts to Im prove Rapid A ssay Sensitivity and Specificity
Following the sensitivity and specificity results achieved in table 4.1.4c, the cards 
spotted with a combination o f all four peptides were chosen for further evaluation work. 
Although the sensitivity and specificity obtained with the combination o f peptides was 
excellent, some improvements were needed to improve the numerical difference 
achieved with the positive samples tested. The intensity o f the colour also needed 
improvement.
The parameters to be examined to improve these areas are
• Spotting dilution
• Incubation times
4.2.1 Investigation o f Optim um  Spotting D ilution
In an attempt to increase the colour intensity o f  the positive samples, variations in the 
spotting dilutions o f  the peptides on the cards were investigated. As Table 4.1.4c 
indicates, the peptide HCV 52 gave the poorest specificity result at 66.6%. Therefore, 
the spotting dilution o f this peptide was not increased. A number o f spotting solutions 
was formulated with peptide dilutions as shown in Table 4.2.1a. Combination ‘A ’ was 
the combination used in Section 4.1.
Spotting
Combination HCV 15 HCV Core HCV 52 HCV NS3-1
A 1/40 1/125 1/30 1/25
B 1/35 1/110 1/30 1/20
C 1/30 1/100 1/40 1/20
Table 4.2.1a. SeroCard spotting combinations used to optimise spotting dilution 
in an attempt to improve test performance.
The peptides were spotted, blocked and dried using the same procedure as previously 
used. A total o f 50 cards were spotted with each combination. They were pouched 
along with a desiccant and stored at 2-8°C for use.
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A total o f 25 samples were tested on the above combination o f cards. These comprised 
o f 13 positive samples and 12 negatives. They were characterised by Recombinant 
ImmunoBlot Assay (RIBA) and were some o f the samples used in Section 3.3.1 o f  the 
ELISA assay development.
4.2.1.1 Testing of Combinations A to C.
RIBA Band Viral Region Specific Peptide
C100 NS4 HCV 52
C33 NS3 HCVNS3-1
C22 Core HCV Core/HCV 15
5-1-1 NS5 None
Table 4.2.1b. RIBA banding and corresponding viral region by Ortho ™assay.
A list o f the positive samples tested, along with the corresponding RIBA banding are 
shown in Table 4.2. lc.
Sample
IEI Lot 
Number
RIBA Banding Viral Region(s) Interpretation
1 711 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
2 712 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
3 713 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
4 714 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
5 717 C100, C33, C22 NS4, NS3, Core Pos.
6 718 5-1-1, Cl 00, C33, C22 NS5, NS4, NS3, Core Pos.
7 753 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
8 754 5-1-1, C100, C33, C22 NS5, NS4, NS3, Core Pos.
9 859 C100, C33, C22 NS4, NS3, Core Pos.
10 865 C33, C22 NS3, Core Pos.
11 937 C22 Core only Neg./Ind.
12 995 C33, C22 NS3, Core Pos.
13 997 C22 Core only Neg./Ind.
Table 4.2.1c. Positive samples and RIBA banding o f  samples 
tested on SeroCard spotting combinations A  to C.
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The results o f  the positive and negative samples tested are shown in Table 4.2. Id. The 
negative samples, C l to C12 were obtained from Cork Blood Bank. The samples were 
tested in duplicate and both readings are shown.
Sample Combination A Combination B Com bination C
1. 711 1,5 0,5 1,6 0,5 0,6 0,5
2. 712 0,3 1,3 0,5 1,5 1,6 0,6
3. 713 1,6 0,6 0,6 1,7 0,6 0,7
4. 714 1,6 1,6 0,6 1,7 0,7 0,6
5. 715 0,7 0,6 1,8 0,7 0,7 0,7
6. 718 0,6 0,5 0,6 0,6 0,7 0,7
7. 753 1,3 1,4 1,4 1,5 0,5 0,4
8. 754 1,6 1,7 0,6 1,7 0,6 0,6
9. 859 0,3 0,4 0,4 0,4 0,4 1,5
10. 865 0,2 0,3 0,3 0,3 0,4 0,3
11. 937 1,1 1,0 1,1 1,1 1,1 0,1
12. 995 0,5 1,6 0,6 1,5 1,6 0,6
13. 997 2,2 2,2 1,2 1,1 1,2 1,2
14. C l 0,0 0,0 0,0 0,0 0,0 0,0
15. C2 1,1 1,1 0,0 1,1 1,1 0,0
16. C3 0,0 0,0 0,0 0,0 0,0 0,0
17. C4 1,1 1,1 0,0 1,1 0,0 0,0
18. C5 2,2 2,1 1,1 1,1 1,1 1,0
19. C6 0,0 0,0 0,0 0,0 0,0 0,0
20. C7 0,1 1,1 1,1 0,0 0,0 0,0
21. C8 0,0 0,0 1,0 0,0 1,1 0,0
22. C9 0,0 0,0 1,0 0,0 0,0 0,0
23. CIO 2,2 2,2 2,1 1,1 1,1 0,0
24. C l l 0,0 0,0 1,0 0,0 1,1 0,0
25. C12 0,0 0,0 0,0 0,0 0,0 0,0
Table 4.2.1& Results o f  samples from  Table 4.2.1c tested with SeroCard spotting 
combinations, designated A  to C (Table 4.2.1a).
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Taking the best duplicate result for each combination, the numerical difference was 
calculated for each sample and was plotted as shown in Figure 4.2. la.
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Figure 4.2.1a. Numerical difference values fo r  25 samples 
tested on three peptide spotting combinations on SeroCard.
The above representation o f results indicates that combination ‘C’ gave the best 
readings. It gave the highest numerical difference values for the positive samples 1 to 
13 and was the only combination, which succeeded in picking up sample 13. For the 
negative samples, all combinations gave the desired numerical value, however, in the 
case o f  combination ‘C’, the lowest actual readings were observed.
All future investigative studies were carried out on cards spotted using the peptide 
dilutions in combination ‘C’, HCV 15 spotted at 1/30, HCV Core at 1/100, HCV 52 at 
1/40 and HCV NS3-1 at 1/20.
4.2.2 Investigation o f A ssay Incubation Tim es
The next study involved varying the incubation times o f the assay to attempt to improve 
the colour intensity while keeping the negative sample readings as low as possible. The 
times used up to this point are shown in Table 4.1.3a, and are summarised as follows.
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Sample Incubation 30 seconds
Post-sample Wash Incubation 30 seconds
Enzyme Incubation 60 seconds
Substrate Incubation 5 min.
The incubation times o f three stages o f  the assay were varied. These variations are 
reflected in Table 4.2.2a.
Incubation Time 1 Time 2 Time 3
Sample Time (Si, S2, S3) 120 seconds 60 seconds 30 seconds
Post-sample Wash Time (Wi, W2, W3) 30 seconds 60 seconds 120 seconds
Enzyme Time (Ei, E2, E3) 60 seconds 90 seconds 120 seconds
Table 4.2.2a. Proposed variations in assay incubation times o f  
SeroCard assay to  improve colour intensity.
4.2.2.1 Sample Incubation Time
A total o f  nine samples were tested with sample incubated as shown above. Six o f  these 
samples were positive, three o f them represented by three RIBA bands and three by two 
RIBA bands. The other three samples were negative. The results are shown in Table 
4.2.2b.
Sample tested Si (120s) S2 (60s) S3 (30s) I
Three Band 701 0,2 0,2 0,3
727 0,4 0,5 0,7
742 0,3 0,4 0,6
Two Band 696 0,3 0,5 0,6
678 0,1 0,2 0,3
736 0,0 0,0 0,1
Negative C13 0,0 0,0 0,0
CIS 0,0 0,0 0,0
C16 0,0 0,0 0,0
Table 4.2.2b. Result o f  nine samples used in study o f variation o f  sample 
incubation time in SeroCard assay. Si, S2 and S3 represent three different 
sample incubation times investigated.
The highest positive readings were achieved with incubation S3 , 30 seconds. Due to the 
clean negative readings observed with this sample incubation, this was chosen for the 
next stage.
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4.2.2.2 Post-Sample Wash Incubation Time
Using the same samples as were used previously, and with a sample incubation o f  30 
seconds, the incubation o f the post-sample wash was examined as in Table 4.2.2c.
Sample tested W , (30s) W 2 (60s) W 3 (120s) I
Three Band 701 0,3 0,2 0,3
727 0,6 0,6 0,8
742 0,6 0,6 0,7
Two Band 696 0,6 0,5 0,7
678 0,3 0,4 0,5
736 0,1 0,2 0,3
Negative C13 0,0 0,0 0,0
C15 0,0 0,0 0,0
C16 0,0 0,0 0,0
Table 4.2.2c Result o f  nine samples used in study o f  variation o f
post-sample wash incubation time in SeroCard assay. Wi, W2 and W3 represent three 
different post-sample wash incubation times investigated.
A post-sample wash time o f 120 seconds (W3) gave the highest positive readings with 
low negatives. This was chosen for the evaluation o f enzyme incubation time.
4.2.2.3 Enzyme Incubation Time
With a sample incubation time o f 30 seconds (Si), and wash time o f 120 seconds (W 3 ), 
the enzyme conjugate times were investigated. The results are recorded in Table 4.2.2d.
Sample Ei (60s) E2 (90s) E3 (120s)
Three Band 701 0,2 0,3 0,4
727 0,7 0,7 0,8
742 0,7 0,8 0,8
Two Band 696 0,7 0,7 0,8
678 0,5 0,5 0,6
736 0,3 0,4 0,5
Negative C13 0,0 0,0 0,0
CIS 0,0 0,0 0,0
C16 0,0 0,0 0,0
Table 4.2.2d. Result o f  nine samples used in study o f  variation o f
enzyme conjugate incubation time in SeroCard assay. Ei, E2 and E$ represent 
three different sample times investigated.
At the longer incubation time o f 120 seconds (E3), the negative sample readings 
remained low. This proved to be the best enzyme incubation time with an increase in 
the positive sample readings. In summary, a sample time o f 30 seconds, a post-sample 
wash time o f 120 seconds and an enzyme time o f 120 seconds were chosen as assay 
times.
4.3 Performance Evaluation-Analysis of Characterised Sera
Upon completion o f the studies to optimise the assay incubation times and parameters, a 
number o f HCV positive and negative serum and plasma samples were evaluated for 
performance.
The assay parameters, which were chosen for the evaluations, were as shown below.
C ard Spotting: 5jal peptide spotted on top right port as follows
HCV 15 at 1/30 
HCV Core at 1/100 
HCV 52 at 1/40 
HCV NS3-1 at 1/20 
5(0.12X PBS spotted on top left port 
10f.il control dilution buffer on bottom right port 
Cards were dried, blocked and pouched according to procedure in Section 2.4.7
Assay Protocol: As per Section 2.4.6., with the following incubation times
Sample incubation 30 seconds at 18-25°C
Post-Sample Wash Incubation Time 120 seconds at 18-25°C
Enzyme Incubation Time 120 seconds at 18-25°C
Substrate Incubation Time 5 minutes at 18-25°
4.3.1 In-house Clinical Trial
A total o f 76 positive and 20 negative samples were used to evaluate the HCV cards. 
The positive material consisted o f 53 samples supplied by International Enzymes Inc. 
(IEI), and 21 samples from Boston Biomedica Inc. (BBI). The negative samples were 
supplied by Cork Blood Bank. The IEI samples were characterised according to Table 
4.2.1b.
The test card results for each o f the IEI samples analysed are shown in Table 4.3.1a 
along with the RIBA banding. The ELISA reading obtained for the chosen samples are 
also included in this table.
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Sample 
Lot No
RIBA
Banding
Viral
Region(s)
Interpretation
ELISA
Result
SeroCard
Result
678 C33, C22 NS3, Core Pos. 1.669 0,6
682 C33, C22 NS3, Core Pos. 2.332 1,8
687 C33, C22 NS3, Core Pos. 2.057 1,6
694 C33, C22 NS3, Core Pos. 2.282 0,8
696 C33, C22 NS3, Core Pos. 2.459 0,7
699 C33, C22 NS3, Core Pos. 2.499 1,5
700 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.387 0,5
701 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.257 0,5
703 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.387 0,8
706 C33, C22 NS3, Core Pos. 2.331 2,6
708 C33, C22 NS3, Core Pos. 2.150 0,5
709 C100, C33, 
C22
NS4, NS3, 
Core
Pos. Over 0,10
710 C33, C22 NS3, Core Pos. 2.046 0,7
711 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.338 0,5
712 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.145 0,3
713 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.168 0,6
714 5-1-1, C100, C33, C22
NS5, NS4, 
NS3, Core Pos.
2.274 0,6
717 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 2.168 0,8
718 5-1-1, ClOO, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.055 0,4
719 5-1-1, ClOO, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.917 0,4
727 5-1-1, ClOO, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.168 0,9
729 ClOO, C33, 
C22
NS4, NS3, 
Core
Pos. 2.435 1,6
731 5-1-1, ClOO, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.435 1,8
736 C33, C22 NS3, Core Pos. 1.810 0,5
738 5-1-1, ClOO, 
C33. C22
NS5, NS4, 
NS3, Core
Pos. 2.170 0,6
739 5-1-1, ClOO, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.428 0,9
741 C33, C22 NS3, Core Pos. 2.155 0,7
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Lot No
RIBA
Banding
Viral
Rcgion(s)
Interpretation
ELISA
Result
SeroCard
Result
742 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.155 0,10
743 C33, C22 NS3, Core Pos. 1.942 0,6
746 C33, C22 NS3, Core Pos. 2.114 0,5
748 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.129 0,3
750 C33, C22 NS3, Core Pos. 2.101 1,8
753 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 1.579 0,3
754 5-1-1, C100, 
C33, C22
NS5, NS4, 
NS3, Core
Pos. 2.155 0,6
865 C33, C22 NS3, Core Pos. 2.016 0,4
935 C22 Core only Neg./Ind. 0.341 1,1
937 C22 Core only Neg./Ind. 0.231 1,1
943 C100, C33 NS4, NS3 Pos. 2.317 1,8
944 C22 Core only Neg./Ind. 0.114 0,1
945 C33, C22 NS3, Core Pos. 2.220 0,8
950 C33, C22 NS3, Core Pos. 0.661 0,7
951 C33, C22 NS3, Core Pos. 1.134 1,3
958 C33, C22 NS3, Core Pos. 2.462 0,10
959 C22 Core only Neg./Ind. 0.147 0,1
961 C33, C22 NS3, Core Pos. 1.814 0,5
981 C33, C22 NS3, Core Pos. 2.056 0,4
993 C22 Core only Neg./Ind. 0.620 0,2
995 C33, C22 NS3, Core Pos. 2.100 0,5
996 C100, C33, 
C22
NS4, NS3, 
Core
Pos. 0.494 0,5
997 C22 Core only Neg./Ind. 0.522 1,1
998 C22 Core only Neg./Ind. 0.440 2,2
999 C22 Core only Neg./Ind. 0.256 1,1
1112 C22 Core only Neg./Ind. 1.203 0,0
Table 4.3.1a, Result o f  IE I samples tested on SeroCard and ELISA test achieved 
during in-house performance evaluation.
The results o f the BBI and the negative samples are shown in Table 4.3.1b. There was 
no RIBA banding available for the BBI positive samples.
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Sample Interpretation
C ard
Result
Sample Interpretation
Card
Result
3304-0424 Positive 0,3 C25 Negative 0,0
1305-1 Positive 0,0 C23 Negative 0,0
1305-4 Positive 0,1 C22 Negative 1,1
3305-0070 Positive 0,0 C31 Negative 0,0
3304-0437 Positive 0,1 C21 Negative 0,0
1305-14 Positive 0,4 C26 Negative 0,0
3305-0076 Positive 0,4 C ll Negative 1,1
3305-0077 Positive 0,3 C24 Negative 0,0
3312-0028 Positive 0,0 C13 Negative 0,0
3305-0060 Positive 0,1 C20 Negative 0,0
3305-0101 Positive 0,1 C14 Negative 1,1
3311-0063 Positive 0,2 C8 Negative 0,0
3311-0312 Positive 0,2 C19 Negative 0,0
3308-0197 Positive 1,8 C18 Negative 1,1
3304-0302 Positive 0,10 C l l Negative 0,0
3311-0341 Positive 1,9 CIO Negative 0,0
3311-0403 Positive 0,10 C16 Negative 0,0
3304-0262 Positive 0,9 C17 Negative 0,0
3311-0315 Positive 0,9 C9 Negative 0,0
3311-0167 Positive 0,8 C28 Negative 1,1
3308-0154 Positive 0,4
Table 4.3.1b. Result o f  BBI and negative samples tested on SeroCard assay achieved
during in-house performance evaluation.
4.3.2 Trial Sensitivity and Specificity
Based on the above results, the sensitivity and specificity were calculated. As before, 
the formulae in section 3.2.5 was used to calculate test sensitivity and specificity.
A  total o f  74 positive samples and 20 negative samples were analysed. Data analysis o f  
the IEI samples show that 9 o f  them contained only one RIBA band and were, therefore, 
indeterminate samples. They were not included in the calculation o f the specificity
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value. Sensitivity calculations were based on 65 positive samples. Results were 
interpreted as outlined in Section 4.1.3.2.
Specificity Sensitivity
20 True Nee.-O False Pos. 
20 True Neg.
65 True Pos.-3 False Neg. 
65 True Pos.
20/20x100 62/65 x 100
100% 95.4%
Table 4.3.2a. Sensitivity and specificity achieved during in-house performance 
evaluation o f  H C V  SeroCard assay.
4.3.3 External Perform ance Evaluation
The performance o f the HCV SeroCard was evaluated at two external trial site. As with 
the ELISA test, one location chosen was Public Health Laboratory Service (PHLS), 
Birmingham and samples results were compared with those achieved with RIBA 
banding. The other site chosen was the Virus Reference Laboratory, University College 
Dublin (UCD). All specimens had been stored at -20°C prior to thawing for testing by 
the rapid test.
4.3.3.1 Evaluation Results-PHLS, Birm ingham
A total o f  509 serum or plasma specimens were tested at the Public Health Laboratory, 
Heartlands Hospital, Birmingham. All specimens had been previously tested as part o f 
routine testing at the Serology Laboratory, PHLS, and had been confirmed by RIBA 
testing. Analysis o f  these samples showed that 244 samples were found to be anti-HCV 
negative and 265 were anti-HCV positive by RIBA banding.
O f those tested, 480 specimens agreed with the RIBA result after initial testing. The 29 
discordant samples were repeat tested. After re-testing, a total o f ten discordant samples 
remained, consisting o f  6 indeterminate samples, 2 false positive and 2 false negative 
samples. For the purpose o f sensitivity and specificity calculations, the 6 indeterminate 
sera were omitted from the final calculations. Therefore, a total o f  259 negative and 
244 positive specimens were included in the calculations as shown in Table 4.3.3a.
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Specificity Sensitivity
259 True Nee. -  2 False Pos. 244 True Pos.- 2 False Nee.
259 True Neg. 244 True Pos.
257/259x 100 242/244 x 100
99.2% 99.1%
Table 4.3.3a. SeroCard performance evaluation results at trial carried out at PHLS. 
4.3.3.2 Evaluation Results- University College, Dublin
The reference test used to confirm the status o f the samples was also the RIBA test. A 
total o f 150 samples and 98 negative samples were positive by RIBA banding. The 
results obtained are shown in Table 4.3.3b.
Specificity Sensitivity
98 True Nee. -  0 False Pos. 150 True Pos.- 2 False Nee.
98 True Neg. 150 True Pos.
98/98 x 100 148/150 x 100
100% 98.6%
Table 4.3.3b. SeroCard performance evaluation results at trial carried out at UCD.
The combined SeroCard performance results from both evaluation sites are combined in 
Table 4.3.3c. This gives a total o f  394 positive and 357 negative samples.
Specificity Sensitivity
357 True Nee. -  2 False Pos. 394 True Pos.- 4 False Neg.
357 True Neg. 394 True Pos.
355/357 x 100 390/394 x 100
99.4% 98.9%
Table 4.3.3c. Combined SeroCard performance evaluation results from  sites at 
PHLS, Birmingham and at University College, Dublin.
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Section 5
Discussion
5.1 Im portance of Diagnosis o f H CV Infection
The hepatitis C virus (HCV), described in 1989, is an RNA virus, o f which there are at 
least nine genotypes. Infection with HCV is the leading cause o f chronic liver disease. 
Detecting the presence of antibodies to the virus initially identifies the presence o f HCV 
infection. The enzyme- linked immunosorbent assay (ELISA) is a serological 
diagnostic test used to confirm the presence o f anti-HCV antibodies in serum. The 
Recombinant Immunoblot assay (RIBA), also a serological antibody test, specifically 
identifies antibodies to hepatitis C viral proteins represented as RIBA bands. A positive 
RIBA result is usually followed by the PCR test. The RNA structure o f the Hepatitis C 
virus is examined by a quantitative PCR test, which confirms whether the virus itself is 
present and replicating in the blood. This is known as the viral load. Liver function 
tests or a liver biopsy is carried out if  the previous tests point toward viral presence.
5.1.1 Routine Screening of Serum Samples for HCV Infection
The importance o f polymerase chain reaction (PCR) in the diagnosis o f  HCV infection 
has established it as the gold standard o f HCV-RNA detection (described in section 
1.6.1). Viral presence and replication are critical to HCV diagnosis and to monitor 
treatment o f  HCV infection. PCR, discovered in 1983 by Kary Mullis (Hengen, 1999), 
works in a specific manner, amplifying a desired sequence o f DNA or RNA, regardless 
of whether the sequence is known. It is a primer extension reaction for amplifying 
specific nucleic acids, allowing a short stretch o f RNA to be amplified to such an extent 
that the size and nucleotide sequence can be determined.
In many cases, testing for HCV infection involves multiple screening o f samples. Such 
wide-scale testing is not feasible by PCR, in most laboratories, as it is a time- 
consuming, high-cost method, requiring extensive specialised equipment, specific 
sample handling procedures and operator training. In developed countries, automated 
systems are widely used to cater for multiple screening. Serological methods o f 
diagnosis are required, where testing can be carried out at low cost using standard 
laboratory equipment, operational with minimum training. The developed anti-HCV
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ELISA plate fills these prerequisites and may be used where initial multiple screening 
o f serum samples is necessary. Table lb  highlights the high-risk and low-risk 
categories where multiple sample screening is required.
While the majority o f  screening o f serum samples is carried out in the comfort o f a 
modern laboratory, this is not always the case. In poorly developed countries, the 
requirement for sample screening is often paramount but not always feasible. 
Temporary mobile clinics replace the standard laboratory and sensitive screening tests 
must be as simple and user-friendly as possible. The development o f the rapid 
SeroCard test provides a means o f carrying out testing o f serum or plasma samples with 
minimal training and no laboratory equipment. Multiple testing using the SeroCard test 
is not feasible, as a limited number o f  samples may be assayed simultaneously. 
However, the advantage is that test results can be obtained within minutes and that 
testing can be conducted at point-of-care (POC). This means that, if  a positive result is 
achieved on a rapid test performed in the presence o f a patient, a fresh blood sample can 
be taken for confirmatory PCR testing at that moment. This would result in 
considerable savings in the money and time spent on recalling patients to give a second 
sample, if  a positive reading is achieved at off-site laboratory testing.
5.1.2 Limitations o f the Assays developed during this Research
It must be pointed out that an important limitation o f the anti-HCV antibody ELISA and 
SeroCard rapid test, developed in this study, is also encountered in other serological 
assays such as Murex Anti-HCV (Version III) ELISA® and the Ortho HCV 3.0 
ELISA®. They do not indicate the presence o f current or recent viral infection and is 
only suitable for anti-HCV antibody screening; a positive result must be followed up by 
the steps outlined above.
In daily laboratory routine, reliable diagnosis with any o f the tests described is not 
always possible since it is well known that EIA’s produce a number o f  false-positive 
results. A study carried out in Germany indicates that the rate o f  false-positive HCV 
results by enzyme immunoassays was determined to be at least 10% among 1,814 
reactive serum samples (Schroter el al, 1999). The results were based on negative 
results achieved in an independent confirmation assay, negative PCR results along with 
the lack o f development o f clinical or biochemical signs o f infection during a 1-year
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follow-up. This is a serious drawback o f serological assays and although much can be 
done to improve specificity the total alleviation o f false-positive results cannot be 
guaranteed.
The development o f a different class antibody assay such as an IgM-specific assay 
would possibly have not improved potential false-positive readings. The presence o f 
rheumatoid factor in sera from anti-HCV positive blood donors has been known to 
interfere with the detection o f  HCV-specific IgM resulting in false positive reactivity 
(Stevenson et al, 1996). Rheumatoid factor is an immune complex found primarily, but 
not limited to serum and synovial fluid o f patients with rheumatoid arthritis. This 
complex is composed o f immunoglobulin autoantibodies directed against and 
complexed with normal serum IgG. They react specifically with antigenic determinants 
on the constant regions o f  IgG heavy chains. IgG rheumatoid factors form aggregates, 
which appear to be self-associated complexes (Williams et al., 1977). The mechanism 
responsible for rheumatoid factor formation is not known, however, the serum o f 
rheumatoid arthritis patients is said to contain IgG molecules, which are 
conformationally altered toward the hinge region. Removal o f  IgG from samples prior 
to IgM testing by Stevenson et al, resulted in a significant loss o f reactivity in the IgM 
anti-HCV assay in 30/41 sera that were positive when tested untreated; 70% o f anti- 
HCV-positive sera were also positive for rheumatoid factor.
The sensitivity o f  the HCV ELISA plate and SeroCard assay could have been 
investigated by the introduction o f  the avidin-biotin amplification system. Avidin is a 
glycoprotein found in the egg white and tissues o f birds, reptiles and amphibia. It 
contains four identical subunits having a combined molecular mass o f 67-68kDa. 
Biotin, a 244 dalton vitamin found in tissue and blood, binds with high affinity to both 
avidin and streptavidin, a 60kDa protein that is isolated from Streptomyces avidinii. A 
format was considered which involved the use o f  commercially available streptavidin- 
HRP conjugate coupled to biotinylated specific antibody and antigen complex. It was 
believed that despite signal amplification, the use o f this tri-complex would be o f  little 
advantage as numerous titration experiments would be required. The use o f a 
streptavidin-coated plate was also eliminated as it proved to be a high-cost material. A 
system involving the biotinylation o f anti-human IgG was also considered but not 
practised.
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5.1.3 HCV-Infected Victims on our Doorstep
The need for multiple screening o f serum samples for antibodies to HCV was 
highlighted in recent years in Ireland as a result o f  the contamination o f blood products 
with the virus. An estimated 62,667 Irish women were screened for the presence o f 
anti-HCV antibodies between 1994 and 1997 (Government Publications, 1997). At the 
time o f initial screening, the availability o f  sensitive second and third generation assays 
was relatively new; the virus itself identified only five years previously.
Extensive research by the Blood Transfusion Service Board (BTSB) revealed that a 
plasma pool containing anti-D immunoglobulin (anti-D), a manufactured blood product, 
was the source o f HCV contamination. Anti-D has been manufactured by the BTSB 
since 1970 and was intended for injection intravenously, rather than the more common 
method o f intramuscularly, to prevent Rhesus (Rh) haemolytic disease. This disease 
may occur when a woman with Rh-negative blood produces a newborn Rh-positive. 
When administered within 48 hours o f pregnancy, anti-D prevents the disease, which 
has caused over 100 Irish stillbirths, by blocking the maternal production o f antibodies 
to the foetal red blood cells. The invasion o f Rh-positive antibodies, in subsequent 
pregnancies, damages the foetus and can lead to severe anaemia and brain damage 
(Government Publications, 1997).
A therapeutic course o f  plasma exchange is necessary in cases where the prevention o f 
harmful antibodies has not been successful. In September 1976, the BTSB used the 
plasma removed from an Rh-positive female patient, during exchange treatment, to 
manufacture anti-D for use in other patients. A month later, the patient became 
jaundiced and was later diagnosed as having developed hepatitis C. Five batches o f 
anti-D immunoglobulin, with an average o f 250-400 doses per batch had been 
manufactured and distributed. Table 5a highlights the number o f infections, which 
occurred as a result o f the receipt o f transfusion, highlighted in Table lb  as a high-risk 
mode o f HCV transmission. The statistics presented in Table 5a leave no doubt as to 
the absolute importance o f  the availability o f  a sensitive anti-HCV test, not only as a 
diagnostic tool but in the conduction o f multiple screening o f human samples in the 
hope o f preventing the reoccurrence o f such a catastrophe
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Recipients N um ber of 
People
Details
Recipients screened for HCV 62,667 56,151 in 1994, 2,636 in 1995, 
3,696 in 1996 and 184 in 1997
Identified recipients o f infected 
anti-D
1,147 294 type lb  infections
Identified recipients who became 
blood donors
103 60% positive by PCR
Blood donations given 504 606 labile components issued
Infections as a result o f  donations 61 49% viral presence by PCR
Positive diagnosis from direct or 
indirect anti-D infection
849 55% show continuing viral 
presence by PCR
Compensation claims paid 1,066 A cost o f  £150,393,732
Table 5a. Details o f  the effects o f  H C V  contamination in Ireland in the m id 90’s 
(Statistics received from  Government Publications, 1998)
5.2 Developm ent and O ptim isation o f H C V  A ssays
One o f the first questions posed at the onset o f test development was the basic issue o f 
assay technique. Along with the short-lived options outlined in section 5.1.2, was the 
choice o f developing a test using the direct or indirect test protocol. The direct method 
originated in the 1940’s using fluorescent-labelled antibodies to mark tissue antigens 
(Pierce, 1997). In this method, a primary antibody is directly labelled with a fluorescent 
probe or enzyme such as HRP or AP, which then reacts with bound antigen. The use o f  
a sole primary antibody has its limitations. Although the cross-reactivity o f a secondary 
antibody with primary antibody is eliminated, the immunoreactivity o f  the sole antibody 
may be reduced as a result o f labelling, and amplification o f signal with this method is 
limited. Therefore, the indirect method was chosen for both the ELISA and SeroCard 
tests. It utilises a labelled secondary antibody as represented in Figure lc, and was first 
described in 1954. A primary HCV specific antibody binds the HCV antigen followed 
by the secondary antibody directed against the primary, in this case, goat-anti-human 
IgG peroxidase or phosphatase labelled. This method offers a more sensitive assay as 
each primary antibody contains several epitopes for binding to the secondary antibody 
increasing the binding capacity at the site o f antigen. Non-specific binding may occur 
as a result o f cross-reactivity between both antibodies, although one o f the advantages 
o f the indirect assay over the direct assay is that the primary antibody is not affected by 
labelling.
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5.2.1 Choosing an Optimum Solid Phase
After deciding on the indirect assay technique, the first part o f  the study involved 
choosing a suitable solid phase support on which to immobilise the specific antigen. 
The C-well microtitre plate, devised as a hybrid o f the flat-bottomed and the round- 
bottomed wells, was used as it carries the advantage o f  good washing and aspirating 
steps while retaining the optical advantage o f  the flat bottom well. The surface chosen 
to bind the solid phase peptides was polystyrene. Adsorption to the well surface is 
controlled by the chemical properties o f the surface and o f the peptide. Polystyrene is a 
long carbon chain with numerous benzene rings, making it a hydrophobic compound. 
The adsorption o f molecules to polystyrene is due to intermolecular attraction forces 
such as van der Waals forces and hydrogen bonding. The chemical properties o f the 
four HCV synthetic peptides chosen for immobilisation to polystyrene were examined. 
The amino acid sequence o f each peptide is shown in Figure 5a. All four peptides 
consist o f both hydrophobic and hydrophilic amino acids, which favours the use o f  the 
NUNC™ Maxisorp microtitre plate. This surface binds molecules with both 
hydrophobic and hydrophilic regions, the enhanced binding achieved by a physical 
method which alters the surface molecules (Rowell, 1997a). The solid phase membrane 
chosen for the SeroCard was supplied by Trinity Biotech
HCV NS3-1 (m.w. 2885)
Gly-Arg-Glu-Iso-Leu-Leu-Gly-Pro-Ala-Asp-Gly-Mct-Val-Ser*Lys-Gly-Try-Arg-
Leu-Leu-Ala-Pro-Thr-Iso-Thr-Ala-Tyr-NH2
HCV 52 (m.w. 3960.5)
Iso-Cys-Asp-Arg-Glu-Val-Leu-Tyr-Arg-Glu-Phc-Asp-Asn-Glu-Cys-Scr-Gln-His-
Leu-Pro-Tyr-Iso-Glu-Gln-Gly-Met-Met-Lcu-Ala-Glu-Gln-NH2
HCV Core (m.w. 3417)
Pro-Gln-Asp-Val-Lys-Phe-Pro-Gly-Gly-Gly-Gln-Iso-Val-Gly-Gly-Val-Tyr-Leu-
Leu-Pro-Arg-Arg-Gly-Pro-Arg-Leu-Gly-Val-Arg-Ala-Thr-Arg-NH2
HCV 15 (m.w. 3143)
Met-Ser-Thr-Asp-Pro-Lys-Pro-Cys-Arg-Lys-Thr-Lys-Arg-Asp-Thr-Asp-Arg-Arg-
Pro-Cys-Asp-VaI-Lys-Thi-Pro-Gly-Gly-Gly-NH2
Figure 5a. Amino acid sequences o f  synthetic peptides used in ELISA and rapid 
tests. Green represents hydrophobic, red represents hydrophilic and 
blue represents neutral amino acids
132
5.2.2 Parameters affecting Coating
Protein binding is influenced by a number o f factors such as time, concentration and 
pH, which were considered to optimise coating o f the peptide to the solid support. As 
recommended by NUNC™, after two hours, maximum coating is achieved but cannot 
withstand stringent washing. Thus, time effects coating stability and so overnight 
coating at 4°C was recommended although maximum stability can be been achieved 
after six hours. Coating at 37°C was avoided as the higher temperature can cause the 
edge effect (Rowell, 1997a). The binding is also dependent on the pH of the coating 
buffer along with its hydrophobicity. Section 3.1 describes the adsorption o f conjugated 
HCV peptide-BSA to polystyrene with carbonate buffer, pH 9.6, as the coating buffer. 
These conditions were suitable for binding all fifteen HCV peptides and four peptide- 
BSA complexes were then chosen. In section 3.5, carbonate buffer, pH 9.6 was 
compared with phosphate buffer, pH 7.2 as coating buffer for unconjugated peptide. 
The phosphate buffer, with the lower pH, was chosen for this direct coating, as can be 
seen in Figure 3.5.1a. The use o f PBS is recommended due to its ability to structure 
water around the surface-bound molecules. Other diluents such as carbonate buffers, do 
not have the same stabilising effect as PBS (Gibbs, 1995). The higher binding affinity 
o f the unconjugated material in carbonate buffer suggests that molecular weight o f the 
peptide is an additional factor affecting coating. At ljag/ml and 0.5jJ,g/ml, the 
absorbance readings o f the positive samples reduced dramatically (Figure 3.5.1a). The 
same effect was not seen to such an extent in Figure 3.1.2a in the case o f  the conjugated 
material. This suggests that in carbonate buffer, pH 9.6, the BSA (m.w. 60,000) has a 
higher affinity than the lower molecular weight peptides (m.w. 3,000-4,000).
5.2.3 The Sequence o f Assay Optimisation
Optimisation o f the assays followed a sequence o f investigations, which lead to 
subsequent evaluation steps. The first phase in the development o f  the microtitre plate 
assay is described in section 5.2.1. The synthetic peptides were adsorbed to the solid 
surface and the peptides, which gave the highest positive-negative ratio on testing with 
characterised sera, were chosen (Table 3.1.1b). These four peptides were further coated 
at various dilutions along with a full peptide pool and core-specific peptide pool as 
shown in Table 3.1.2a. Optimum binding was achieved on the solid phase coated with 
full peptide pool at 1/10,000 as seen by the absorbance readings in Figure 3.1.3a. 
Although each specific peptide had affinity to the polystyrene when coated alone,
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optimum binding o f the positive samples occurred in the presence o f peptides specific to 
all viral genomic regions (Figure 3.1.3a). This suggests that specific detection o f the 
HCV antibody required the presence o f the full compliment o f peptides, covering both 
the structural and non-structural regions o f the HCV genome (see Figure 3.1.2a).
On plates coated with the full peptide pool, the sample diluent was next to be evaluated. 
This study involved the addition o f serum and inert proteins to the control dilution 
buffer to improve the positive-negative ratios (personal communication, Dr. Edward 
Balbirnie, Trinity Biotech). The effect o f  bovine serum albumin, normal human serum, 
rabbit serum and goat serum was investigated. The concept o f positive-negative ratio 
was used to choose 5% goat serum as a component in the sample diluent, as seen in 
Figure 3.2.1a. Section 5.2.4 on non-specific binding outlines a possible explanation for 
the beneficial effect o f goat serum on negative samples.
With the sample diluent chosen, two anti-human IgG-HRP conjugates were evaluated 
(section 3.2.2). The Kirkegaard and Perry Laboratories (KPL) conjugate gave greater 
definition between positive and negative samples tested, than did the Genzyme 
conjugate (see Figure 3.2.2a and Figure 3.2.2b). Both were titred based on the 
manufacturer’s recommendations, and 1/80,000 dilution o f the KPL conjugate was 
chosen, as the absorbance reading o f  the positive sample was 1.458 with a negative 
reading o f 0.184 (Table 3.2.2a). Evaluation o f the KPL conjugate diluent involved the 
addition o f surfactant and serum (section 3.2.3). Figure 3.2.3a shows that Triton X-100, 
Tween 20 and goat serum were examined with 0.05% Triton X-100 chosen as an 
additive. The effect o f  detergents is discussed in section 5.2.4. Optimum sample 
dilution was next to be evaluated with dilutions carried out within the microtitre plate 
well (section 3.2.4). Premixed samples had been used to evaluate various parameters up 
to this point, which held the disadvantage o f an additional assay step. Table 3.2.4c 
shows that the 1 in 10 in-well sample dilution was chosen based on positive-negative 
ratios achieved. This is also represented in Figure 3.2.4b.
With the parameters chosen as outlined above, a number o f characterised serum samples 
were evaluated (section 3.3.1). A sensitivity o f  88.6% and specificity o f  85% was 
achieved (Table 3.3.3a). Improvements to these results involved the fine-titre o f the 
solid phase peptides at coating dilutions greater than the initial 1/10,000 dilution, as 
shown in section 3.4.1. Further testing on clinical samples resulted in an improved 
sensitivity o f  94.3% and specificity o f  93.3% (Table 3.4.3a). Further work was carried
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out on the solid phase in an attempt to improve this data. It was believed that the large 
carrier protein, bovine serum albumin, with a molecular weight o f  60,000 (Rowell, 
1997b), may be blocking the complete adsorption o f HCV peptide (each with m.w. 
3,000 to 4,000) to the surface, allowing only limited binding. This theory was 
investigated by coating the peptide directly dissolved in coating buffer (section 3.5.1). 
This method did improve the positive readings but coating o f the conjugated peptide 
gave lower negative readings (Figure 3.5.2b). For this reason, the KPL conjugate and 
the conjugate diluent were re-evaluated (section 3.5.3). The conjugate was used at a 
more dilute 1/100,000 and foetal bovine serum was added to the conjugate diluent. 
These changes in peptide coating methods, along with those o f the conjugate titre and 
conjugate diluent, succeeded in improving specificity to 98.9%, and sensitivity to 100% 
as described in section 3.6.2 and shown in Table 3.6.2b.
The sensitivity and specificity achieved with peptides coated on the microtitre plate 
format led progressively to the adsorption o f the same peptides on a membrane for use 
in the rapid assay (section 4.1). The calculation o f the spotting dilutions and spotting 
volumes is shown in Table 4.1.2a. The wash reagent, enzyme conjugate reagent and 
substrate reagent were supplied by Trinity Biotech pic. As was done in the initial phase 
o f the microtitre plate assay, the peptides were spotted individually and were also 
combined for spotting as a full peptide pool (section 4.1.2). Figure 4.1.4a shows that, 
following testing with characterised sera, optimum binding o f the positive samples 
occurred on the membrane spotted with peptides specific to all viral genomic regions. 
The need for the full compliment o f  peptides was also seen in the microtitre plate assay. 
Although the positive samples were higher on the full peptide pool than on individually 
spotted peptide (Figure 4.1.4a), the spotting dilutions were increased to improve colour 
intensity o f the positive sample, as described in section 4.2.1. Table 4.2. Id shows the 
values achieved on the re-evaluated combinations, represented in Figure 4.2.1a.
To further improve the colour intensity o f  the positive readings while keeping the 
negative values low, the various assay incubation times were examined (section 4.2.2). 
The sample incubation time, post-sample wash incubation time and enzyme incubation 
time were optimised using a number o f  clinical samples. This resulted in a thirty- 
second sample incubation, two-minute post sample wash incubation and two-minute 
enzyme incubation time. In the in-house performance evaluation o f the rapid test, the 
sensitivity achieved was 95.4% with a specificity o f 100%, as shown in Table 4.3.2a.
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5.2.4 The Problem of Non-Specific Binding
The concept o f  non-specific binding (NSB) occurs frequently and constantly during the 
various stages o f development and optimisation o f  an immunoassay. This is particularly 
true o f the enzyme immunoassay due to its increased sensitivity. At any stage o f the 
assay, for example, during blocking, an unspecific reactant may have an affinity to the 
solid surface and become immobilised. This in turn can lead to the immobilisation o f 
succeeding reactants throughout the assay. During the course o f an ELISA or during 
peptide immobilisation, non-bound reagents are removed from the surface leaving a 
liquid film behind. After coating and spotting, blocking agents were used in the ELISA 
and rapid test to block excess solid surface. This was to avoid unspecific 
immobilisation o f reactants to the liquid film and also to protect adsorbed protein from 
surface denaturation. Low background is usually achieved by blocking with an inert 
protein. Bovine serum albumin was used in the microtitre plate test, with casein and 
Triton X-405 detergent used to block non-specific sites on the rapid test membrane. 
After blocking, plates can be stored at refrigerated temperatures without loss o f 
sensitivity.
Detergents are molecules consisting o f  a distinct hydrophobic and hydrophilic part. 
Triton X-100 (m.w. 646) contains branched hydrophobic octyl part and the hydrophilic 
part o f  Tween (m.w. 1240) is divided into three separate arms (Rowell, 1997b). They 
are examples o f non-ionic surfactants as opposed to ionic sodium dodecyl sulphate 
(SDS). Their blocking effect is based on the ability to compete for both hydrophobic 
and hydrophilic sites. One o f  the main causes o f  NSB in microtitre plate assays is 
improper washing and aspirating, leaving unbound residue on the well surface. Tween 
20 is present in the ELISA wash buffer, its washing effect based on the ability to 
disperse hydrophobic molecules in aqueous medium. In some instances, it is o f  no 
benefit to simultaneously use a blocking agent, such as BSA and a detergent such as 
Triton X-405 or Tween 20, as an immobilised detergent may affect specificities in 
secondary reactants. Detergent is used at a later stage o f the ELISA test. The effect o f 
addition o f detergent to the conjugate diluent is shown in Figure 3.2.3a. Triton X-100 
was chosen based on the positive-negative ratios achieved. No detergent was used in 
the secondary reactants o f the rapid test.
The effect o f the addition o f serum during optimisation o f the ELISA assay was to 
reduce the non-specific adsorption o f  molecules from the liquid phase. The addition o f
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various sera to the sample diluent was investigated. Results were based on positive- 
negative ratios and as can be seen in Figure 3.2.1a, the addition o f goat serum had the 
greatest effect with 5% (v/v) giving a negative absorbance o f 0.156 with a positive 
reading of 1.202 (Table 3.2.1a). A possible explanation for the effect o f  goat serum lies 
in the fact that the affinity purified antibody used in the conjugate was isolated from a 
pool o f serum from goats immunised with purified human IgG. As a protein stabiliser, 
goat serum was added to the conjugate by the manufacturer. The further introduction o f 
goat serum in the sample diluent may explain the decrease in negative absorbance 
readings.
Section 3.5.3 describes an attempt to further improve specificity by the addition o f 
serum to the conjugate diluent. Goat serum and foetal bovine serum were introduced at 
5, 10 and 20% (v/v). The addition o f  goat serum reduced the negative readings but also 
had the effect o f significantly reducing the positive readings. As represented in Figure 
3.5.3b, foetal bovine serum did not cause a decrease in positive readings but had the 
desired effect on negative samples; 5% (v/v) was chosen based on absorbance values.
5.2.5 Variations in ELISA and Rapid Tests
The enzyme conjugates used in the ELISA and the rapid assays employ goat anti-human 
IgG antibody labelled to horseradish peroxidase and alkaline phosphatase respectively. 
The alkaline phosphatases are a widely distributed family o f  isoenzymes found in large 
numbers o f  species and tissues. Horseradish peroxidase is the most commonly used 
immunoassay enzyme, which catalyses an enzymatic reaction with a rapid high turnover 
rate as opposed to the linear reaction rate o f  alkaline phosphatase (Pierce, 1997). HRP 
is an inexpensive material and its complexes usually retain enzymatic activity at 4°C for 
long periods o f time. The main distinguishing feature o f  both enzymes is the molecular 
weights; HRP was a molecular weight o f  40,000 with AP being a far larger enzyme 
with a molecular weight o f 140,000. The characteristics o f both enzymes suggest they 
are not interchangeable between the ELISA and the rapid assays. The smaller 
molecular weight o f HRP is unsuitable for use on a porous membrane-based solid 
support. An attempt was made to use the peroxidase-labelled conjugate on the rapid test 
but it was unsuitable and resulted in immediate strong colour on addition o f  chromagen. 
The linear reaction rate o f alkaline phosphatase was suitable in the rapid assay, whereas 
the short linear phase o f HRP was used on the plate assay. The activity o f  HRP is 
inhibited by azide while phosphate buffers inhibit phosphatase activity. HRP is most
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commonly detected by the cheap and ready-to-use chromagen, TMB (tetramethyl 
benzene). It is a safer alternative to the possible use o f  o-phenylenediamene (OPD) 
substrate, which is known to have carcinogenic properties. Another safe and 
inexpensive chromagen, BCIP, is used to detect alkaline phosphatase in the rapid assay.
Throughout the optimisation o f both assays and due to the nature o f  both tests, result 
interpretation differed. Customer interpretation o f the rapid test is visual only; the 
presence o f blue colour on addition o f  substrate indicating a positive result. The 
intensity o f the blue colour is directly proportional to the quantity o f specific antibody 
present in the test specimen. The concept o f  numerical difference as described in 
section 4.1.4, was limited to use as a guide during development o f the assay, to enable 
documentation o f results in tabular and in graphical form. On the other hand, result 
interpretation in the ELISA assay was based on calculation o f a cut-off numerical value 
based on comparison with kit control specimens.
5.3 The use o f Protein C oupling and Purification during Developm ent
The concept o f protein coupling and its application in ELISA is described in section 1.7. 
Evaluation o f synthetic peptides formed the basis o f the first stage in the development 
o f the assays for the detection o f antibodies to hepatitis C virus (HCV). Both the 
microtitre plate format and the rapid membrane-based format incorporated the use o f 
proteins on the solid phase matrix. The protein was coupled to a carrier substance, in 
this case, bovine serum albumin (BSA), a commercially available protein with a 
molecular weight o f approximately 60,000. This conjugation is an example o f 
homobifunctional coupling. The first cross-linking reagents used for modification and 
conjugation o f macromolecules consisted o f  bireactive compounds containing the same 
functional groups at both ends. Most o f  these homobifunctional reagents were 
symmetrical in design with a carbon chain spacer connecting the two identical reactive 
ends as shown in Figure 5.3a.
Spacer Arm _____
<Z3r
Reactive Group 1 Reactive Group 1
Figure 5.3. a. Representation o f  a homobifunctional reagent, such as glutaraldehyde 
used to conjugate H C V  peptide to bovine serum albumin
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These reagents link one protein to another by covalently reacting the lysine s-amines or 
N-terminal amines o f  one protein to the same functional group on a second protein 
(Hermanson, 1996). A number o f  different groups capable o f  reacting with amines have 
been described such as aldehydes, succinimide esters, aryl halides and isocyanates.
Glutaraldehyde, also known as glutardialdehyde or pentanedial, is the most commonly 
used reagent in homobifunctional coupling. The reaction o f  an aldehyde with an amine 
to form a Schiff base is shown in Figure 5.3a and is the basis o f the conjugation o f HCV 
peptide to BSA, which contains 59 lysine amino groups, 39 o f which are free to react.
XR [H] / R
R-NH2 + 0=C  ► R'-N=C  ► R-NH-CH
H V H
Amine Aldehyde Schiff Base Reduced product
Figure 5.3b. Formation o f Schiff base during homobifunctional coupling
The use o f  glutaraldehyde as a homobifunctional reagent is represented in Figure 5.3c.
Quiocho and Richards, in 1966, showed that the chemistry o f  glutaraldehyde is far more
complicated than this reaction suggests (Aslam and Dent, 1998). They observed that 
the effects o f  glutaraldehyde could not be reversed by a reagent capable o f cleaving 
imine bonds under many circumstances.
H ^. / H  Condensation / H
R-NH2+ C CH2CH2CH2-(’ ------------------► R-N=CH-CH2CH2CHj-C^
o o
Glutaraldehyde (m.w. 100.ll) Primary Product
R'-NH2
IH1
R-NHCH2CH2CH2CH2CH2NH-R' <  R-N=CH-CH2CH2CH2-CH=N-R'
Reduction
Reduced Linked Protein Secondary Product
Figure 5.3c. Reaction o f  glutaraldehyde as a homobifunctional reagent as in the 
coupling o f  H CVpeptide to protein and its reduction using sodium cyanoborohydride
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Richards and Knowles further supported this in 1968 when they carried out NMR on 
commercial glutaraldehyde solutions. They observed strong evidence for the presence 
o f a , p-unsaturated aldehydes forming conjugates more stable than those expected from 
simple Schiff base conjugation. In 1974, Whipple and Ruta further evaluated the 
problem and concluded that commercial 25% (v/v) glutaraldehyde consisted 
predominantly o f  cis and /ra«.s-isomers, plus monohydrate, dihydrate and native 
glutaraldehyde. These studies confirmed that protein cross-linking reactions done using 
homobifunctional reagents could result in large complexes o f  multiple sizes and infinite 
molecular structure including polymerised products that may even precipitate. This 
inherent potential to polymerise is characteristic o f  all homobifunctional reagents, even 
in multistep protocols. The impurity composition varied with temperature and pH. 
Figure 5.3c represents the reaction o f glutaraldehyde with a protein forming an active 
intermediate, which can cross-link with a second protein.
Reduction o f the Schiff base structure was originally carried out using sodium 
borohydride. However, the products o f  reduction yielded modifications o f  the original 
structure. For this reason the weaker reductant, sodium cyanoborohdride was used in 
the reduction o f the HCV peptide-BSA conjugate as it targeted the Schiff base 
formation only. Ukeda et al carried out an examination o f the reaction o f BSA with a 
glutarldehyde-derivatised solid phase (Aslam and Dent, 1998). This revealed complex 
kinetics and at least two different binding sites. It was discovered that blocking the 
solid phase with ethanolamine reduced the amount o f BSA bound by only 40% with 
that figure increased to 70% using borohydride as the reductant. Purification o f the 
reduced structure was then carried out, as now described.
Although the protein used in the assay, development in this study, was in solution when 
ready for purification, many proteins are present in cellular structures that render them 
insoluble in water. Proteins may frequently be dissolved by extraction with water or 
with salt solutions o f low ionic strength (White et al, 1978). Proteins may also be 
solubilised by the use o f weak detergent solutions, such as polyoxyethylenesorbitan 
monolaurate (Tween 20), by lipid removal from treatment with non-polar solvents, such 
as acetone and ether, or by treatment with butanol, to disrupt cellular structures.
Advances in chromatography have had the greatest impact on protein purification. 
Chromatography describes the separation method o f a mixture o f  dissolved substances
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through a porous solid support irrespective o f the forces that lead to the separation o f 
the mixture (White et al, 1978). Purification o f  the HCV peptide-BSA complex was 
carried out either by dialysis or by gel filtration chromatography. Gel filtration was 
chosen because separation o f compounds occurred on the basis o f  molecular size and 
shape. Purification o f the high molecular weight conjugate containing the HCV 
peptide-BSA complex was carried out by separation from the unconjugated peptide and 
glutaraldehyde o f smaller size. The purification process is described below.
A gel matrix can be prepared by suspending diverse insoluble materials such as 
synthetic resins, porous glass or polysaccharides such as dextran and agarose in an 
appropriate solvent. The formation o f two solvents occurs, one within the internal space 
o f the gel particles and the other outside the particles. The sephacryl S-200 column o f 
granular matrix acted as a molecular sieve allowing certain molecules to pass through 
the solid support. Separation o f solutes occurred by gel filtration. The smaller solute, 
the free HCV peptide or glutaraldehyde, could freely enter the internal space within the 
gel particles. A higher molecular weight molecule, such as unconjugated BSA, could 
enter the inner space but not as freely as the smaller molecule. The high molecular 
weight molecule, the HCV peptide-BSA complex could not enter the internal space o f 
the gel particle and passed down the S-200 column outside the particles and was the 
first molecule to be eluted from the column. Separation occurred as the smaller 
unconjugated molecules were finally eluted from the column having entered the gel 
particles o f the matrix. The granular matrix can be chemically modified to a fixed 
porosity and can therefore be used to establish the approximate molecular weight o f 
substances that have the capacity to penetrate the internal phase. The shape o f  a 
molecule along with the size determines whether it can enter the gel particle. Spherical 
molecules o f a certain molecular weight may able to enter the internal phase whereas 
asymmetric molecules o f  the same molecular weight may not.
Following purification o f the peptide-BSA complex by gel filtration chromatography, 
the eluted material is analysed by spectrophotometry as described in section 2.5.3. The 
fractions were read at a wavelength o f 280nm, where much protein absorption occurs. 
The protein content o f  each fraction may be estimated based on the Beer-Lambert law, 
which states that A=scl, where A corresponds to absorbance, s is the molar extinction 
coefficient, c is the concentration and 1 is the light path, usually 1cm (Aslam and Dent, 
1998). Measurement o f protein content is not essential and serves only to obtain the
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yield, if  required; the peptide complex is spotted using a spotting dilution, rather than 
quantitatively. It must be noted that free peptide and free BSA, inevitably present in 
certain fractions, absorb at 280nm and so the fractions must be further analysed by the 
neutralisation assay, described in section 2.5.4. This procedure will determine which 
fractions contain the desired purified conjugated peptide, for immobilisation on the 
solid phase. A small volume o f each fraction to be analysed is added to HCV-positive 
material, the neutralisation reagent. A positive result, upon testing, indicates that the 
added fraction did not contain purified HCV peptide; a negative result indicates that any 
HCV peptide, present in the fraction, binds the HCV antibody in the neutralisation 
reagent, and so it acts as a negative sample. Whether the conjugated peptide is purified 
by dialysis or by chromatography, it is titrated to determine the dilution, at which, it will 
be immobilised on the solid phase. This served as the first evaluation step in assay 
development and is outlined in section 3.1 and section 4.1, for use in the microtitre plate 
assay and the membrane-based assay, respectively.
5.4 Com parison o f A ssays with C urrent M arket Leaders
The world-wide market size for HCV assays was estimated to be worth $900 million in 
1998, with a steady growth observed since the mid-nineties. Due to the fact that there 
are so few rapid HCV tests currently available, this market has not been fully exploited. 
However, estimates predict that the size o f the rapid test market would be 4%  o f  the 
total available market. The patent related to the marketing o f HCV assays is owned by 
Chiron Corporation and has been granted in over 20 countries. It was not the intention 
o f Trinity Biotech at the time o f  the development o f  these kits to market in the United 
States, therefore, they were not submitted for approval to the Food and Drugs 
Administration.
Since the discovery o f HCV in 1989, various tests have become available for the 
detection o f HCV antibodies. Based on customer requirements, the tests are available in 
formats such as PCR-based tests, western blot assays, ELISA tests and rapid tests. 
Roche Diagnostic Systems provide the widely used Amplicor™ HCV detection kit, an 
easy-to-use PCR assay. Western blot assays include those from ©Ortho Chiron, (!) 
Sanoffi DP and ® Genelabs Diagnostics. As is the case with PCR-based assays, 
western blot assays are costly, time-consuming and require complex laboratory 
equipment.
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The ELISA assays offer a cheaper and less complex method o f detection o f HCV 
antibodies and are suitable for use with automated systems. Current market leaders in 
HCV EIA testing include © Abbott Diagnostics HCV EIA 3.0, © General Biologicals 
Corp. NANBASE C-96 anti-HCV EIA, © General Biologicals Corp. NANBDINE125 C 
anti-HCV RIA, © INNOGENETICS INNOTEST HCV Ab III, © Murex anti-HCV 
(Version III), © Ortho Chiron HCV 3.0 ELISA, ® Sanofi Diagnostics MONOLISA® 
anti-HCV EIA, © Syntron Bioresearch Inc., Microwell HCV EIA and © United 
Biomedical HCV EIA. A limited number o f rapid tests are currently available including 
© Bionike Laboratories HCV test, © Genelabs Diagnostics HCV Spot and © SERO- 
Med® Rapid Test.
There are certain factors to be considered when comparing the assays developed during 
this research, with those currently available. The performance characteristics o f the 
assay, achieved upon testing o f  positive and negative clinical specimens, are the most 
significant factors. Therefore, it is imperative that the test should be both sensitive and 
specific. The length o f time required to achieve a test result, along with the assay 
temperature, are both influential features o f an assay. The incubation times o f the 
commercially available ELISA and rapid tests outlined above, along with the assay 
incubation temperatures and reagent preparation necessary, are shown in Appendix 6. 
The clinical trial performance o f  each these assays were not obtainable and so 
sensitivity and specificity values were not included (personal communication, 
Marketing Department, Trinity Biotech).
The HCV ELISA, developed in this study, was compared with two o f the market 
leaders, the Murex anti-HCV Version III EIA and the General Biologicals Corp. 
NANBASE C-96 EIA. Comparisons were carried out in relation to the aforementioned 
assay protocols. Excluding washing steps, the Murex assay required a total assay time 
o f two hours and the General Biologicals test required 90 min. The total assay time o f 
the test, developed in this research, was 75 min. In addition, it offered the advantage o f 
ready-to-use conjugate and substrate reagent. The Murex and General Biologicals tests 
both necessitated two additional steps, the preparation o f conjugate reagent and 
substrate reagent. The incubation temperature o f the test, developed in this study, and 
the Murex test are both at 37°C, whereas that o f  the General Biologicals test is at 40°C, 
to be carried out under humid conditions. It also uses o-phenylenediamene, OPD, 
which is replaced by the safer option, TMB, in the both other tests. In terms o f total
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assay time, reagent preparation, assay temperature and safety, the assay developed in 
this research, compared favourably to both the Murex and General Biologicals assays.
The assay protocol o f the SeroCard assay was also compared to other membrane-based 
tests. As stated previously only a limited number o f rapid, membrane-based tests are 
available to detect HCV antibodies. Results can be achieved with the SeroCard assay in 
10 min., as is the case with both the Bionike Laboratories HCV test and the Genelabs 
Diagnostics HCV Spot. The SERO-Med® Rapid Test, a colloidal gold-based assay 
requires trained staff to carry out the test, which must be performed on fresh whole 
blood or serum samples.
Along with assay parameters, as described above, the performance o f the Murex and 
General Biologicals assays was evaluated and compared to the both the microtitre plate 
assay and the rapid SeroCard assay, in a study involving testing o f samples o f unknown 
status. A total o f 75 samples were tested in this ‘blind’ study and all procedures were 
followed according to the manufacturer’s instructions. The interpretation o f readings is 
shown only, in Appendix 7, as results were calculated based on the recommended 
procedure. A comparison o f absorbance readings was not made, as different cut-off 
values were achieved for each assay.
A positive result was achieved on the ELISA test for a total o f 47 samples. A total o f 
43 o f these samples gave a positive reading on both the Murex test and the General 
Biologicals test. A further one o f the samples was positive on Murex test only. Three 
samples positive on the ELISA, developed in this study, were negative on both o f the 
competitor tests. A total o f 28 samples gave a negative reading on the ELISA, 23 o f 
which were also negative on both the Murex and the General Biologicals assays, and 
one o f which was positive. O f the remaining four negative samples, two were also 
negative on the Murex test only and two on the General Biologicals test only. The rapid 
SeroCard assay also gave good correlation with the competitor assays. Three o f the 
SeroCard readings gave indeterminate results and two negative results were positive on 
the other tests. All positive readings on the SeroCard assay correlated with positive 
readings on all three ELISA assays tested.
The favourable comparison o f  both the microtitre plate assay and the rapid membrane- 
based assay, developed as a result o f this research, indicates that sensitive and specific
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assays for the detection o f HCV antibodies have been achieved. Both assays 
incorporate the use o f  HCV peptides from the Core and non-structural regions o f  the 
HCV genome. The microtitre plate assay has a shorter total assay time than current 
market leaders. It is suitable for use in laboratories, which utilise standard equipment 
and may be also used where automated systems are preferable. The rapid assay 
provides a highly sensitive and specific method o f HCV antibody detection. This assay 
may be conducted at point-of-care resulting in a cost-effective test, which could 
eliminate the time and cost involved in recalling patients to donate a sample for test 
confirmation, in the event o f  a positive result on the rapid test. The test does not require 
sample preparation and may be conducted by untrained personnel. Both the microtitre 
plate assay and the rapid assay eliminate the preparation steps necessary in the other 
tests by offering the advantage o f safe, ready-to-use assay reagents,.
It is difficult to acknowledge that so much time and effort has been devoted, in recent 
years, to all aspects o f  hepatitis C, not least because it is a novel virus, its identification 
only ten years old. This time has been divided between researching effective treatment 
options for HCV infection, to HCV genotyping and, in the diagnostic field, developing 
specific and sensitive tests for antibody detection and HCV-RNA. The current 
procedures are constantly being improved and updated in an attempt to better the quality 
o f  life and the chances o f  survival o f  the many people who have fallen victim to this 
disease. The development o f  the microtitre plate assay, and the rapid membrane-based 
assay, has provided an aid to the detection o f antibodies to HCV, and is indicative o f 
ongoing research in the hepatitis field.
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Section 6
Conclusion
Hepatitis C virus, HCV, was discovered in 1989 and is the causative agent o f the 
majority o f  post-transfusion non-A, non-B hepatitis cases (Bradley et al., 1987). The 
aim o f the research undertaken in this study was to develop and evaluate two enzyme 
immunoassays for the detection o f antibodies to HCV in human serum. The first test 
was in the format o f a microtitre plate assay, and was developed for use in clinical 
laboratories, which utilise either standard laboratory equipment or automated systems. 
This was followed by the development o f a membrane-based assay, which is a simple, 
and rapid, user-friendly test requiring no laboratory equipment. One o f the advantages 
o f the rapid test is that it can be conducted at point-of-care with ready-to-use reagents. 
Both tests are indirect enzyme immunoassays, incorporating the adhesion o f HCV- 
specific peptide on the solid phase. HCV antibody is detected with anti-human IgG- 
peroxidase conjugated. The intensity o f colour formed, on addition o f chromagen, is 
directly proportional to the quantity o f HCV antibody present in the sample.
The evaluation steps, which led to the development o f both tests, followed a similar 
format. A number o f peptides, specific for various regions o f HCV, was immobilised to 
the microtitre plate well. They were tested with HCV-positive and negative material, 
with four peptides subsequently chosen, based on the positive-negative ratio achieved. 
These four peptides were specific for the core and non-structural regions o f the HCV 
genome. The proceeding steps involved the evaluation o f various test parameters such 
as suitable sample diluent, optimum conjugate titration, suitable conjugate diluent and 
sample dilution. The optimisation o f the rapid test also involved the immobilisation and 
evaluation o f HCV peptides for use on the solid phase membrane. Assay optimisation 
required less evaluation steps as the reagents were supplied by Trinity Biotech pic. 
During the course o f development o f both assays, HCV-positive and HCV-negative 
samples were used to validate test parameters.
Upon optimisation o f both the microtitre plate assay and the rapid assay, the 
performance o f  the tests was evaluated. A number o f  clinical positive and negative 
samples was tested and the specificity and sensitivity o f  each assay was obtained. The 
performance o f  the microtitre plate assay was determined at Public Health Laboratory
146
Service (PHLS), Birmingham by analysis o f  530 samples. RIBA testing confirmed that 
281 samples were found to be anti-HCV negative and 249 were anti-HCV positive. The 
microtitre plate assay detected 275 negative samples and 233 positive samples, giving a 
specificity o f  97.9% and a sensitivity o f  93.6%. The rapid test was evaluated at the 
Virus Reference Laboratory, University College Dublin (UCD), and also at PHLS, 
Birmingham. A combined total o f 357 negative samples and 394 positive samples were 
confirmed by RIBA banding. Two false positive and four false negative samples gave 
an overall specificity and sensitivity o f  99.4% and 98.9%, respectively, for the rapid 
membrane-based assay.
In a separate trial, conducted ‘on-site’, the plate assay and the rapid assay were 
compared with two HCV microtitre plate tests from current market leaders, Murex anti- 
HCV Version III ELISA and General Biologicals Corp. NANBASE C-96 EIA. A total 
o f 75 positive and negative samples, o f unknown clinical status, were assayed on all 
tests. Both the plate assay and the rapid assay correlated well with the results achieved 
on the competitor assays. Parameters such as total assay time, assay temperature and 
reagent preparation steps were also evaluated. The microtitre plate assay was shown to 
have a shorter assay incubation time (75 min.) than both the Murex test (assay time, two 
hours) and the General Biologicals test (assay time, 90 min.). Also, it was the only 
assay to supply ready-to-use reagents, requiring no conjugate or substrate preparation. 
The use o f  tetramethyl benzidine as a chromagen is favourable over the potentially 
carcinogenic o-phenylenediamene, used in one o f the competitor kits.
In conclusion, the research undertaken in this study resulted in the successful 
development o f  a microtitre plate assay and a rapid membrane-based assay for HCV 
detection. Both tests compare favourably to current market leaders, and whether use is 
intended for multiple sample screening in the clinical laboratory, or for use at point-of- 
care, this study provides a sensitive and specific means o f detecting antibodies to 
hepatitis C virus in human serum.
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Section 8
Appendix I.
Absorbance values o f  45 Cork blood bank negatives in ELISA test with parameters in 
section 3.2.5. Represen ted in Figure 3.3.1a.
i Sample Absorbance Sample Absorbance
C l 0.141 C24 0.111
C2 0.126 C25 0.142
C3 0.070 C26 0.077
C4 0.217 C l l 0.066
C5 0.082 C28 0.072
C6 0.068 C29 0067
C7 0.110 C30 0.059
C8 0.069 C31 0.075
C9 0.068 C32 0.079
CIO 0.065 C33 0.095
C ll 0.082 C34 0.104
C12 0.098 C35 0.067
C13 0.085 C36 0.066
C14 0.071 C37 0.072
C15 0.081 C38 0.069
C16 0.143 C39 0.107
C l 7 0.135 C40 0.076
C18 0.074 C41 0.085
C19 0.110 C42 0.097
C20 0.085 C43 0.070
C21 0.065 C44 0.098
C22 0.105 C45 0.073
C23 0.058
I
Comparison o f  IEI OD samples tested on new combination and fu ll pool coated at 
1/10,000. Represented in Figure 3.4.2a.
Appendix 2.
Neg.=Negative sample, Ind.=Indeterminate sample
No. IEI No. RIKA Bund In t.
Viral 
Region (x)
New
reading
Full pool
1 473 C100, C33 Pos. NS4, NS3 0.472 0.520
2 678 C33, C22 Pos. NS3, Core 1.696 0.292
3 682 C33, C22 Pos. NS3, Core 2.006 0.641
4 687 C33, C22 Pos NS3, Core 2.109 1.348
5 694 C33, C22 Pos, NS3, Core 2.055 0.613
6 696 C33, C22 Pos. NS3, Core 2.025 0.852
7 699 C33, C22 Pos. NS3, Core 1.890 0.819
8 700
5-1-1, C100, 
C33, C22
Pos.
NS5, NS4, 
NS3, Core
2.141 1.198
9 701
5-1-1,C100, 
C33, C22
Pos.
NS5. NS4, 
NS3, Core
1.605 0.482
10 702 C22 Neg/Ind. Core only 0.612 0.138
11 703
5-1-1, C l00, 
C33, C22
Pos.
NS5, NS4, 
NS3, Core
2.143 1.237
12 706 C33, C22 Pos NS3, Core 2.013 0.646
13 708 C33, C22 Pos NS3, Core 1.733 0.173
14 709
C100, C33, 
C22
Pos.
NS4, NS3, 
Core
2.001 1.339
15 710 C33, C22 Pos. NS3, Core 1.983 0.564
16 711
5-1-1, C100, 
C33, C22
Pos.
NS5, NS4, 
NS3, Core
2.244 1.290
17 712
5-1-1, C100, 
C33, C22
Pos
NS5, NS4, 
NS3, Core
1.612 0.835
18 713
5-l-l,C100, 
C33, C22
Pos.
NS5, NS4, 
NS3, Core
2.372 0.203
II
No. IEI No. RIBA Band Int.
Viral 
Region (s)
New*
reading
Full pool
19 714
5-1-1, ClOO, 
C33, C22
Pos.
NS5, NS4, 
NS3, Core
2.398 0.408
20 717
ClOO, C33, 
C22
Pos.
NS4, NS3, 
Core
2.032 0.822
21 718 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
1.687 0.613
22 719 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
1.670 1.683
23 722 C22 Neg/Ind. Core only 1.403 0.169
24 725 ClOO, C33, 
C22
Pos. NS4, NS3, 
Core
0.204 0.081
25 727 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
2.144 1.125
26 728 C33, C22 Pos NS3, Core 0.666 0.417
27 729 ClOO, C33, 
C22
Pos NS4.NS3,
Core
2.408 0.900
28 731 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
0.764 0.092
29 736 C33, C22 Pos. NS3, Core 1.313 0.956
30 738 5-1-1, ClOO, 
C33, C22
Pos NS5, NS4, 
NS3, Core
1.921 0.373
31 739 5-1-1, ClOO, 
C33, C22
Pos NS5, NS4, 
NS3, Core
2.480 0.430
32 741 C33, C22 Pos. NS3, Core 2.193 0.225
33 742 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
Over 0.121
34 743 C33, C22 Pos. NS3, Core 1.556 0.214
35 746 C33, C22 Pos. NS3, Core 1.856 0.815
36 748 5-1-1, ClOO, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
1.845 0.286
37 750 C33, C22 Pos NS3, Core 1.678 0.171
Ill
No. IFJ No. RIBA Band Int.
Viral 
Region (s)
New
reading
Full pool
38 753 5-1-1, C l00, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
2,040 0.405
39 754 5-1-1, C100, 
C33, C22
Pos. NS5, NS4, 
NS3, Core
1.839 0.211
40 762 C22 Neg/Ind. Core only 0.586 0.121
41 767 C22 Neg/Ind Core only 0.450 0.112
42 779 C100, C33, 
C22
Pos NS4, NS3, 
Core
1.119 0.670
43 859 C100, C33, 
C22
Pos. NS4, NS3, 
Core
1.383 0.316
44 865 C33, C22 Pos. NS3, Core 1.552 1.468
45 894 C22 Neg/Ind. Core only 0.592 0.122
46 903 C22 Neg/Ind Core only 0.287 0.123
47 904 C22 Neg/Ind. Core only 0.107 0,065
48 913 C22 Neg/Ind. Core only 0.483 0.076
49 935 C22 Neg/Ind. Core only 0.142 1.103
50 937 C22 Neg/Ind. Core only 0.535 0.078
51 943 C100, C33 Pos. NS4, NS3 2.364 0.214
52 944 C22 Neg/Ind. Core only 0.114 0.087
53 945 C33, C22 Pos NS3, Core 0.942 0.303
54 946 C l00, C33, 
C22
Pos. NS4, NS3, 
Core
1.649 0.845
55 947 C22 Neg/Ind. Core only 0.133 0.882
56 950 C33, C22 Pos. NS3, Core 1.875 0.894
57 951 C33, C22 Pos. NS3, Core 1.632 0.348
58 953 C22 Neg/Ind. Core only 0,477 0.102
59 958 C33, C22 Pos. NS3, Core 0.198 0.082
60 959 C22 Neg/Ind. Core only 0.189 0.060
61 961 C33, C22 Pos. NS3, Core 1,934 1.589
62 963 C33, C22, 5- 
1-1
Pos. NS3, Core, 
NS5
2.144 0.748
IV
No. IEI No. RIBA Band Int.
Viral 
Region (s)
New
reading
Full pool
63 981 C33, C22 Pos. NS3, Core 0.201 0.190
64 985 C22 Neg/Ind. Core only 0.237 0.095
65 991 C22 Neg/Ind. Core only 0.296 0.133
66 992 C22 Neg/Ind. Core only 0.154 0.083
67 993 C22 Neg/Ind. Core only 0.503 0.164
68 995 C33, C22 Pos. NS3, Core 1.673 0.916
69 996 ClOO, C33, 
C22
Pos. NS4, NS3, 
Core
0.902 0.112
70 997 C22 Neg/Ind. Core only 0.519 0.158
71 998 C22 Neg/Ind. Core only 0.385 0.197
72 999 C22 Neg/Ind. Core only 0.135 0.091
73 1013 C22 Neg/Ind. Core only 0.739 0.114
74 1025 C22 Neg/Ind. Core only 0.307 0.134
75 1039 C22 Neg/Ind. Core only 1.110 0.194
76 1053
ClOO, C33, 
C22, 5-1-1
Pos. NS4, NS3, 
Core, NS5
1.989 0.619
77 1055 C22 Neg/Ind. Core only 0.179 0.090
78 1059 C22 Neg/Ind. Core only 0.415 0.129
79 1070 C33 Neg/Ind. NS3 only 0.576 0.085
80 1072 C22 Neg/Ind. Core only 0.827 0.282
81 1076 C22 Neg/Ind. Core only 0.192 0.074
82 1077 C33 Neg/Ind. NS3 only 0.761 0.074
83 1081 C22 Neg/Ind Core only 1.412 0.220
84 1086 C22 Neg/Ind. Core only 0.371 0.116
85 1110 C22 Neg/Ind. Core only 0.495 0.287
86 1112 C22 Neg/Ind Core only 0.236 0.113
87 1115 C33, C22 Pos. NS3, Core 0.463 0.108
88 1265 C33 Neg/Ind NS3 only 0.571 0.263
V
Absorbance values o f  a number o f  IEI positive and Cork negative samples on ELISA 
solid phase with directly coated combinations 1 to 6. Represented in Figure 3.5.2a.
Appendix 3.
Sample Region I 2 4 5 6
678 NS3, Core 2.216 1.554 2.122 2.002 2.221 1.961
682 NS3, Core 1.709 1.945 Over 2.387 Over 1.629
687 NS3, Core 1.745 1.423 2.461 2.211 2.076 1.804
694 1SJS3, Core 2.115 1.945 Over 2.234 2.338 1.881
696 IN S3, Core 2.181 2.053 2.442 2.311 2.295 2.221
699 NS3, Core 2.323 2.061 Over 2.354 2.421 2.281
700 NS3, Core, NS4 2.347 2.003 2.406 2.189 2.338 2.198
701 NS3, Core, NS4 1.251 1.041 1.591 1.574 1.842 1.096
703 NS3, Core, NS4 2.046 2.447 2.442 2.459 Over Over
706 NS3, Core 2.163 1.971 Over 2.311 2.385 2.255
708 NS3, Core 1.944 1.911 Over 2.201 2.421 2.438
709 NS3, Core, NS4 2.463 Over Over Over Over Over
710 NS3, Core 1.574 2.029 1.574 2.281 1.029 2.353
711 NS3, Core, NS4 1.937 2.094 Over Over 1.744 2.131
712 NS3, Core, NS4 2.016 1.838 Over 2.254 2.323 2.172
713 NS3, Core, NS4 1.981 1.993 2.341 2 M 3 2.338 2.182
714 NS3, Core, NS4 1.573 2.331 2.341 2.308 2.267 2.322
717 NS3, Core, NS4 2.145 2.149 2.407 2.323 2.405 2.462
718 NS3, Core, NS4 2.481 1.767 2.032 2.087 2.371 2.069
719 NS3, Core, NS4 2.145 1.682 2.063 2.105 2.113 1.591
729 NS3, Core, NS4 2.113 2.248 2.296 2.388 2.424 2.442
731 NS3, Core, NS4 2.098 1.973 Over Over Over 2.386
727 NS3, Core, NS4 2.055 2,085 Over 1.922 2.086 2.052
736 NS3, Core 1.164 0.364 1.322 1.053 1.149 1.017
738 NS3, Core, NS4 2.287 2.173 2.455 Over 1.608 1.722
739 NS3, Core, NS4 2.002 2.342 2.317 Over 2.481 2.452
741 NS3, Core 1.655 2.159 Over 2.454 2.481 2.452
742 NS3, Core, NS4 1.365 2.031 2.262 2.167 2.378 2.334
743 NS3, Core 1.097 0.951 2.115 1.651 1.976 1.226
746 NS3, Core 2.035 1.795 2.484 2.482 Over 2.378
VI
Sample Region 1 2 3 6
748 NS3, Core, NS4 1.771 0.847 1.655 1.268 1.331 1.217
750 NS3, Core 1.928 1.409 1.979 2.035 2.402 2.044
753 NS3, Core, NS4 1.333 1.282 2.197 2.025 2.077 1.722
754 NS3, Core, NS4 2.035 1.948 2.484 2.316 2.427 2.355
859 NS3, Core, NS4 1.213 0.537 1.682 1.081 1.537 0.988
865 NS3, Core 2.053 1.551 2.359 2.127 2.295 1.764
935 Core only 0.225 0.196 0.191 0.209 0.248 0.141
937 Core only 0.191 0.185 0.724 0.296 0.355 0.242
943 NS4, Core 1.743 2.171 2.476 2.389 2.267 Over
944 Core only 0.122 0.139 0.503 0.157 0.239 0.137
945 NS3, Core 1.533 2.153 2.194 2.474 Over 2.491
950 NS3, Core 2.214 1.904 Over 2.234 2.331 2.135
951 NS3, Core 0.702 0.532 1.463 1.125 1.338 1.061
958 NS3, Core 1.841 1.981 Over 2.494 Over Over
959 Core only 0.237 0.184 0.199 0.264 0.261 0.196
961 NS3, Core 0.246 0.251 0.495 0.404 0.298 0.241
981 NS3, Core 1.968 1.523 1.946 2.088 2.267 2.014
993 Core only 0.446 0.231 1.331 0.311 0.691 0.471
995 NS3, Core 0.831 2.091 1.520 1.597 1.982 2.443
996 NS3, Core, NS4 0.411 0.426 0.782 0.578 0.673 0.357
997 Core only 0.256 0.381 0.385 0.279 0.503 0.473
998 Core only 0.191 0.215 0.547 0.279 0.437 0.208
999 Core only 0.135 0.149 0.108 0.199 0.192 0.168
1112 Core only 1.608 0.562 1.521 0.997 1.461 0.373
C l Negative 0.215 0.236 0.204 0.197 0.186 0.198
C2 Negative 0.222 0.185 0.288 0,262 0.202 0.251
C3 Negative 0.264 0.222 0.221 0.253 0.212 0.257
C4 Negative 0.262 0.251 0.282 0.298 0.243 0.276
C5 Negative 0.216 0.123 0.211 0.209 0.206 0.222
C6 Negative 0.199 0.142 0.279 0.144 0.129 0.163
C7 Negative 0.206 0.237 0.238 0.204 0.195 0.227
C8 Negative 0.188 0.075 0.188 0.176 0.168 0.169
C9 Negative 0.178 0.186 0.162 0.181 0.151 0.164
CIO Negative 0.194 0.229 0.166 0.158 0.158 0.185
VII
Sample Region
C ll Negative 0.257 0.169 0.175 0.163 0.161 0.177
C12 Negative 0.209 0.136 0.159 0.185 0.156 0.168
C13 Negative 0.183 0.137 0.198 0.175 0.172 0.186
C14 Negative 0.273 0,251 0.281 0.205 0.201 0.279
CIS Negative 0.161 0.128 0.178 0.171 0.157 0.175
C16 Negative 0.251 0.174 0.251 0.262 0.245 0.255
C l 7 Negative 0.187 0.096 0.186 0.204 0.172 0.189
C18 Negative 0.239 0.107 0.121 0.176 0.168 0.173
C19 Negative 0.184 0.115 0.166 0.186 0.145 0.146
C20 Negative 0.179 0.141 0.158 0.163 0.164 0.157
Appendix 4.
Absorbance values o f  IEI samples on conjugated and directly coated peptide fo r  fin al 
evaluation o f  H C V  ELISA. Represented in Figure 3.6.1cl
No.
IEI Lot
No.
Int. Viral Region (s)
Conjugated
Peptide
Directly
Coated
1 473 Pos. NS4, NS3 0.472 0.598
2 678 Pos. NS3, Core 1.696 1.669
3 682 Pos. NS3, Core 2.006 2.332
4 687 Pos. NS3, Core 2.109 2.057
5 694 Pos, NS3, Core 2.055 2.282
6 696 Pos NS3, Core 2.025 2.459
7 699 Pos. NS3, Core 1.890 2.499
8 700 Pos. NS5, NS4, NS3, Core 2.141 2.387
9 701 Pos. NS5, NS4, NS3, Core 1.605 1.257
10 702 Neg./Ind. Core only 0.612 0.432
11 703 Pos. NS5, NS4, NS3, Core 2.143 2.387
12 706 Pos. NS3, Core 2.013 2.331
13 708 Pos NS3, Core 1.733 2.150
VIII
No.
1 E l Lot
No.
Int. Viral Region (s)
Conjugated
Peptide
Directly
Coated
14 709 Pos. NS4, NS3, Core 2.001 Over
IS 710 Pos. NS3, Core 1.983 2.046
16 711 Pos. NS5, NS4, NS3, Core 2.244 2.338
17 712 Pos. NS5, NS4, NS3, Core 1.612 2.145
18 713 Pos. NS5, NS4, NS3, Core 2.372 2.168
19 714 Pos. NS5, NS4, NS3, Core 2.398 2.274
20 717 Pos. NS4, NS3, Core 2.032 2.168
21 718 Pos. NS5, NS4, NS3, Core 1.687 2.055
22 719 Pos. NS5, NS4, NS3, Core 1.670 1.917
23 722 Neg./Ind. Core only 1.403 0.465
24 725 Pos. NS4, NS3, Core 0.204 1.234
25 727 Pos. NS5, NS4, NS3, Core 2.144 2.168
26 728 Pos. NS3, Core 0.666 1.320
27 729 Pos. NS4, NS3, Core 2.408 2.435
28 731 Pos. NS5, NS4, NS3, Core 0.764 2.435
29 736 Pos. NS3, Core 1.313 1.810
30 738 Pos. NS5, NS4, NS3, Core 1.921 2.170
31 739 Pos. NS5, NS4, NS3, Core 2.480 2.428
32 741 Pos NS3, Core 2.193 2.155
33 742 Pos. NS5, NS4, NS3, Core Over 2.155
34 743 Pos. NS3, Core 1.556 1.942
35 746 Pos. NS3, Core 1.856 2.114
36 748 Pos. NS5, NS4, NS3, Core 1.845 1.129
37 750 Pos NS3, Core 1.678 2.101
38 753 Pos. NS5, NS4, NS3, Core 2.040 1.579
39 754 Pos. NS5, NS4, NS3, Core 1.839 2.155
40 762 Neg./Ind. Core only 0.586 0.489
41 767 Neg./Ind. Core only 0.450 0.313
42 779 Pos NS4, NS3, Core 1.119 2.196
43 859 Pos. NS4, NS3, Core 1.383 1.162
IX
No.
IEI Lot
No.
Int. Vital Region (s)
Conjugated
Peptide
Directly
Coated
44 865 Pos. NS3, Core 1.552 2.016
45 894 Neg./Ind. Core only 0.592 0.459
46 903 Neg./Ind. Core only 0.287 0.362
47 904 Neg./Ind. Core only 0.107 0.458
48 913 Neg./Ind Core only 0.483 0.426
49 935 Neg./Ind. Core only 0.142 0.341
50 937 Neg./Ind. Core only 0.535 0.231
51 943 Pos. NS4, NS3 2.364 2.317
52 944 Neg./Ind. Core only 0.114 0.114
53 945 Pos. NS3, Core 0.942 2.220
54 946 Pos. NS4, NS3, Core 1.649 2.141
55 947 Neg./Ind. Core only 0.133 0.231
56 950 Pos. NS3, Core 1.875 0.661
57 951 Pos. NS3, Core 1.632 1.134
58 953 Neg./Ind. Core only 0.477 0.323
59 958 Pos. NS3, Core 0.198 2.462
60 959 Neg./Ind. Core only 0.189 0.147
61 961 Pos. NS3, Core 1.934 1.814
62 963 Pos. NS3, Core, NS5 2.144 2.145
63 981 Pos. NS3, Core 0.201 2.056
64 985 Neg./Ind. Core only 0.237 1.340
65 991 Neg./Ind. Core only 0.296 0.354
66 992 Neg./Ind. Core only 0.154 0.189
67 993 Neg./Ind. Core only 0.503 0.620
68 995 Pos. NS3, Core 1.673 2.100
69 996 Pos NS4, NS3, Core 0.902 0.494
70 997 Neg./Ind. Core only 0.519 0,522
71 998 Neg./Ind. Core only 0.385 0.440
72 999 Neg./Ind. Core only 0.135 0.256
73 1013 Neg./Ind. Core only 0.739 0.597
X
No.
IEI Lot
No.
Int. Viral Region (s)
Conjugated
Peptide
Directly
Coated
74 1025 Neg./Ind. Core only 0.307 0.256
75 1039 Neg./Ind. Core only 1.110 0.911
76 1053 Pos. NS4, NS3, Core, NS5 1.989 1.519
77 1055 Neg./Ind. Core only 0.179 0.398
78 1059 Neg./Ind. Core only 0.415 0.589
79 1070 Neg./Ind. NS3 only 0.576 0.356
80 1072 Neg./Ind. Core only 0.827 0.697
81 1076 Neg./Ind. Core only 0.192 0.418
82 1077 Neg./Ind. NS3 only 0.761 0.269
83 1081 Neg./Ind. Core only 1.412 0.894
84 1086 Neg./Ind. Core only 0.371 0.258
85 1110 Neg./Ind. Core only 0.495 0.564
86 1112 Neg./Ind. Core only 0.236 1.203
87 1115 Pos. NS3, Core 0.463 0.958
88 1265 Neg./Ind. NS3 only 0.571 0.212
Appendix 5.
Absorbance values o f  negative samples assayed on directly coated and conjugated 
peptide fo r  fin a l e\’aluation o f  H CV ELISA. Represented in Figure 3.6.1b.
Sample
Conjugated
Peptide
Directly
Coated
Sample
Conjugated
Peptide
Directly
Coated
Cl 0.151 0.106 C9 0.133 0.095
C2 0.174 0.076 CIO 0.127 0.070
C3 0.153 0.106 C ll 0.099 0.061
C4 0.256 0.122 C12 0.139 0.088
C5 0.190 0.111 C13 0.160 0.118
C6 0.103 0.062 C14 0.182 0.090
C7 0.147 0.083 CIS 0,150 0.074
C8 0.148 0.087 C l 6 0.232 0.147
XI
Sample
Conjugated
Peptide
Directly
Coated
Sample
Conjugated
Peptide
Directly
Coated
C l 7 0.167 0.072 C50 0.175 0.069
C18 0.136 0.090 C51 0.166 0.078
C19 0.149 0.082 C52 0.241 0.132
C20 0.127 0.068 C53 0.152 0.084
C21 0.113 0.057 C54 0.147 0.093
C22 0.122 0.062 C55 0.198 0.104
C23 0.143 0.101 C56 0.213 0.109
C24 0.153 0.073 C57 0.154 0.051
C25 0.184 0.124 C58 0.189 0.120
C26 0.143 0.111 C59 0.222 0.099
C27 0.165 0.108 C60 0.135 0.048
C28 0.163 0.095 C61 0.164 0.101
C29 0.116 0.057 C62 0.192 0.122
C30 0.172 0.087 C63 0.178 0.083
C31 0.187 0.101 C64 0.155 0.085
C32 0.132 0.065 C65 0.163 0.076
C33 0.198 0,102 C66 0.178 0.056
C34 0.212 0.132 C67 0.215 0.118
C35 0.102 0.059 C68 0.159 0.087
C36 0.155 0.078 C69 0.137 0.059
C37 0.111 0.046 C70 0.164 0.097
C38 0.141 0.068 C71 0.196 0.088
C39 0.165 0.116 C72 0.144 0.081
C40 0.125 0.063 C73 0.172 0.069
C41 0.194 0.089 C74 0.219 0.108
C42 0.191 0.072 C7S 0.233 0.117
C43 0.185 0.069 C76 0.121 0.058
C44 0.197 0.113 C77 0.148 0.047
C45 0.181 0.088 C78 0.193 0.071
C46 0.201 0.123 C79 0.127 0.065
C47 0,165 0.084 C80 0.099 0.049
C48 0.132 0.057 C81 0.158 0.096
C49 0.206 0.114 C82 0.166 0.059
XII
Sample
Conjugated
Peptide
Directly
Coated
Sample
Conjugated
Peptide
Directly
Coated
C83 0.209 0.131 C89 0.184 0.081
C84 0.189 0.092 C90 0.216 0.094
C85 0.158 0.107 C91 0.167 0.057
C86 0.167 0.059 C92 0.129 0.068
C87 0.210 0.140 C93 0.236 0.119
C88 0.181 0.115
XIII
Details o f  the procedural protocols o f  the H CV ELISA and rapid competitors, showing assay incubation times, temperatures and reagent 
preparation necessary. Discussed in section 5.4.
HCV ELISA competitors
Appendix 6.
Sample Performance daia/comments
incubations volume
(D Abbott Diagnostics HCV EIA 
3.0
3 Conjugate and substrate 2 hours Seram or plasma lOuls Incubation temperature at 40°C. 
Bead assay. No performance data.
®General Biologicals Corp. 
NANBASE C-96 anti-HCV EIA
3 Conjugate, substrate and wash 1 lA hours Serum or plasma IOjoJs Pre-dilution of sample necessary. 
Humidified incubations.
(3 ) General Biologicals Corp. 
NANBDINE125 C anti-HCVRIA
3 Conjugate and wash 2 hours Serum or plasma lOfjls Radioactive label has safety 
implications.
mNNOGENETICS INNOTEST 
HCV Ab III
3 Conjugate and wash 2 lA hours Serum or plasma lOjils Performance data given. 3rd 
generation assay.
©Murex anti-HCV (Version III) 3 Conjugate, substrate and wash 2 hours Serum or plasma 20jils Good performance data available. 
Colour on sample addition.
®Ortho Chiron HCV3.0 ELISA 3 Wash and substrate 2 'A hours Serum or plasma lO^ls Heat treated samples cannot be used. 
No performance data given.
®Sanofi Diagnostics 
MONOLISA ® anti-HCV EIA
3 Wash and substrate 2 hours Serum 20(jls No performance data given.
®Syntron Bioresearch Inc., 
Microwell HCV EIA
2 Wash 1 Va hours Serum or plasma lOpls No performance data given. 2nd 
generation test not as sensitive.
®United Biomedical HCV EIA 3 Conjugate, substrate and wash 1 hour Serum or plasma 15uis Heat treated samples cannot be used
TCV Rapid competitors
Test Number o f Reagent preparation time Sample medium Sample Performan ce data/comments
incubations required volume
(D B'wnike Laboratories 1 None 10 min. Serum or plasma 1 drop Product not yet launched
© Genelabs Diagnostics 6 None 5 min. Serum or plasma 1 drop Multiple steps. Performance data
given
® SERO-Med® Rapid Test 4 None 5 min. Serum or whole blood I drop Fresh samples necessary.
XIV
Comparison o f  both assays, developed in this research, with Murex anti-HCV Version III EIA and General Biologicals Corp. NANBASE C-96 
EIA. A total o f  75 samples o f  unknown status were assayed. Discussed in section 5.4.
Appendix 7.
Sample
Number
Murex
General
Biologicals
ELISA SeroCard
Test
correlated
Sample
Number
Murex
General
Biologicals
ELISA SeroCard
Test
correlated
1 Pos. Pos. Pos. Ind. ELISA 15 Pos. Pos. Pos. Pos. Both
2 Pos. Neg. Pos. Neg. Ind. 16 Pos. Pos. Pos. Pos. Both
3 Neg. Neg. Pos. Neg. SeroCard 17 Pos. Pos. Pos. Pos. Both
4 Pos. Pos. Pos. Pos. Both 18 Pos. Pos. Pos. Pos. Both
5 Neg. Neg. Pos. Ind. None 19 Pos. Pos. Pos. Pos. Both
6 Pos. Pos. Pos. Pos. Both 20 Pos. Pos. Pos. Pos. Both
7 Pos. Pos. Pos. Pos. Both 21 Pos. Pos. Pos. Pos. Both
8 Pos. Pos. Pos. Pos. Both 22 Pos. Pos. Pos. Pos. Both
9 Pos. Pos. Pos. Pos. Both 23 Pos. Pos. Pos. Neg. ELISA
10 Pos. Pos. Pos. Pos. Both 24 Pos. Pos. Pos. Pos. Both
11 Pos. Pos. Pos. Pos. Both 25 Neg. Neg. Neg. Neg. Both
12 Pos. Pos. Pos. Pos. Both 26 Pos. Pos. Pos. Pos. Both
13 Pos. Pos. Pos. Pos. Both 27 Pos. Pos. Pos. Pos. Both
14 Pos. Pos. Pos. Pos. Both 28 Pos. Pos. Pos. Pos. Both
XV
Sample
Number
Murex
General
Biological*
ELISA SeroCard
Test
correlated
29 Pos. Pos. Pos. Pos Both
30 Pos. Pos. Pos. Pos. Both
31 Pos. Pos. Pos. Pos. Both
32 Neg. Neg. Neg. Neg. Both
33 Pos. Pos. Pos. Pos. Both
34 Pos. Pos. Pos. Pos. Both
35 Pos. Pos. Pos. Pos. Both
36 Pos. Pos. Pos. Pos. Both
37 Pos. Pos. Pos. Pos. Both
38 Pos. Pos. Pos. Pos. Both
39 Neg. Neg. Neg, Neg. Both
40 Pos. Pos. Pos. Pos. Both
41 Pos. Neg. Neg. Neg. Both
42 Neg. Neg. Neg. Neg. Both
43 Neg. Neg. Neg. Neg. Both
44 Pos. Pos. Pos. Pos. Both
45 Neg. Neg. Neg. Neg. Both
46 Pos. Pos. Pos. Pos. Both
Sample
Number
Murex
General
Biologicals
ELISA SeroCard
Test
correlated
47 Pos. Pos. Pos. Pos. Both
48 Neg. Neg. Neg. Neg. Both
49 Neg. Neg. Neg. Neg. Both
50 Neg. Neg. Pos. Ind. None
51 Pos. Neg. Neg. Neg. Both
52 Pos. Pos. Pos. Pos. Both
53 Neg. Neg. Neg. Neg. Both
54 Pos. Pos. Pos. Pos. Both
55 Pos. Pos. Pos. Pos. Both
56 Pos. Pos. Pos. Pos. Both
57 Pos. Pos. Pos. Pos. Both
58 Pos. Pos. Pos. Pos. Both
59 Neg. Neg. Neg. Neg. Both
60 Neg. Pos. Neg. Neg. Both
61 Neg. Neg. Neg. Neg. Both
62 Neg. Pos. Neg. Neg. Both
63 Neg. Neg. Neg. Neg. Both
64 Neg. Neg. Neg. Neg. Both
XVI
Sample
Number
Murex
General
Biologicals
ELISA SeroCard
Test
correlated
Sample
Number
65 Neg. Neg. Neg. Neg. Both 71
66 Neg. Neg. Neg. Neg. Both 72
67 Neg. Pos. Neg. Neg. Both 73
68 Neg. Neg. Neg. Neg. Both 74
69 Neg. Neg. Neg. Neg. Both 75
70 Neg. Neg: Neg. Neg. Both
XVII
Murex
General
Biologicals
ELISA SeroCard
Test
correlated
Neg. Neg. Neg. Neg. Both
Neg. Neg. Neg. Neg. Both
Neg. Neg. Neg. Neg. Both
Neg. Neg. Neg. Neg. Both
Neg. Neg. Neg. Neg. Both
